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OUTLINE OF THE THESIS 
This thesis is structured in eight major chapters: 
In chapter I, the background for this study will be presented, providing a clinical 
contextualization and stressing the role of four key proteins (COX-2/15-
PGDH/MRP4/PGT) involved in prostaglandin E2 (PGE2) regulation in tumor 
development and the potential contribution of polymorphisms for colorectal cancer 
burden. This chapter is further subdivided in A and B. 
A systematic review and meta-analysis on published studies addressing the 
contribution of COX polymorphisms in gastrointestinal carcinogenesis, including 
the description of all COX-2 polymorphisms previously analyzed in colorectal 
tumors will be provided to readers in Chapter IA. 
In Chapter IB, a case-control study will be described and discussed to 
demonstrate as proof-of-concept, the impact of three specific COX-2 
polymorphisms, shown to modulate the susceptibility for colorectal tumors in the 
meta-analysis, in the development of CRC in a Northern Portuguese population. 
The purpose and aims of this thesis are disclosed in Chapter II. 
Considering that an increased risk for CRC in individuals carrying of rs689466G 
allele (-1195G allele) in COX-2 gene was reported in the proof-of-concept study 
and the lack of consistency noticed among published studies, in Chapter III, an in 
vitro approach assessing the repercussion of this SNP in COX-2 transcriptional 
activity in CRC cell lines is displayed, offering a biological plausibility behind the 
epidemiological data. 
Chapters IV and V are characterized by two retrospective observational studies 
addressing the influence of COX-2 and three other important genes regulating 
PGE2 leveles in CRC (HPGD, SLCO2A1 and ABCC4), on the predisposition for 
CRC and colorectal precancerous lesions onset, respectively. Furthermore, 
Chapter V also reports not only the influence on the development of 
metachronous adenomas in patients with previous history of adenomas, but also 
the time at which those lesions recur.  
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OUTLINE OF THE THESIS 
In Chapter VI, a study assessing the repercussion of SNPs identified as risk 
markers for colorectal carcinogenesis on Chapters IV and V on mRNA expression 
is reported. 
Finally, in Chapter VII a global discussion and main conclusion will be provided, 
followed by the suggestion for future research in this field of knowledge 
presentedin Chapter VIII.  
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Systematic review on the role of COX polymorphisms in 
gastrointestinal cancers 
Proof-of-concept study investigating the involvement of COX-2 
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SUMMARY 
Colorectal adenomatous polyps are well-characterized CRC precursors upon 
which the majority of CRC will develop in 10-15 years. Although the 
implementation of population-based CRC screening guidelines focused on the 
endoscopic detection and removal of these precancerous lesions is highly 
recommended, the compliance rates are far from the desirable for a sussessfull 
impact on CRC burden.  
Complementary, aspirin regular has been consistently effective in the primary 
prevention of colorectal tumors, by targetting the cyclooxygenase-2 (COX-2) 
enzyme, nevertheless its use is currently hampered by the onset of serious 
gastrointestinal side effects in average-risk population. So, the challenge for CRC 
prevention falls in the identification of biomarkers that could target higher-risk 
populations for colorectal screening and/or chemopreventive strategies.  
COX-2-derived prostaglandin E2 (PGE2), the major PG produced in colorectal 
tumors, plays a key contribution to the hallmarks of cancer, by stimulating cell 
proliferation, invasiveness and migration, enhancing angiogenesis, evading 
apoptosis and modulating the antitumor immune response.  
In a preliminar study involving 373 participants from the Northern region of 
Portugal, we reported the involvement of a specific polymorphism in COX-2 gene 
on the susceptibility for CRC development. In opposition, with earlier reports, 
individuals carrying the rs689466G allele (-1195A>G) were not only at an 
increased susceptibility but also had a 7-years antecipation on CRC development.  
With this in mind, and to lend further support to the epidemiologic data, we carried-
out a functional study and observed that COX-2 promoters’ containing the 
rs689466G allele had a two to three-fold increase in transcriptional activity in 
comparison with the ones encompassing the ra689466A allele in CRC cell lines. 
The positive finding in the proof-of-concept study, suggested we were focusing on 
the right genetic pathway, so we decided not only to increase our study population 
but also expand our search for genetic biomarkers to other key players in COX-
2/PGE2 pathway. The hydroxyprostaglandin dehydrogenase (HPGD) gene directly 
counteracts the COX-2 oncogenic PGE2 pathway. The ATP-binding cassete sub-
family C member 4 (ABCC4) gene and solute carrier organic anion transporter  
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family, member 2A1 (SLCO2A1) gene, code for specific prostaglandin membrane 
transporters that regulate PGE2 levels in the extracellular microenvironment.  
Seven tagSNPs were implicated in CRC development using a tagSNP approach 
including 51 genetic polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 PGE2 
pathway and nearly 750 participants: rs689466, rs1346271, rs1426945, rs6439448, 
rs7616492, rs1751051 and rs1751031. Consistently, individuals ever-smokers 
carriers of rs689466 GG homozygous genotype had a nearly six-fold increased 
susceptibility for CRC onset (95%CI: 1.49-22.42, P=0.011). Furthermore, the 
multifactor dimensionality reduction (MDR) analysis identified an overall four-factor 
best gene-gene interactive model, including the rs1426945, rs6439448, rs1751051 
and rs1751031 polymorphisms (cross-validation consistency: 10/10, accuracy: 
0.6957; OR=5; 95%CI: 3.89-7.02, P<0.001). 
We then questioned if polymorphisms in the aforeentioned genes would also be 
relevant in early stages of colorectal tumor development and recurrence of 
colorectal adenomas. 
Ten tagSNPs were identified as susceptibility biomarkers for the development of 
colorectal adenomas: the rs689466 in COX-2, the rs2555639, rs1346271, 
rs1863642 and rs12500316 in HPGD, the rs6439448 and rs1131598 in SLCO2A1 
and rs9524821, rs1751051 and rs1678405 in ABCC4 genes. The haplotype 
carying the rs9524821 and rs1751051 SNPs in ABCC4 gene had a risk of 3.9 for 
adenomas development (95%CI:2.28-6.65, P<0.001). Furthermore, the best four-
locus gene-gene interaction model included the rs1346271, rs186342 and 
rs12500316 SNPs in HPGD and rs1678405 in ABCC4 genes and was associated 
with a 13-fold increased susceptibility (95%CI:3.84-46.3, P<0.001, cross-validation 
(CV) accuracy: 0.78 and CV consistency: 8/10). Interesting, in high risk patients 
the rs1678405 ABCC4 SNP had a lower HR and half the crude risk for adenoma 
recurrence at 36 months, when comparing with the overall high risk patients (7% 
vs 14%). 
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A functional study characterizing the influence of polymorphisms previously 
identified as risk markers on the genes’ mRNA expression was performed in 
colonic mucosa. This approach provided the biological plausibility behind some of 
the associations lending further surport to the involvement of genetic variants in 
PGE2 pathway in colorectal carcinogenesis. In fact, the rs689466GG genotype, 
reported to have a higher transcriptional activity in CRC cell lines was further 
associated with a seven-fold COX-2 overexpression in CRC tissues (-1.57±0.10 vs 
-4.42±1.58 with the AA genotype, P=0.021).  
Although additional studies are needed, specific low penetrance genes in the pro-
carcinogenic PGE2 pathway appear to modulate the genetic susceptibility for 
colorectal tumors onset and recurrence. A clearer understanding on CRC etiology 
through the identification of biomarkers of colorectal carcinogenesis might allow a 
better definition of risk models that are more likely to benefit from targeted 
preventive and surveillance strategies to reduce CRC burden.
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Pólipos adenomatosos são lesões premalignas a partir dos quais a maioria dos 
cancros colo-retais (CCR) se irão desenvolver em média após 10-15 anos. 
Embora a implementação de rastreio de CCR através da detecção e remoção 
endoscópica dessas lesões seja recomendado a aderência a esses programas 
estão longe do desejável para um notório impacto na redução de CCR. 
O consumo regular da aspirina tem sido consistentemente eficaz na prevenção 
primária de tumores colo-rectal por inibir a enzima cyclooxygenase-2 (COX- 2), no 
entanto, o seu uso está actualmente comprometido pelo desenvolvimento de 
efeitos secundários graves a nível gastrointestinal em população com risco médio 
para CCR. Assim, o desafio na prevenção de CCR passa pela identificação de 
biomarcadores que permitam direcionar populações com um risco aumentado 
para estratégias otimizadas de rastreio e prevenção primária de CCR. 
A prostaglandina E2 (PGE2) produzida pela COX-2, desempenha um papel 
importante na activação de várias vias carcinogénicas, incluindo estimulação da 
proliferação celular, invasão, migração celular, inibição da apoptose e 
imunossupressão. 
Num estudo preliminar, envolvendo 373 participantes da região Norte de Portugal, 
um polimorfismo especifico no gene COX-2 foi implicado no desenvolvimento de 
CCR. Contrastando com a bibilografia disponível, indivíduos portadores do alelo 
rs689466G (-1195G), apresentaram não só um aumento na susceptibilidade, 
assim como, uma antecipação no diagnóstico de CCR.   
Tendo este trabalho como base desenvolvemos um estudo funcional que permitiu 
constatar que a região promotora contendo o alelo rs689466G conduz um 
aumento 2 a 3 vezes superior na actividade transcripcional do gene COX-2. 
Posteriormente, decidimos não só aumentar o número de participantes no nosso 
estudo caso-contolo, como expandir a pesquisa da variantes genéticas a outros 
genes relevantes na via da COX-2/PGE2. 
O gene hydroxyprostaglandin desidrogenase (HPGD) antagoniza os efeitos 
carcinogénicos da via PGE2. O gene ATP-binding cassete member sub- family C 
4 (ABCC4) e o solute carrier organic anion transporter family, member 2A1 
(SLCO2A1), que codificam transportadores de membrana específicos para o  
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transporte de prostaglandina, regulam os níveis de PGE2 no microambiente 
extracelular. 
Sete tagSNPs foram associados ao desenvolvimento de CCR, numa análise que 
incluiu 51 polimorfismos nos genes COX-2/HPGD/SLCO2A1/ABCC4 em cerca de 
750 participantes: rs689466, rs1346271, rs1426945, rs6439448, rs7616492, 
rs1751051 e rs1751031. Consistentemente, indivíduos ex ou atuais fumadores 
portadores do genótipo homozigótico rs689466GG apresentaram um aumento na 
susceptibilidade em 6 vezes (IC95%:1.49-22.42, P=0.011). Além disso, observou-
se uma interação entre quatro polimorfismos (rs1426945, rs6439448, rs1751051 e 
rs1751031) que conduziu a um aumento no risco cinco vezes superior para CCR 
(IC95%:3.89-7.02, P <0.001). 
Em seguida, questionamos se polimorfismos nos genes mencionados 
anteriormente também seriam relevantes em fases iniciais de desenvolvimento de 
CCR e recorrência de adenomas colo-rectais.  
Dez tagSNPs foram identificados como biomarcadores de susceptibilidade para o 
desenvolvimento de adenomas: o rs689466, rs2555639, rs1346271, rs1863642, 
rs12500316, rs6439448, rs1131598, rs9524821, rs1751051 e o rs1678405. O 
haplótipo portador dos polimorfismos rs9524821 e rs1751051 no gene ABCC4 
apresentaram um risco para o desenvolvimento de adenomas de 3.9 (IC95%: 
2.28–6.65, P<0.001). Curiosamente, em pacientes de alto risco o polimorfismo 
rs1678405 no gene ABCC4 apresentou um HR inferior a metade do risco bruto de 
recorrência de adenoma aos 36 meses, comparativamente com os pacientes de 
alto risco (7% vs 14%). 
De forma a caracterizar funcionalmente os polimorfismos anteriormente 
identificados como marcadores de risco, foi avaliada a repercussão destes na 
expressão génica. Esta abordagem suportou o envolvimento de variantes 
genéticas em genes da via da PGE2 na carcinogénese colorectal. De fato, o 
genótipo rs689466GG que conduz a um aumento na actividade transcripcional 
associou-se a uma sobre-expressão de COX-2 em tecidos de CCR (-1.57±0.10 vs 
-4.42±1.58 parao genótipo AA, P=0.021). 
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Embora sejam necessários mais estudos, polimorfismos na via pró-carcinogénica 
PGE2 parecem modular a suscetibilidade genética para o desenvolvimento e 
recorrência de tumores colo-retais. Uma melhor compreensão sobre a etiologia de 
CCR através da definição de biomarcadores de suscetibilidade colo-retal pode 
permitir uma melhor definição de modelos de risco, que permitirão otimizar as 
atuais estratégias de prevenção, rastreio e vigilância de tumores colo-rectais. 
27   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I: BACKGROUND 
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1.1. Colorectal cancer 
1.1.1.  Epidemiology and risk factors 
Colorectal cancer (CRC) is malignant neoplasm arising from the lining of large 
intestine and represents a major public health problem worldwide, with an anual 
incidence of approximately 1.36 million cases and a mortality of nearly 693.881. 
Geographically, there is at least a ten-fold variation in CRC burden among both 
genders, with the highest rates reported in the more developed regions (65.8 per 
100.000 in males), as can be observed in Figure 1 [1].  
 
 
 
 
 
 
 
 
Figure 1. Incidence distribution of colorectal cancer among males in 2012 (per 100.000). Retrieved 
from Globocan 2012 online database (http://globocan.iarc.fr/).  
 
In European countries, CRC is the third most common cancer in males (241.813 
cases, 13% of total) and the second in females (205.323, 13% of cases). In 2012, 
214.814 deaths were estimated due to CRC, making it the second most frequent 
cause of cancer death (12% of mortality) [1].  
Unfortunately, the epidemiological picture in Portugal is even worse. CRC is the 
second leading neoplasia with the highest incidence, only behind prostate and 
breast cancers in males (4209, 15% of cases) and females (2920, 14% of total), 
respectively. Overall 90% of all cases are diagnosed in individuals with or over 60 
years of age and males have a 44% higher incidence, with a cumulative risk for 
the development of CRC of 5% in contrast with the 3% reported in females [1]. 
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The burden of CRC is expected to increase over the next decades in developed 
countries as a reflection of population aging and growth, through a complex 
interaction between inherited susceptibility and environmental factors [1-5]  
Approximately 75% of patients have neither a clear family history nor any know 
predisposition condition [6]. In this context, the increasingly adoption of a 
“westernized” lifestyle, including physical inactivity, obesity, smoking, high 
consumption of red or processed meats and moderate-to-heavy alcohol drinking is 
believed to be a major determinant in the occurrence of sporadic cancer [4,5,7-9]. 
In fact, Kirkegaard and colleagues [10], suggest that following a healthy lifestyle 
could reduce the occurrence of CRC by 25%. 
Individuals with first-degree relatives diagnosed with CRC, particularly under the 
age of 45 years, have a 2 to 3-fold increased risk for developing this neoplasia [11]. 
Furthermore, personal histories of CRC, chronic inflammatory bowel diseases 
(IBD), or previous occurrence of colorectal adenomas, known precancerous 
lesions, are also associated with CRC development [12,13]. The latter will be 
further explored in the next session. 
Five-percent of cases are associated with one of two well-defined genetic 
syndromes that are characterized by the development of CRC at an early age 
[14,15]. The familial adenomatous polyposis (FAP) accounts for 1% of all CRC 
cases and is characterized by the occurrence of hundreds of adenomas that left 
without intervention progress to cancer in nearly 100% of patients [15]. Although 
with a lower penetrance the lifetime risk for CRC in hereditary non-polyposis 
colorectal cancer (HNPCC or Lynch syndrome) is around 80 to 90% [15].  
1.1.2.  Natural history 
Colorectal adenocarcinoma arising from the glandular tissues represent over 95% 
of cancers in the colon and rectum and were the focus of this thesis [16]. 
Regardless of etiology, CRC are thought to evolve from noncancerous polyps in 
orderly multistep process slowly over a period of 10-15 years [17]. The so-called 
adenomatous polyps are the most likely to progress into cancer and commonly 
found in older groups [18,19]. Approximately one-third to one-half of people will 
develop colorectal adenomas by the age of 60 years [19,20]. Most adenomas are 
asymptomatic with fewer than 10% progressing into cancer [18]. The size, 
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multiplicity, degree of villous component and grade of dysplasia are  bevieved to 
influence the risk of development to CRC [21-24]. Polyps between 1 and 2 cm or 
greater than 2 cm in diameter have a 10 and 50% probability of malignant 
transformation, respectively [23]. 
Furthermore, patients with previous history of colorectal adenomas are at 
increased risk for the recurrence of adenomas even after removal of those 
precancerous lesions [25]. Likewise, predictors for colorectal adenoma recurrence 
include multiple or large adenomas, severe dysplasia, villous componente and 
adenomas detected in the proximal colon [26]. The rate for the occurence of 
metachronous adenomas  can achieve the 40% to 50% [25] 
The adenoma-carcinoma sequence is the phenotypic manifestation of the 
cumulative effects of acquired molecular events due to loss of genomic stability 
[27-29]. Briefly, the multiple tumor-associated mutations acquired during colorectal 
carcinogenesis are driven by at least two major pathways. The chromosomal 
instability (CIN) is implicated in 60% to 70% of CRCs and includes widespread 
numeric chromosomal aberrations [30], most frequently observed in chromosome 
5q, 18q and 17p and mutation of KRAS oncogene [31]. These chromosomes 
encode the noteworthy APC, DCC and TP53  genes, respectively, found to be 
deregulated in different stages of tumor development [31]. The microsatellite 
instability (MSI) pathway is characterized by the accumulation of somatic 
alterations in microsatellite repeat lenght as consequence of aberrant promoter 
hypermethylation of mismatch repair genes (MMR) [29]. BRAF mutations are 
commonly reported in the context of MSI mainly due to MLH1 promoter 
hypermethylation [32]. These entities  contribute to the deregulation of important 
pathways contributing to the hallmarks of cancer [33,34]. 
1.1.3.  Screening, surveillance and prevention 
Colorectal cancer is particularly suitable of prevention considering its natural 
history with a long latency period providing an excellent window of opportunity for 
early detection [17]. Current guidelines endorse several tests and strategies as 
can be observed in Table 1 [35]. These approaches contrast on their sensitivity to 
detect different stages of colorectal carcinogenesis with further repercussion on 
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the interval between examinations, length of observed colon, examination time, 
prior colon preparation, cost and associated risks [35]. 
The screening and surveillance of individuals previously diagnosed with colorectal 
adenomatous polyps is the cornerstone in CRC prevention by effectively reducing 
CRC incidence and mortality [36,37]. In fact, the United States is the only country 
presenting a significantly decrease in incidence rates in both genders most 
attributable to the detection and removal of these colorectal precancerous lesions 
[38,39] 
To date, only faecal occult blood test (FOBT) has been recommended for 
population-based CRC screening in average-risk males and females aged 50 to 
74 years in the European Union [40]. The detection of CRC earlier in more 
treatable stages has been shown to reduce the risk of death by 15% to 33% [35]. 
Despite strong evidence supporting the effectiveness of the several tests and 
strategies, the screening rates for CRC remain low for a meaningful impact in CRC 
burden. In the United States only half of adult population aged 50 or older reported 
being screened within recommended intervals [41]. 
Furthermore, endoscopic surveillance of patients previously diagnosed with 
colorectal adenomas is recommended considering the high risk of reccurence due 
to missed or incompletely removed lesions at baseline colonoscopy or to an 
accelerated tumor growth in apparently normal mucosa that could also account for 
the development of cancers between colonoscopies [42-46]. 
The implementation of population-based screening strategies focused primarily on 
the early detection of CRC and the lower than desirable adherence rate in 
countries with endoscopic-based CRC screening programmes, emphasize the 
search for complementary approaches targeting the primary prevention of CRC.  
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Table 1. Screening tests for colorectal cancer (adapted from [41]) 
Test Benefits 
Performance & 
Complexity* 
Limitations 
Test time 
interval 
Flexible 
sigmoidoscopy 
-Fairly quick 
-Few complications 
-Minimal bowel 
preparation 
-Minimal discomfort 
-Does not require 
sedation or a specialist 
Performance: 
-High for rectum & lower 
one-third of the colon 
 
Complexity: 
-intermediate 
-Views only one-third of colon 
-Bowel preparation needed 
-Small risk of infection or bowel 
tear 
-Slightly more effective when 
combined with annual fecal 
accult blood testing 
-Colonoscopy necessary if 
abnormalities are detected 
5 years 
Colonoscopy -Examines entire colon 
-Can biopsy and remove 
polyps 
-Can diagnose other 
diseases 
-Required for abnormal 
results from all other tests 
Performance: 
-Highest 
 
Complexity: 
-Highest 
-Can miss some polyps and 
cancers 
-Full bowel preparation needed 
-Can be expensive 
-Sedation of some kind usually 
needed, necessitating a 
chaperon 
-Patient may miss a day work 
-Highest risl of bowel tears or 
infections compared to other 
tests 
10 years 
Double-
contrast 
barium enema 
-Can usually view entire 
colon 
-Few complications 
-No sedation needed 
Performance: 
High 
 
Complexity: 
High 
-Can miss some small polyps 
and cancers 
-Full bowel preparation needed 
-Cannot remove polyps 
-Exposure to low-dose radiation 
-Colonoscopy necessary if 
abnormalities are detected 
5 years 
Computed 
tomography 
colonography 
-Examines entire colon 
-Fairly quick 
-Few complications 
-No sedation needed 
-Noninvasive 
Performance: 
High 
 
Complexity: 
Intermediate 
-Can miss some polyps and 
cancer 
-Full bowel preparation needed 
-Cannot remove polyps 
-Exposure to low-dose radiation 
-Colonoscopy necessary if 
abnormalities are detected 
5 years 
Fecal occult 
blood test 
-No bowel preparation 
-Sampling is done at 
home 
-Low cost 
-Noninvasive 
Performance: 
Intermediate for cancer 
 
Complexity: 
Lowest 
-May require multiple stool 
samples 
-Will miss most polyps and 
some cancers 
-Higher rate of false-positives 
than other tests 
-Pre-test dietary limitations 
-Slightly more effective when 
combined with flexible 
sigmoidoscopy every five years 
-Colonoscopy necessary if 
abnormalities are detected 
Annual 
Stool DNA test -No bowel preparation 
-Sampling is done at 
home 
-Requires only a single 
stool sample 
-Noninvasive 
Performance: 
-Intermediate for cancer 
Complexity: 
Low 
-Will miss most polyps and 
some cancers 
-High cost compared with other 
stool tests 
-New technology with uncertain 
nterval between testing 
-Colonoscopy necessary if 
abnormalities are detected 
Uncertain 
* Complexity involves patient preparation, inconvenience, facilities and equipment needed, and patient discomfort. 
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Chemoprevention is defined as the use of natural, synthetic or biological agents to 
reverse, suppress or prevent the development or progression tumors in the initial 
phases of carcinogenesis [47].  
The rationale for the development of chemopreventive approaches in CRC 
prevention arose from observational studies highlighting the long-term use of 
aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in the reduction 
of CRC incidence and mortality. In 1988, Kune and colleagues [48], in the first 
population-based case-control study, reported a nearly 50% risk reduction for CRC 
development in regular aspirin consumers. Thereafter, a large body of 
epidemiological evidences consistently corroborated the protective role of aspirin 
in all stages of colorectal carcinogenesis [49,50]. Two trials reported that aspirin 
also reduces the risk of recurrent adenomas in the context of CRC or previous 
history of adenomas [51-53]. Baron and colleagues [51], observed a relative risk 
(RR) of 0.81 (95%CI:0.69-0.96) and 0.59 (95%CI:0.38-0.92) for the recurrence of 
any adenomas and advanced adenomas, respectively, in patients allocated to low 
doses of aspirin. 
In 2007, Flossmann and Rothwell [49] systematically reviewed relevant 
observational studies and analyzed the long-term effect of aspirin in two 
randomized trials with more than 20 years of post-trial follow-up. In the clinical 
setting, allocation to 300 mg of aspirin daily for a minimum period of 5 years 
resulted in an effective primary prevention of CRC with a 10 years latency period 
[49]. Furthermore, the long–term use of aspirin also contributes to a decrease in 
CRC mortality in five randomized trials [54].  
Although effective, the prolonged use of aspirin is associated with serious 
gastrointestinal side effects that compromised their generalized use in the primary 
prevention of CRC in populations at average risk [55]. However, and quoting Arder 
and Levin [56] “…to ignore the potential benefit of chemoprevention is to continue 
to accept a higher than necessary death rate from CRC in patient populations that 
are not fully compliant with screening for colorectal neoplasia”. 
A more comprehensive understanding of colorectal carcinogenesis, through the 
identification of genetic and environmental risk factors, might contribute to CRC 
prevention by targeting screening and chemoprevention to higher-risk individuals. 
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1.2. Role of COX-2/PGE2 pathway in colorectal carcinogenesis: focus on 
COX-2, 15-PGDH, PGT and MRP4 proteins 
Chronic inflammation clearly is an important driver of cancer, by stimulating the 
proliferation and angiogenesis, as well as, inhibiting apoptosis and immune 
surveillance, as reviewed by Coussens and Werb [57]. In fact, inflammatory bowel 
diseases (IBD) such as, ulcerative colitis and Crohn’s disease are well-established 
conditions with increased predisposition for CRC [58]. Furthermore, drugs 
targeting inflammatory-related molecules were shown to exert anticancer 
properties, lending further support to the inflammation-cancer cascade [59].  
The mechanism underlying the protective actions of NSAIDs is not completely 
understood but cyclooxygenases (COX) enzymes are their best-known targets [60]. 
There are at least two COXs isoenzymes identified. COX-1 is a constitutive 
enzyme ubiquitously expressed and responsible for normal tissue homeostasis, 
including maintenance of gastric mucosa and regulation of renal blood [61]; 
whereas COX-2 is an immediate-early response gene normally undetected in most 
cells but shown to be progressively overexpressed in colorectal adenomas (40 to 
50%) and CRC (85%) [62,63] Furthermore, deletion of COX-2 gene in the ApcMin/+ 
and APCΔ716 CRC mouse model resulted in a decreased tumor formation [64,65].  
The COX enzymes catalyze the rate-limiting step of converting free arachidonic 
acid (AA) to prostaglandin (PG) G2, which in turn is reduced to an unstable 
endoperoxide intermediate, PGH2 and finally metabolized into five structurally 
related prostanoids by cell type-specific PG synthases, including PGE2, PGI2 and 
thromboxane A2 (TxA2) [66,67].  
COX-2-derived prostaglandin E2 (PGE2) is the most abundant PG found in 
colorectal tumors [68]. This bioactive lipid portrays a predominant role during 
colorectal carcinogenesis by binding to specific transmembrane G-protein-couple 
cell surface receptors (EP1 to EP4) and activating a plethora of signaling 
pathways that contribute to most if not all hallmarks of cancer, as reviewed by 
several authors (see Figure 2) [69,70,71]. In a mouse model for intestinal 
neoplasia bearing inactivating mutations in the APC gene, ApcMin/+ stimulation with 
PGE2 led to a dramatic increase in the burden of small and large intestinal tumors 
and significantly enhanced colon tumor incidence and multiplicity in the colon 
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carcinogen azoxymethane (AOM)-induced mouse cancer model [72,73]. Moreover, 
in humans the regression of adenomas was particularly noticeable when PGE2 
levels were deeply decreased by NSAIDs [74]. Moreover, increasingly levels of 
urinary metabolite PGE2 (PGE-M, 11 alpha-hydroxy-9,15-dioxo-2,3,4,5-tetranor-
prostane-1,20-dioic acid) were associated with higher risks for CRC development 
in a prospective study [75]  
 
 
 
 
 
Figure 2. Mechanisms of COX-2-derived PGE2 contribution to tumor development. Adapted from 
Wang and colleagues [70]. In colorectal tumors, PGE2, through both autocrine and paracrine 
regulation can: transactivate EGFR, which results in stimulation of cell migration and invasion 
through increased PI3K-Akt signaling; induce the production of angiogenic factors, such as, VEGF 
and bFGF that promote proliferation, migration and vascular tube formation; promote tumor 
survival by activating PPARδ via PI3K-Akt pathway and inducing antiapoptotic protein expression, 
like Bcl-2; and modulate immunosurveillance via inhibition of dendritic cell differentiation and T cell 
proliferation and suppression of antitumor activity of NK cells and macrophages, as reviewed by 
Wang and colleagues [69,71]. bFGF, basic fibroblast growth factor; COX-2, cyclooxygenase-2; 
EGFR, epidermal growth factor receptor; NK, natural killer; NSAIDs, nonsteroidal anti-inflammatory 
drugs; PGE2, prostaglandin E2; PI3K, phosphoinositide-3 kinase; PPAR, peroxisome proliferator-
activated receptor; VEGF, vascular endothelial growth factor.  
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A balance between COX-2-dependent biosynthesis and PGE2 degradation 
maintains the steady-state cellular levels of PGE2. It as been suggested that 
inactivation of PGE2 in microenvironment is a two-step process [76]. After being 
synthesized, intracellular PGE2 is carried through the membrane via specific PG 
efflux transporters, the multidrug resistance-associated protein 4 (MRP4), in an 
ATP-dependent manner or by simple diffusion and hence their pleiotropic effect on 
tumor development are triggered [77]. The first step on PGE2 inactivation requires 
the carrier-mediated transport by the specific PG transporter (PGT) from the 
extracellular milieu into the cytoplasm, where the rate-limiting step of PG 
catabolism is promoted by the NAD+-dependent 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) [76,78]. The 15-PGDH is a natural antagonist of COX-
2 pro-carcinogenic effects in colonic mucosa and shown to ubiquitously lost in 
colorectal tumors [79,80]. Genetic deletion of 15-PGDH was reported to increase 
tissues levels of PGE2 promoting colon tumor growth in Apc
Min/+ [79] and that loss 
of 15-PGDH expression confers resistance to Celecoxib (COX-2-specific inhibitor) 
anti-tumor effects [81]. 
Holla and colleagues [82] reported that PGT expression was decreased in human 
CRC tissues and in polyps from ApcMin/+ mice. Additionally, forced PGT 
overexpression reduced PGE2 levels extracellularly and increased its inactive 
metabolite 15-keto PGE2 intercellular levels. In turn, MRP4 expression was 
significantly increased in colorectal tumors compared with normal tissue [82].  
The efflux-dominated flow of PG during carcinogenesis as a reflection of an 
increased expression of COX-2 and MRP4 and down-regulation of 15-PGDH and 
PGT leads to an accumulation of PGE2 in the extracellular milieu culminating in 
the activation of a plethora of pathways that stimulate tumor development [68-71].  
1.3.  Polymorphisms as risk factors for colorectal cancer 
Colorectal cancer has a sizable heritable component. In a large twin study it was 
estimated that more than one-third of variance in CRC is attributable to heritable 
factors [83]. Less than 10% of CRC fulfill the criteria for hereditary cancers [14] 
suggesting that the remaining familiarity might be accounted to a large number of 
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common, low-penetrance genetic variants each exerting a small influence on risk, 
mostly represented by single nucleotide polymorphisms (SNP) [84].  
Single Nucleotide Polymorphisms (SNPs) are the simplest type of polymorphism 
and result from a single base mutation, which substitutes one nucleotide for 
another [85]. Since SNPs are inherited from one generation to the next, less 
mutable and have high frequency in the genome, they are largely used in the 
genetic dissection of diseases such as cancer [85]. 
A decade ago the release of the first human draft allowed a deeper knowledge on 
the architecture and function of the human genome [86].  Collectively with the 
HapMap Project, more than 17 million common variants are catalogued in the SNP 
database (dbSNP; http://www.ncbi.nlm.nih.gov/snp). Due to the high degree of 
linkage disequilibrium (LD) observed between SNPs within genomic blocks the 
majority of common genetic variations can be captured by typing a subset of SNPs, 
mostly referred as tagSNPs [87]. Association studies based on tagSNPs 
genotyping have, therefore, been proposed as a comprehensive approach to 
identify causal genetic variation underlying complex diseases and have become 
an important tool in clinical studies [87]. 
Not disregarding the importance of underlying cellular phenotypes, the expression 
levels of many genes naturally differ among individuals. Studies uncovering the 
genetic basis of variation in gene expression further support the involvement of 
polymorphisms on the genesis of common diseases as some are expected to 
influence gene expression [88].   
Theodoratou and colleagues [89] recently performed a field synopsis of genetic 
association studies in CRC. Over 600 studies studies were published reporting 
445 polymorphisms in 110 different genes, highlighting the attention this field of 
research captures. 
Our group has previously identified and characterized two genetic variants in 
inflammatory-related genes as risk biomarkers for CRC occurrence in the Northern 
Portuguese population [90] (see appendix). 
The search for genetic biomarkers in 15-PGDH, MRP4 and PGT coding genes, 
the hydroxyprostaglandin dehydrogenase (HPGD), ATP-binding cassete sub-
family c member 4 (ABCC4) and solute carrier organic anion transporter family, 
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member 2A1  (SLCO2A1) genes, respectively, on colorectal carcinogenesis has 
been rather neglected [91-95]. Three genetic variants in HPGD gene were 
previously identified as susceptibility biomarkers for CRC development (rs8752, 
rs2612656 and rs2555639) in the few published studies [91,92]. 
Most of the efforts have been focused on COX-2 gene, also known as 
prostaglandin-endoperoxide synthase 2 (PTGS2). A systematic review on the 
available data up to this study design is described in the following subchapter [96]. 
Taken all together, it is reasonable that some genetic polymorphisms in COX-
2/HPGD/ABCC4/SLCO2A1 genes might modulate the susceptibility for the 
development and recurrence of colorectal tumors, thereby yielding the recognition 
of individuals at higher risk for this disease. 
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Cyclooxygenase polymorphisms in gastric and colorectal
carcinogenesis: are conclusive results available?
Carina Pereiraa,b, Rui M. Medeirosa and Ma´rio J. Dinis-Ribeirob,c,d
Objective Cyclooxygenases (COX) are important enzymes
not only in the maintenance of mucosal integrity but also in
pathological processes, namely in inflammation and tumor
development in the gastrointestinal tract. Our goal was to
understand whether there is a clear role for COX
polymorphisms in gastric and colorectal carcinogenesis.
Methods A systematic review was conducted on
observational studies assessing the involvement of COX
polymorphisms at the onset of gastric or colorectal lesions,
retrieved through a MEDLINE database search by May 2008.
The dominant genetic model was assumed for each
polymorphism and a random-effect model was used for
pooling results.
Results Twenty-two studies were retrieved reporting a total
of 26 COX polymorphisms (nine in COX1 and 17 in COX2
genes). Carriers of –1329A, –899C alleles, and *429TT
genotype revealed increased risk for gastric cancer [odds
ratio (OR)=1.83; 95% confidence interval (CI): 1.07–3.10,
OR=2.02; 95% CI: 1.00–4.10 and OR=1.34; 95% CI: 1.06–
1.71, respectively). For colorectal lesions, the –899G>C and
–1329G>A polymorphisms also showed an increased risk
for cancer (OR=1.35; 95% CI: 1.01–1.81 and OR=1.36; 95%
CI: 1.11–1.66, respectively). Furthermore, C allele carriers of
V102V single nucleotide polymorphisms presented a
decreased risk for colorectal adenoma onset (OR=0.77;
95% CI: 0.58–1.03).
Conclusion Although further studies, namely cohorts
and/or adequately matched case–control studies, are
required to unravel the impact of most COX
polymorphisms, clearly there are evidences that support
the involvement of – 899G>C and –1329G>A COX2
polymorphisms in either gastric or colorectal
carcinogenesis. These markers could be used to optimize
management strategies (follow-up and/or
chemoprevention). Eur J Gastroenterol Hepatol
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Introduction
Gastrointestinal cancers are amongst the leading causes
of cancer mortality. Gastric and colorectal cancers
(CRCs), with the second and fourth highest cancer
mortalities, respectively, were responsible for 1 229 327
deaths, approximately 18.3% of all cancer-related mortal-
ity in 2002 [1].
Several types of studies demonstrated that gastric and
colorectal carcinogenesis develops upon a multistep
process involving the transformation of normal mucosa
to benign precancerous lesions, such as atrophy and
intestinal metaplasia (AIM) in gastric adenocarcinoma
(GC) (according to Correa’s model), [2] and adenoma-
tous polyps in CRC [3,4].
Furthermore, these cancers are complex and multifactorial
diseases, emerging from the combined influence of environ-
mental factors such as diet, lifestyle, Helicobacter pylori
infection, and the individual genetic background [5–8].
Inflammation, nowadays, is a field of highlighted interest
in the development and progression of several gastro-
intestinal cancers [9–11]. Epidemiological and animal
data revealed that the use of NSAIDs might reduce the
risk of gastric cancer, colorectal polyps, and cancer
[12–15]. Although not clearly understood, the ability of
NSAIDs to suppress inflammation is strongly credited to
the inhibition of cyclooxygenase (COX) enzyme [16,17].
COXs or prostaglandin endoperoxide synthases (PTGS)
are rate-limiting enzymes that catalyze the formation of
prostaglandins (PG) from arachidonic acid (AA) [18].
COX-1 is constitutively expressed in the majority of
tissues and is associated with housekeeping functions like
vascular homeostasis and platelet aggregation [19]. The
second isoform (COX-2), almost undetectable under
normal physiological conditions, is readily induced in res-
ponse to mitogens, tumor promoters, cytokines, growth
factors, stress-inducing agents promoting inflammatory
reactions, and tumor development [19–21]. COX-2
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overexpression was reported in several common human
malignancies, predominantly of the gastrointestinal tract
[22,23], including in 85% of CRC and 67% of GC tumors
also as in their associated precancerous lesions [24,25].
Therefore, it is not surprising that functional polymorph-
isms in COXs genes have been studied to define their
influence in the susceptibility to develop gastrointestinal
malignant diseases.
The discovery of single nucleotide polymorphisms (SNPs)
as potential biomarkers in early gastrointestinal tumorigen-
esis [26] has prompted the development of several studies
that are often limited by the small statistical power,
hindering a clear definition of the impact of those
polymorphisms in gastric and CRC development.
Therefore, we conducted a systematic review to unravel
the influence of COX polymorphisms in gastrointestinal
cancers and associated lesions. This could ultimately
allow the recognition of individuals at higher risk that
may benefit from surveillance programs and/or chemo-
preventive strategies.
Materials and methods
Type of study
A systematic review was conducted on manuscripts
obtained after applying the inclusion and exclusion criteria
(see below) to abstracts collected by introducing a specific
query in an on line database (PubMed). Selected studies
were then characterized in a structured sheet, the quality
assessed and the pooled data statistically analyzed.
Search strategy and papers selection
A MEDLINE database (PubMed) search was performed
to retrieve papers linking COX polymorphisms and risk of
gastrointestinal cancers available on line by May 2008,
using the following query:
‘{[cox OR cox1 OR cox2 OR ptgs1 OR ptgs2 OR ‘Cyclooxygenase
2’(MeSH) OR ‘Cyclooxygenase 1’(MeSH)] AND [polymorphism
OR polymorphisms OR ‘Polymorphism, Genetic’(MeSH) OR
‘Polymorphism, Single Nucleotide’(MeSH)]} AND {[‘gastro-
intestinal cancers’(All Fields) OR ‘Gastrointestinal Neoplasms’
(MeSH) OR ‘Digestive System Neoplasms’(MeSH) OR ‘Gastro-
intestinal Stromal Tumors’(MeSH)] OR [gastric OR ‘Stomach’
(MeSH)] AND [cancer OR ‘Neoplasms’(MeSH) OR ‘precancer-
ous lesions’ OR ‘Precancerous Conditions’(MeSH) OR adeno-
carcinoma OR atrophy OR dysplasia OR ‘Polyps’(MeSH)
OR ‘Adenomatous Polyps’(MeSH)]} OR ‘intestinal metaplasia’
OR ‘Gastritis, Atrophic’(MeSH) OR {[‘Esophagus’(MeSH) OR
esophageal] AND [cancer OR ‘Neoplasms’(MeSH) OR adeno-
carcinoma OR ‘squamous cell carcinoma’]} OR ‘barrett
syndrome’(All Fields) OR ‘Barrett Esophagus’(MeSH) OR
{[‘Colon’(MeSH) OR colonic OR colorectal OR intestinal
OR bowel OR jejunal OR ileal OR rectal] AND [cancer OR
‘Neoplasms’(MeSH) OR ‘precancerous lesions’ OR ‘Precancerous
Conditions’(MeSH) OR adenocarcinoma OR ‘Polyps’(MeSH)
OR ‘Adenomatous Polyps’(MeSH)]}’.
One hundred and fifty-one abstracts gathered through
this search were then read and the inclusion/exclusion
criteria applied independently by two researchers (PC
and DRM) (Fig. 1).
Observational studies (case–control and cohort) aimed at
assessing the association between COX polymorphisms
and sporadic gastrointestinal cancers and/or its precancer-
ous lesions were included in this systematic review.
Of the 32 articles meeting the primary criteria [27–58],
seven were promptly excluded: four studies investigating
esophageal cancer were omitted (two with overlapping data
on esophageal squamous cell carcinoma [27,28] and the two
studies focusing on esophageal adenocarcinoma examined
different COX2 polymorphims [29,30]); the other three did
not include patients with and without gastrointestinal
lesions in their studies [i.e. not allowing the odds ratio (OR)
estimation] [33,34,58]. We also retrieved one paper
published in Chinese without English, French, Spanish, or
Portuguese version [31]. To overcome this language barrier,
a genotype distribution extraction sheet was sent, by
e-mail, to the authors. After exploring full papers another
report was excluded. In the study developed by Sitarz et al.
[57], an extremely high frequency of diffuse and mixed-
type GC was noticed (over 60%) and as COX-2 is mainly
associated with the intestinal histological-type multistep
cascade [59], considering this study in the pooled analysis
could disguise the real impact of COX2 naturally occurring
genetic variations in gastric carcinogenesis.
Finally, the reference list of all selected publications and
review articles excluded was also checked for additional
studies missed on the PubMed search, although no
further studies were included.
Data extraction and quality assessment
From each of the included articles the following informa-
tion was extracted: first author, year of publication, country,
ethnicity, study design, histological type, gene and poly-
morphisms analyzed, number of cases and controls by
genotype, representativeness of cases, source of controls,
histopathological confirmation of cases and controls,
genotyping examination, confounding factors, variables
used in statistical adjustments, and evidence
of Hardy–Weinberg equilibrium (HWE). If an article
reported results from different study populations, those
populations were assessed independently [42,47]. From the
studies by Koh et al. [49] and Tan et al. [44], only the pooled
CRC’s genotype frequencies were extracted, although they
had data concerning colon and rectal cancer independently.
Furthermore, two overlapping reports were found from
Siezen et al. [32,40]. Likewise, the paper written by Poole
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et al. [56] had duplicated data with both studies from Ulrich
et al. [37,38]. All articles were included for quality
assessment, but only the more recent and/or complete
article was incorporated in the pooled data [37,38,40].
Articles with stratified results by sex were pooled together
[39,50]. Data regarding the use of NSAIDs were assessed
either independently or combined [37,38,40,42].
The quality of papers was also independently assessed by
two researchers (MR and DRM) based on two published
quality score systems, one created by Thakkinstian et al. [60]
and the STROBE statement [61] (Supplementary data,
Table A). Scores ranged from 0 (lowest) to 50 (highest).
Polymorphism characterization
In this systematic review, the different COX polymorph-
isms were designated following the nomenclature pro-
posed by den Dunnen and Antonarakis in 2001 [62]. The
different polymorphisms are characterized in Table B of
the supplementary data.
Some ambiguity across studies when defining the variant
allele for the – 1329G>A COX2 polymorphism was
observed. Therefore, considering the functional study
developed by Zhang et al. [27] we defined the A allele as
the variant one since it was shown to increase COX2
transcriptional activity.
Statistical analysis
Pooled variant allele frequencies in control
populations
The pooled frequency of each COX polymorphism,
stratified by ethnicity, was estimated only in the control
populations. Heterogeneity across studies was measured
through the w2 test [degrees of freedom (df) equal to the
number of studies minus one].
Hardy–Weinberg equilibrium assessment in control
populations
Before the effect estimation of the several COX
polymorphisms in gastric and colorectal carcinogenesis,
the HWE was assessed for all the polymorphisms in each
study, whenever unavailable in the original papers, by
using the w2 test or Fisher’s exact test, where appropriate
(n<5) (1df). If P value was less than 0.05 then control
genotype distributions were assumed to deviate from
HWE.
Fig. 1
PubMed search
(May 2008)
n=151 abstracts
n=32 full papers
n=24 manuscripts (£)
included for analysis
not included n=119
excluded n=8
– 44 studies not related to gene polymorphisms;
– 59 studies involving exclusively others than COX polymorphisms;
– 34 studies not involving cancer patients or involving others than
   gastrointestinal cancers;
– 12 studies concerning HNPCC or FAP;
– 18 reviews (§), letters, case-reports, case-series and animal studies.
– 3 studies that didin’t include subjects with and without gastrointestinal
   cancers;
– 4 studies reporting COX polymorphisms in esophageal cancer (¥);
– 1 study reporting high frequency of diffuse or mixed-type gastric
   adenocarinoma.
Fluxogram for retrieval and papers selection. }, the reference list from reviews was checked for missing papers in the PubMed search. No additional
studies were found; f, four studies involving esophageal cancer were omitted: two with overlapping data on esophageal squamous cell carcinoma
[27,28] and the other two studies focusing on esophageal adenocarcinoma examined different COX2 polymorphims [29,30]; d, one study was
reported in Chinese without Portuguese, English, French, or Spanish version [31]. It was only considered in the statistical analysis; FAP, familial
adenomatous polyposis; HNPCC, hereditary nonpolyposis colorectal cancer.
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Estimated effect of cyclooxygenase polymorphisms in
gastric and colorectal carcinogenesis
For both individual or pooled OR and the corresponding
95% confidence interval (95% CI) estimation, data was
inserted on RevMan 4.2.10 statistical program (Copenhage,
Denmark) [63]. The dominant model was assumed for
every polymorphism and the ORs were estimated under a
random-effect model [64]. The heterogeneity statistics was
based on Q-value that follows a w2 distribution (df equal to
the number of studies minus one) [65]. When P value was
under 0.05, a statistically significant heterogeneity was
assumed among studies. Sources of heterogeneity were
appraised by subgroup stratification, based on several study
characteristics, like ethnicity and source of control
individuals (population or hospital based).
The influence of COX1 and COX2 polymorphisms in
gastric and colorectal carcinogenesis was assessed inde-
pendently for each of the following groups: the gastric
precancerous lesions group that included patients with
AIM; [35,36,53] the gastric cancer patients with lesions
as severe as low-grade dysplasia [31,35,36,52,53,55],
excluding those with lesions indefinite for dysplasia from
the study by Liu et al. [36]; the colorectal adenoma group
[37–42,54], disregarding patients with hyperplastic
polyps reported in both studies by Ulrich et al. [37,38]
and finally, the CRC group [42–48,51].
Sensitivity analysis and publications bias
By including and excluding studies deviating from HWE
sensitivity analysis was performed. Publication bias was
assessed through funnel plot asymmetry tests [66].
Results
Studies description
Table 1 summarizes all studies included in this meta-
analysis. There were 24 manuscripts [31,32,35–56]
reporting 22 studies [31,35–55] included in this review:
(i) six studies addressed gastric carcinogenesis [31,35,
36,52,53,55], three of which had information not only
characterizing gastric cancer patients but also a group
with precancerous lesions [35,36,53]. and (ii) 16 studies
evaluated the risk of adenoma (n=6) [37–41,54] or CRC
(n=9) [43–51] or had data regarding both (n=1) [42].
Nine COX1 polymorphisms were addressed to uncover
their role in the development of gastrointestinal tumors:
IVS7+14delA (rs3215925), IVS7 – 45T>C (rs3842798),
Q41Q (rs3842788), G213G (rs5788), L15_L16del, R8W
(rs1236913), P17L (rs3842787), L237M (rs5789) and
V481I (rs5794). In COX2, 17 polymorphisms were
characterized: –1462_1461delTG (rs689464), –1423A>G
(rs689465), –1329G>A (rs689466), –899G>C
(rs20417), –798A>G, –646C>T (rs20420), –196C>G
(rs20424), –125T>G (rs5721), V511A (rs5273),
IVS5–275T>G (rs20432), IVS7+111T>C (rs4648276),
V102V (rs5277), G587R (rs3218625), *429T>C (rs5275),
*1806A>G (rs4648298), *2291G>A (rs689469), *2430C
>T (rs689470).
Studies design
All studies were considered as case–controls, including
the four nested case–controls [39,42,48,49]. The median
quality was 34.4 points (ranging from 24 [46] to 40 [39]).
Twelve studies used hospital-based cases and controls
[35,37,38,40,41,43,45–47,51,52,54] and eight described a
population-based design [36,39,44,48–50,53,55]. In the
study by Lin et al. [42], the risk assessment for colorectal
adenoma and cancer pursued a hospital and population-
based design, respectively. Only seven studies reported
case and control group matching, at least, for age and sex
[40–42,45,48,50,55]. All studies adjusted their data for
potential confounders [35–42,44–55].
Only 12 studies reported the endoscopic and/or histo-
logical confirmation of the cancer-free status for the
control groups [36–44,52–54]. Cases and controls were
mainly defined through endoscopy procedures, with
histological assessment.
Number of participants and addressed populations
A total of 20 576 individuals were studied: 2951 within
the precancerous gastric lesions group analysis; 4272 in
the gastric carcinoma; 6871 in the colorectal adenoma,
and 8172 in the colon cancer groups. Globally, the median
number of individuals included was 653, with a minimum
of 140 [42] and an upper limit of 2300 participants in the
study by Tan et al. [44].
Five ethnicities were addressed: eleven studies focused
on Caucasian populations [35,37–41,45–48,55], seven on
Asiatic [31,36,43,44,49,51,54], three on African–American
[42,47,50], one on a Hispanic [53], and one on a
Northern Indian population [52]. The African–Americans
were only regarded in colon tumors, whereas the
Hispanics and an adult population from Northern Indian
were exclusively analyzed for onset of gastric lesions.
Allele frequencies in control populations
The genotype distribution of COXs polymorphisms
following the dominant model and the variant allele
frequency is described in Tables 2–5. Briefly, there
was homogeneity among study populations for all
COX1 polymorphisms, except for the L237M between
Caucasians (P=0.012). The A allele frequency ranged
from 2 [40,47,55] to 4% [48]. In COX2, heterogeneity
was detected across the six studies evaluating the
– 899G>C SNP in Caucasians (P=0.022) and the
pooled C allele frequency ranged from 13 [40] to 22%
[35]. Likewise, the six Asiatic studies reporting
this polymorphism were also heterogeneous (P<0.001)
(2 [31,43,44] to 8% [51]). The *429T>C genetic
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Table 1 Study characterization by histological type
Study Country Ethnicity Design
Quality
(max 50) Na
Representativeness
of cases
Source of
controls
Histopathological or
endoscopic confirmation
Gene
(polymorphisms)
Main variables
addressed
Gastric precancerous lesions AIM
Pereira
et al. [35]
Portugal Caucasians Case–control 33 247 Hospital Blood
donors
All cases (EMB) COX2 ( – 899G>C) Adjustment for age and sex
Liu et al.
[36]
China Asians Case–control 33 841 Population Population
(SG/CAG)
All controls and
cases (EMB)
COX2 ( – 899G>C, –1329G>A, G587R) Adjustment and stratification for age, sex,
H. pylori infection, smoking, alcohol drinking
Canzian
et al. [53]
Venezuela Hispanics Case–control 39 1863 Population Population
(including
CG)
All controls and
cases (EMB)
COX1 (Q41Q, G213G, L237M, V481I,
IVS7+14delA, IVS7–45T>C); COX2
(IVS5–275T>G, V102V, *429T>C)
Adjustment for age, sex, H. pylori infection,
smoking, fruit and starchy intake, and other
Gastric adenocarcinoma
Pereira
et al. [35]
Portugal Caucasians Case–control 33 283 Hospital Blood
donors
All cases (EMB) COX2 ( – 899G>C) Adjustment for age and sex
Liu et al.
[36]
China Asians Case–control 33 816 Population and
hospital
Population All controls and cases
(EMB)
COX2 ( – 899G>C, –1329G>A, G587R) Adjustment and stratification for age, sex, H.
pylori infection, smoking, alcohol drinking
Zhang
et al. [31]b
China Asians Case–control — 969 — — — COX2 ( – 1423A>G, –1329G>A,
–899G>C)
—
Saxena
et al. [52]
India Indians Case–control 34 303 Hospital Hospital
(NUD)
All controls and
cases (E)
COX2 ( – 899G>C) Adjustment for age and sex; stratification for
H. pylori infection
Canzian
et al. [53]
Venezuela Hispanics Case–control 39 1169 Population (Dys) Population All controls and cases
(EMB)
COX1 (Q41Q, G213G, L237M, V481I,
IVS7+14delA, IVS7–45T>C); COX2
(IVS5–275T>G, V102V, *429T>C)
Adjustment for age, sex, H. pylori infection,
smoking, fruit and starchy intake and other
Hou et al.
[55]
Poland Caucasians Case–control 33 732 Hospital Population All cases (nt) COX1 (L237M, V481I); COX2 ( – 899G>C,
IVS5–275T>G, IVS7+111T>C, V102V,
*429T>C, *2430C>T)
Matching for age and sex; adjustment for age,
sex, smoking, family history of cancer, diet
Colon adenoma
Ulrich
et al. [37]c
USA Caucasians Case–control 36 1142 Hospital Hospital All controls and
cases (C)
COX1 (R8W, L15—L16del, P17L, L237M) Adjustment for age, sex, BMI, ethnicity,
physical activity, smoking, diet and other;
stratification for NSAIDs use
Ulrich
et al. [38]c
USA Caucasians Case–control 36 1078 Hospital Hospital All controls and
cases (C)
COX2 ( – 899G>C) Adjustment for age, sex, BMI, alcohol drinking,
smoking, diet; stratification for NSAIDs use
Ali et al.
[39]
USA Caucasians Nested
case–control
40 1505 Population Population All controls and
cases (S)
COX2 ( –798A>G, IVS5–275T>G,
*429T>C, –1462_ –1461delTG)
Matching for sex; adjustment for age, sex,
smoking and NSAIDs use; stratification for
sex, smoking, and NSAIDs use
Siezen
et al. [32]d
The
Netherlands
Caucasians Case–control 37 787 Hospital Hospital All controls and
cases (E)
COX1 (R8W, L237M); COX2 ( – 1329A>G,
V102V, *429T>C)
Adjustment for age, sex, alcohol drinking;
stratification for diet
Siezen
et al. [40]
d,e
The
Netherlands
Caucasians Case–control 37 784 Hospital Hospital All cases and
controls (E)
COX1 (R8W, L237M); COX2 ( – 1329A>G,
-899G>C, V102V, *429T>C)
Matching for age, sex and setting;
adjustment for age, gender, duration of
smoking; stratification for sex, smoking,
family history of cancer, total and fatty fish
intake
Gunter
et al. [41]e
USA Caucasians Case–control 38 475 Hospital Hospital All controls (S)
and all cases (S or C)
COX2 ( –899G>C, V102V, IVS5–275T>G,
*429T>C)
Matching for age and sex; adjustment for age,
sex, ethnicity
Lin et al.
[42]
USA African–
Americans
Case–control 35 240f/
140g
Hospital Hospital All controls and cases f
(FS) and All controls
and cases g (C)
COX2 (V511A) Matching for age, sex, and setting; adjustment
for age and sex; stratification by NSAIDs
use
Ueda et al.
[54]
Japan Asians (men) Case–control 39 1507 Hospital Hospital All controls and
cases (C)
COX2 ( – 1329G>A, –899G>C,
*1806A>G)
Adjustment for age, alcohol drinking, smoking
BMI, setting
Poole
et al. [56]c
USA Caucasians Case–control 37 1114 Hospital Hospital All controls and
cases (C)
COX1 (R8W, P17L); COX2 ( –899G>C) Adjustment for age, sex, BMI, ethnicity,
alcohol drinking, smoking, diet, NSAIDs
use; stratification for fish intake
Colon adenocarcinoma
Hamajima
et al. [43]
Japan Asians Case–control 389 Hospital Hospital All controls (E)
and cases (nt)
COX2 ( – 899G>C, –125T>C,
–163C>G)
Tan et al.
[44]
China Asians Case–control 30 2300 Hospital Population All controls (E)
and cases (CP or E)
COX2 ( – 899G>C, –1329A>G,
–1423A>G)
Adjustment for age and sex
Cox et al.
[45]
Spain Caucasians Case–control 35 566 Hospital Hospital All cases (nt) COX2 ( –899G>C, V102V, IVS5–275T>G,
*429T>C, –1423A>G, *1806A>G,
–196C>G, *2291G>A)
Matching for age and sex; adjustment for age
and sex
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Table 1 (continued)
Study Country Ethnicity Design
Quality
(max 50) Na
Representativeness
of cases
Source of
controls
Histopathological or
endoscopic confirmation
Gene
(polymorphisms)
Main variables
addressed
Landi et al.
[46]
Spain Caucasians Case–control 24 703 Hospital Hospital nt COX1 (V481I) Adjustment for age and sex
Goodman
et al. [47]
USA Caucasians
and African–
Americans
Case–control 30 511h/
315i
Hospital Hospital &
Population
nt COX1 (L237M, V481I); COX2 ( – 646C>T,
V511A)
Adjustment for age, sex; stratification for
ethnicity
Siezen
et al. [48]
The
Netherlands
Caucasians Nested
case–control
37 603 Population (PPHV) Population
(PPHV)
nt COX1 (R8W, L237M); COX2 ( –1329A>G,
V102V, *429T>C, *1806A>G)
Matching for age, sex, and setting; adjustment
for age, sex, smoking
Koh et al.
[49]
China Asians Nested
case–control
38 1487 Population Population All cases, except three
(ascertained by death
records and clinical
evidence)
COX2 ( – 899G>C) Adjustment for age, sex, BMI, smoking,
alcohol drinking, familial history of
colorectal cancer; stratification by diet
Lin et al.
[42]
USA African–
Americans
Nested
case–control
35 396 Population Population nt COX2 (V511A) Adjustment for age and sex; stratification by
NSAIDs use
Sansbury
et al. [50]e
USA African–
Americans
Case–control 31 566 Population Population nt COX2 (V511A) Matching by age and sex; adjustment for age,
sex, offset term; stratification for NSAIDs
use
Xing et al.
[51]
China Asians Case–control 30 336 Hospital Hospital All cases (nt) COX2 ( – 899G>C) Adjustment for age, sex, smoking, alcohol
drinking, and BMI; stratification for smok-
ing, alcohol drinking, and BMI
aNumber of individuals studied.
bFrom this study written in Chinese without English, French, Spanish, or Portuguese version we obtained the genotypes distribution through e-mail contact with authors. The other information was extracted directly from the
abstract.
cOverlapping data. Only the studies by Ulrich et al. [37,38] were comprised in this study (higher number of individuals genotyped).
dDuplicated data. Only the more recent and complete study [40] was included in the meta-analysis.
eSupplemental information regarding study description was collected from the cited references.
fIn University of Southern California/Kaiser study.
gIn University of North Carolina study.
hCaucasian population.
iAfrican–American population.
AIM, atrophy or intestinal metaplasia; BMI, body mass index; C, colonoscopy; CG, chronic gastritis; CP, coloprotectomy; Dys, dysplasia; E, endoscopy; EMB, endoscopic multiple biopsies; FS, flexible sigmoidoscopy;
nt, method not mentioned; NUD, nonulcer dyspepsia; PPHV, project on cardiovascular disease risk factors; S, sigmoidoscopy; SG/CAG, superficial gastritis/chronic atrophic gastritis.
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Table 2 Random effects odds ratio (unadjusted) and 95% CI estimated in this analysis following the dominant model of inheritance for
gastric precancerous lesions onset
Cases (%) Controls (%)
Polymorphism First author, year [ref]
Dominant
homozygotes
Variant allele
carriers
Dominant
homozygotes
Variant allele
carriers
Variant allele
frequency OR (95% CI)
COX1
Q41Q (A>G) Canzian et al. [53]a 752 (93) 53 (7) 957 (92) 84 (8) 0.04 0.80 (0.56–1.15)
G213G (C>A) Canzian et al. [53] 471 (59) 333 (41) 613 (58) 439 (42) 0.24 0.99 (0.82–1.19)
L237M (C>A) Canzian et al. [53]a 776 (96) 32 (4) 1020 (97) 33 (3) 0.02 1.27 (0.78–2.09)
V481I (G>A) Canzian et al. [53]a 798 (98) 12 (2) 1038 (99) 12 (1) 0.01 1.30 (0.58–2.91)
IVS7–45T>C Canzian et al. [53] 404 (52) 369 (48) 513 (51) 496 (49) 0.29 0.94 (0.78–1.14)
IVS7+14delA Canzian et al. [53] 472 (61) 307 (39) 618 (60) 406 (40) 0.23 0.99 (0.82–1.20)
COX2
–1329G>A Liu et al. [36] 106 (26) 308 (74) 105 (25) 322 (75) 0.50 0.95 (0.69–1.29)
– 899G>C Liu et al. [36] 373 (90) 41 (10) 384 (90) 43 (10) 0.05 0.98 (0.63–1.54)
Pereira et al. [35] 27 (73) 10 (27) 130 (62) 80 (38) 0.22 0.60 (0.28–1.31)
Pooled OR 0.86 (0.56–1.32)
IVS5–275T>G Canzian et al. [53] 467 (61) 299 (39) 611 (61) 392 (39) 0.22 1.00 (0.82–1.21)
V102V (G>C) Canzian et al. [53]a 619 (77) 183 (23) 839 (80) 214 (20) 0.11 1.16 (0.93–1.45)
G587R (G>A) Liu et al. [36] 379 (96) 14 (4) 384 (94) 23 (6) 0.03 0.62 (0.31–1.22)
*429T>C Canzian et al. [53] 332 (42) 468 (58) 398 (38) 644 (62) 0.38 0.87 (0.72–1.05)
aContact with authors (through e-mail) was established to recover the discriminated genotypes distribution.
CI, confidence interval; OR, odds ratio.
Table 3 Random effects odds ratio (unadjusted) and 95% CI estimated in this analysis following the dominant model of inheritance for
gastric cancer onset
Cases (%) Controls (%)
Polymorphism First author, year [ref]
Dominant
homozygotes
Variant allele
carriers
Dominant
homozygotes
Variant allele
carriers
Variant allele
frequency OR (95% CI)
COX1
Q41Q (A>G) Canzian et al. [53]a 107 (95) 6 (5) 957 (92) 84 (8) 0.04 0.64 (0.27–1.50)
G213G (C>A) Canzian et al. [53] 72 (63) 42 (37) 613 (58) 439 (42) 0.24 0.81 (0.55–1.21)
L237M (C>A) Canzian et al. [53]a 112 (97) 3 (3) 1020 (97) 33 (3) 0.02 0.83 (0.25–2.74)
Hou et al. [55] 292 (96) 13 (4) 402 (97) 14 (3) 0.02 1.28 (0.59–2.76)
Pooled OR 1.13 (0.59–2.15)
V481I (G>A) Canzian et al. [53]a 113 (97) 3 (3) 1038 (99) 12 (1) 0.01 2.30 (0.64–8.26)
Hou et al. [55] 317 (99) 4 (1) 429 (99) 3 (1) 0.00 1.80 (0.40–8.12)
Pooled OR 2.08 (0.78–5.50)
IVS7–45T>C Canzian et al. [53] 58 (52) 53 (48) 513 (51) 496 (49) 0.29 0.95 (0.64–1.40)
IVS7+14delA Canzian et al. [53] 72 (66) 37 (34) 618 (60) 406 (40) 0.23 0.78 (0.52–1.19)
COX2
–1423A>G Zhang et al. [31] 283 (88) 40 (12) 592 (92) 54 (8) 0.04 1.55 (1.01–2.39)c
–1329G>A Liu et al. [36] 73 (19) 316 (81) 105 (25) 322 (75) 0.50 1.41 (1.01–1.98)b,c
Zhang et al. [31] 32 (10) 291 (90) 136 (21) 510 (79) 0.52 2.43 (1.61–3.66)c
Pooled OR 1.83 (1.07–3.10)c
–899G>C Liu et al. [36] 346 (89) 42 (11) 384 (90) 43 (10) 0.05 1.08 (0.69–1.70)b
Zhang et al. [31] 288 (89) 35 (11) 620 (96) 26 (4) 0.02 2.90 (1.71–4.91)c
Pereira et al. [35] 36 (49) 37 (51) 130 (62) 80 (38) 0.22 1.67 (0.98–2.86)
Saxena et al. [52] 14 (23) 48 (77) 171 (71) 70 (29) 0.16 8.38 (4.34–16.16)c
Hou et al. [55] 210 (72) 80 (28) 288 (70) 121 (30) 0.16 0.91 (0.65–1.27)
Pooled OR 2.02 (1.00–4.10)c,d
IVS5–275T>G Canzian et al. [53] 72 (67) 36 (33) 611 (61) 392 (39) 0.22 0.78 (0.51–1.19)
Hou et al. [55] 218 (70) 93 (30) 298 (71) 123 (29) 0.16 1.03 (0.75–1.42)
Pooled OR 0.93 (0.71–1.21)
V102V (G>C) Canzian et al. [53]a 83 (72) 32 (28) 839 (80) 214 (20) 0.11 1.51 (0.98–2.3)
Hou et al. [55] 230 (76) 72 (24) 285 (70) 125 (30) 0.16 0.71 (0.51–1.00)
Pooled OR 1.03 (0.49–2.14)d
G587R (G>A) Liu et al. [36] 368 (95) 18 (15) 384 (94) 23 (6) 0.03 0.82 (0.43–1.54)b
*429T>C Canzian et al. [53] 53 (49) 56 (51) 398 (38) 644 (62) 0.38 0.65 (0.44–0.97)c
Hou et al. [55] 137 (45) 167 (55) 165 (40) 251 (60) 0.36 0.80 (0.59–1.08)
Pooled OR 0.74 (0.59–0.94)c
IVS7+111T>C Hou et al. [55] 221 (74) 78 (26) 307 (73) 114 (27) 0.15 0.95 (0.68–1.33)
*2430C>T Hou et al. [55] 289 (94) 19 (6) 399 (98) 10 (2) 0.01 2.62 (1.20–5.73)c
aContact with authors (through e-mail) was established to recover the discriminated genotypes distribution.
bDysplasia and gastric adenocarcinoma pooled together.
cStudies with statistical significant results (P<0.05).
dHeterogeneity detected across studies (P<0.05).
CI, confidence interval; OR, odds ratio.
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variation also showed heterogeneity among Caucasians
(P<0.001) [39–41,45,48,55]. The study developed by
Gunter et al. [41] revealed a *429C allele distribution
outside the ones observed in the other five studies
(65% vs. 30–36%, P<0.001). The – 1423A>G and
– 1329G>A were detected at a higher frequency among
Caucasians than in Asiatic populations (17 [45] vs. 5%
[31,44], for – 1423G allele, P<0.001 and 79 [40,48]
versus 51% [31,36,44,54] for – 1329A allele, P<0.001).
With the exception of V511A [47] and – 646C>G [47]
COX2 SNPs in Caucasians, and *1806A>G in a Japanese
population [54], all the other genetic variations are
present, by definition, in at least 1% of the population
[67]. Through the different studies, all polymorphisms
were in HWE but the IVS5 – 275T>G COX2 SNP
characterized by Ali et al. [39].
Gastric carcinogenesis and COX polymorphisms
Fifteen COX polymorphisms were assessed for their role
in gastric carcinogenesis. In Tables 2 and 3, the random-
effect ORs following the dominant genetic model for
each polymorphism on the risk of gastric lesions is
summarized. No publication bias was evident for COXs
polymorphisms in gastric lesions.
Risk of gastric precancerous lesions
Estimated risk of COX1 polymorphisms: only the study by
Canzian et al. [53] reported the involvement of COX1
polymorphisms in AIM development. No statistically
significant association was observed for any of the six
polymorphisms.
Estimated risk of COX2 polymorphisms: the – 899G>C
was the only COX2 polymorphism addressed in more than
one study. No heterogeneity between the two studies was
observed, although different ethnic populations were
studied [35,36]. No modified risk for AIM was noticed for
– 899C allele carriers. It should be mentioned that three
COX2 SNPs: G587R, V102V, and *429T>C showed
association trends for AIM onset.
Table 4 Random effects odds ratio (unadjusted) and 95% CI estimated in this analysis following the dominant model of inheritance for
colorectal adenoma onset
Cases (%) Controls (%)
Polymorphism
First author,
year [ref]
Dominant
homozygotes
Variant allele
carriers
Dominant
homozygotes
Variant allele
carriers
Variant allele
frequency OR (95% CI)
COX1
L15_L16del Ulrich et al. [37] 510 (98) 11 (2) 616 (99) 5 (1) 0.00 2.66 (0.92–7.70)
R8W (C>T) Siezen et al. [40]a 334 (90) 39 (10) 339 (87) 53 (14) 0.07 0.75 (0.48–1.16)
Ulrich et al. [37] 445 (85) 76 (15) 539 (87) 82 (13) 0.07 1.12 (0.80–1.57)
Pooled OR 0.94 (0.63–1.40)
L237M (C>A) Siezen et al. [40]a 300 (96) 14 (4) 332 (97) 12 (3) 0.02 1.29 (0.59–2.84)
Ulrich et al. [37] 493 (95) 28 (5) 585 (94) 36 (6) 0.03 0.92 (0.56–1.53)
Pooled OR 1.02 (0.66–1.56)
P17L Ulrich et al. [37] 451 (87) 70 (13) 527 (85) 94 (15) 0.08 0.87 (0.62–1.22)
COX2
–1462_ –1461delTG Ali et al. [39] 702 (96) 32 (4) 704 (94) 45 (6) 0.03 0.71 (0.45–1.14)
– 1329G>A Siezen et al. [40] 22 (6) 349 (94) 16 (4) 377 (96) 0.80 0.67 (0.35–1.30)
Ueda et al. [54] 106 (23) 349 (77) 227 (22) 725 (78) 0.53 0.91 (0.70–1.18)
Pooled OR 0.87 (0.68–1.11)
– 899G>C Siezen et al. [40]a,b 237 (70) 100 (30) 274 (74) 94 (26) 0.13 1.23 (0.88–1.71)
Gunter et al. [41] 151 (72) 59 (28) 141 (72) 55 (28) 0.15 1.00 (0.65–1.54)
Ulrich et al. [38] 344 (70) 150 (30) 405 (69) 179 (31) 0.17 0.99 (0.76–1.28)
Ueda et al. [54] 440 (97) 15 (3) 989 (94) 62 (6) 0.03 0.54 (0.31–0.97)c
Pooled OR 0.96 (0.74–1.25)
–798A>G Ali et al. [39] 490 (66) 251 (34) 493 (66) 257 (34) 0.19 0.98 (0.79–1.22)
IVS5–275T>G Ali et al. [39] 534 (71) 213 (29) 530 (70) 223 (30) 0.17 0.95 (0.76–1.18)
Gunter et al. [41] 149 (71) 61 (29) 136 (69) 61 (31) 0.16 0.91 (0.60–1.40)
Pooled OR 0.94 (0.77–1.15)
V102V (G>C) Siezen et al. [40]a 284 (74) 100 (26) 267 (66) 136 (34) 0.19 0.69 (0.51–0.94)c
Gunter et al. [41] 154 (73) 56 (27) 142 (72) 55 (28) 0.15 0.94 (0.61–1.45)
Pooled OR 0.77 (0.58–1.03)
V511A (T>C) Lin et al. [42]a
USS/K study
113 (95) 6 (5) 109 (90) 12 (10) 0.05 0.48 (0.17–1.33)
Lin et al. [42]a UNC
study
39 (93) 3 (7) 88 (90) 10 (10) 0.05 0.68 (0.18–2.60)
Pooled OR 0.55 (0.24–1.23)
*429A>G Siezen et al. [40] 159 (42) 219 (58) 196 (50) 200 (50) 0.30 1.35 (1.02–1.79)c
Gunter et al. [40] 30 (14) 180 (86) 18 (9) 179 (91) 0.65 0.60 (0.32–1.12)
Ali et al. [39] 311 (41) 438 (58) 347 (46) 409 (54) 0.33 1.19 (0.97–1.47)
Pooled OR 1.11 (0.82–1.51)
*1806A>G Ueda et al. [54] 451 (99) 4 (1) 1042 (99) 9 (1) 0.00 1.03 (0.31–3.35)
aContact with authors (through e-mail) was established to recover the discriminated genotypes distribution.
bGenotype distributions given by the author. These frequencies do not overlap with the ones presented in the original paper.
cStudies with statistical significant results (P<0.05).
CI, confidence interval; OR, odds ratio; UNC, University of North Carolina study; USC/K, University of Southern California/Kaiser study.
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Risk of gastric adenocarcinoma
Estimated risk of COX1 polymorphisms: the two studies
evaluating the L237M and V481I COX1 polymorphisms
were homogeneous, although reporting two different
ethnical populations [53,55]. No statistically significant
results were observed.
Estimated risk of COX2 polymorphisms: considering only
functionally expected polymorphisms (see table B of the
Supplementary data), the analysis of – 899G>C re-
vealed heterogeneity across studies that could not be
explained even after data stratification by ethnicity. A
2.02-fold impact was observed for – 899C allele carriers
(95% CI: 1.00–4.10, Pheterogeneity< 0.001). Likewise, the
– 1329G>A COX2 polymorphism conferred an increased
susceptibility of 1.83 (95%CI: 1.07–3.10) in A allele
carriers and of 2.18 among AA genotype carriers (95% CI:
1.36–3.49) for GC development. Interestingly, not only
Table 5 Random effects odds ratio (unadjusted) and 95% CI estimated in this analysis following the dominant model of inheritance for
colorectal cancer onset
Cases (%) Controls (%)
Polymorphism First author, year [ref]
Dominant
homozygotes
Variant allele
carriers
Dominant
homozygotes
Variant allele
carriers
Variant allele
frequency OR (95% CI)
COX1
R8W (C>T) Siezen et al. [48]a 168 (84) 33 (16) 335 (86) 56 (14) 0.08 1.18 (0.74–1.88)
L237M (C>A) Siezen et al. [48]a 182 (96) 8 (4) 348 (92) 31 (8) 0.04 0.49 (0.22–1.10)
Goodman et al. [47]
(Caucasians)
161 (90) 17 (10) 309 (96) 14 (4) 0.02 2.33 (1.12–4.85)b
Goodman et al. [47]
(African–Americans)
113 (99) 1 (1) 184 (96) 7 (4) 0.02 0.23 (0.03–1.92)
Pooled OR (Caucasians) 1.08 (0.23–4.98)
V481I (G>A) Landi et al. [46] 280 (99) 3 (1) 265 (98) 5 (2) 0.01 0.57 (0.13–2.40)
Goodman et al. [47]
(Caucasians)
173 (98) 3 (2) 324 (98) 6 (2) 0.01 0.94 (0.23–3.79)
Goodman et al. [47]
(African–Americans)
115 (100) 0 (0) 196 (99) 1 (1) 0.00 —
Pooled OR (Caucasians) 0.73 (0.27–2.00)
COX2
–1423A>G Cox et al. [45] 201 (73) 76 (27) 181 (70) 78 (30) 0.17 0.88 (0.60–1.28)
Tan et al. [44] 914 (91) 86 (9) 1180 (91) 120 (9) 0.05 0.93 (0.69–1.24)
Pooled OR 0.91 (0.72–1.14)
– 1329G>A Siezen et al. [48] 10 (5) 186 (95) 20 (5) 371 (95) 0.79 1.00 (0.46–2.19)
Tan et al. [44] 178 (18) 822 (82) 300 (23) 1000 (77) 0.50 1.39 (1.13–1.70)b
Pooled OR 1.36 (1.11–1.66)b
–899G>C Cox et al. [45] 150 (68) 70 (32) 170 (66) 87 (34) 0.19 0.91 (0.62–1.34)
Koh et al. [49]a 273 (88) 37 (12) 1067 (91) 110 (9) — 1.31 (0.89–1.95)
Hamajima et al. [43] 140 (95) 8 (5) 230 (95) 11 (5) 0.02 1.19 (0.47–3.04)
Tan et al. [44] 919 (92) 81 (8) 1237 (95) 63 (5) 0.02 1.73 (1.23–2.43)b
Xing et al. [51] 119 (87) 18 (13) 169 (85) 30 (15) 0.08 0.85 (0.45–1.60)
Pooled OR 1.21 (0.90–1.61)
Pooled OR (Asians) 1.35 (1.01–1.81)b
–646C>T Goodman et al. [47]a
(Caucasians)
175 (99) 1 (1) 331 (100) 1 (0) 0.00 1.89 (0.12–30.42)
Goodman et al. [47]a
(African–Americans)
104 (91) 10 (9) 181 (91) 17 (9) 0.04 1.02 (0.45–2.32)
Pooled OR 1.08 (0.49–2.36)
– 196C>G Cox et al. [45]a 280 (97) 10 (3) 263 (98) 6 (2) — 1.57 (0.56–4.37)
– 125T>G Hamajima et al. [43] 141 (97) 5 (3) 230 (97) 7 (3) 0.01 1.17 (0.36–3.74)
IVS5–275T>G Cox et al. [45] 187 (64) 103 (36) 174 (64) 97 (36) 0.20 0.99 (0.70–1.40)
V102V (G>C) Cox et al. [45] 180 (62) 110 (38) 183 (67) 89 (33) 0.18 1.26 (0.89–1.78)
Siezen et al. [48] 142 (70) 61 (30) 287 (72) 111 (28) 0.15 1.11 (0.77–1.61)
Pooled OR 1.19 (0.92–1.53)
V511A (T>C) Goodman et al. [47]a
(Caucasians)
177 (100) 0 (0) 329 (100) 0 (0) 0.00 —
Goodman et al. [47]a
(African–Americans)
109 (95) 6 (5) 186 (93) 14 (7) 0.04 0.73 (0.27–1.96)
Lin et al. [42]a 129 (93) 9 (7) 237 (92) 21 (8) 0.04 0.79 (0.35–1.77)
Sansbury et al. [50] 223 (93) 17 (7) 292 (90) 34 (10) 0.05 0.65 (0.36–1.20)
Pooled OR 0.71 (0.46–1.09)
*429A>G Cox et al. [45]a 140 (48) 150 (52) 126 (47) 145 (53) 0.31 0.93 (0.67–1.30)
Siezen et al. [48] 97 (48) 103 (52) 190 (49) 198 (51) 0.30 1.02 (0.72–1.43)
Pooled OR 0.97 (0.77–1.23)
*1806A>G Cox et al. [45]a 257 (91) 24 (9) 258 (96) 10 (4) — 2.41 (1.13–5.14)b
Siezen et al. [48]a 194 (97) 5 (3) 368 (95) 21 (5) 0.03 0.45 (0.17–1.22)
Pooled OR 1.08 (0.21–5.56)c
*2291G>A Cox et al. [45]a 245 (92) 20 (8) 241 (96) 10 (4) — 1.97 (0.90–4.29)
aContact with authors (through e-mail) was established to recover the discriminated genotypes distribution.
bStudies with statistical significant results (P<0.05).
cHeterogeneity detected across studies (P<0.05).
CI, confidence interval; OR, odds ratio.
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were these two polymorphisms associated with GC in
normal individuals, but also, when pooled together,
seemed to potentiate the progression into malignant
lesions in patients with AIM (OR=1.47; 95% CI: 1.00–
2.16) (Fig. 2). The *429T>C analysis revealed that
C allele carriers were more protected for GC onset
(OR=0.74; 95% CI: 0.59–0.94). Furthermore, when
addressing the risk-associated genotypes of the three
polymorphims mentioned above, ( – 1329A allele, – 899C
allele, and *429TT genotype), the pooled analysis
revealed an increased susceptibility for GC (OR=1.77;
95% CI: 1.25–2.50, Pheterogeneity< 0.001) (Fig. 2). The
lack of homogeneity, not explained after an ethnicity-
based subanalysis, was dissolved within population-based
studies (OR=1.21; 95% CI: 1.01–1.46) [36,53,55].
For the nonfunctional expected V102V polymorphism
the two reported studies seemed to be heterogeneous
(Pheterogeneity = 0.007), showing strong opposing trends
that might be explained as both studies were developed
in different ethnical populations. The – 1423A>G and
*2430C>T noncoding region polymorphisms, addressed
only once by Zhang et al. [31] and by Hou et al. [55],
respectively, revealed an increased risk of GC.
Colorectal carcinogenesis and COX polymorphisms
A total of 19 COX polymorphisms were considered
throughout 16 studies [37–51,54] assessing their impact
on colorectal carcinogenesis. Five were identified within
the coding region of COX1 and 14 throughout COX2 gene.
The random-effect ORs, under the dominant genetic
model, for the onset of colorectal lesions are characterized
in Tables 4 and 5. We did not observe any obvious
publication bias for either COX1 or COX2 polymorphisms
in colorectal tumors.
Risk of colorectal adenoma
Estimated risk of COX1 polymorphisms: the studies by
Ulrich et al. [37] and Siezen et al. [40] addressed,
altogether, four COX1 polymorphisms (L15_L16del,
R8W, P17L and L237M) in colorectal adenoma. For the
functional expected polymorphisms, R8W, P17L, and
L237M polymorphisms [68–71], no genetic effect was
observed. The L15_L16del COX1 polymorphism,
although characterized only once in the study by Ulrich
et al. [37], it seemed to increase the risk of colorectal
adenoma, although not reaching the significance level.
Estimated risk of COX2 polymorphisms: nine COX2 poly-
morphisms ( –1462_–1461delTG, –1329G>A, –899G>
C, – 798A>G, IVS5 – 275T>G, V102V, V511A,
*429T>C, and *1806A>G) were appraised for colo-
rectal adenoma in a total of six studies [38–42,54]. Only
the pooled data for the V102V and V511A suggested a
protective trend for colorectal adenoma. Excluding the
study by Gunter et al. [41] from the pooled analysis of
*429T>C COX2 polymorphism, (C allele frequency very
different from all the others in the control populations)
we detected an OR of 1.25 (95% CI: 1.06–1.47) in C
allele carriers. No influence on adenoma onset suscept-
ibility was noticed for the – 899G>C and – 1329G>A
COX2 polymorphisms. The sensibility was tested by
omitting the study by Ali et al. [39] from the
IVS5 – 275G>Tanalysis. No change in the SNP behavior
was observed.
Risk of colorectal cancer
Estimated risk of COX1 polymorphisms: three studies
characterized COX1 polymorphisms [46–48]. No gene–
disease association was noticed for both R8W and V481I
COX1 coding region SNPs. Contradictory data were
presented in the individual studies assessing L237M
SNP in Caucasians [47,48]. Owing to the limited number
of studies we were not able to identify the source of
heterogeneity among studies (Pheterogeneity = 0.006).
Estimated risk of COX2 polymorphisms: nine studies were
conducted in Caucasian, African–American, or Asiatic
populations, gathering a total of 12 COX2 polymorphisms
examined [42–45,47–51]. The overall random-effect OR
for – 899G>C polymorphism was 1.21 (95% CI:
0.90–1.6). This value achieved statistical significance in
Asiatic populations (OR=1.35; 95% CI: 1.01–1.81)
[43,44,49,51]. A 1.36-fold increased risk of CRC devel-
opment was also observed for the – 1329G>A poly-
morphism (95% CI: 1.11–1.66). The *429T>C
polymorphism which was associated with increased risk
of colorectal adenoma, did not seem to play any role in
the development of CRC. Strong heterogeneity was
detected across the two studies [45,48] enrolled invol-
ving *1806A>G polymorphism (Pheterogeneity = 0.004).
Several study characteristics could be used to explain this
lack of homogeneity, but the limited number of studies
restricted the interpretation of this heterogeneity. The
V511A COX2 polymorphism, only identified in African–
Americans, showed a protective tendency for CRC. All
the other genetic variations did not alter the suscept-
ibility to developed CRC, although the *2291G>A SNP,
assessed once by Cox et al. [45], showed a strong
increased risk trend for cancer.
No single study addressed the CRC risk onset in
colorectal adenoma patients.
Discussion
In November 2002, Lin et al. [42] reported the first study
addressing COX polymorphisms in the susceptibility for
CRC onset. Nearly 6 years later, more than 20 studies
were developed gathering a total of 26 COX polymorph-
isms appraised in gastrointestinal tumors: nine in COX1
and 17 in COX2 genes [31,35–55]. Now, do we have
conclusive results that could lead to clinical reasoning
or research?
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Fig. 2
Study
or sub-category
OR (random)
95% CI
OR (random)
95% CI
01 Role of –899G>C in GC onset
 Liu et al. [36] (2006)
 Zhang et al. [31] (2006)
 Pereira et al. [35] (2006)
 Hou et al. [55] (2007)
 Saxena et al. [52] (2008)
Subtotal (95% CI)
1.08 [0.69, 1.70]
2.90 [1.71, 4.91]
1.67 [0.98, 2.86]
0.91 [0.65, 1.27]
8.38 [4.34, 16.16]
2.02 [1.00, 4.10]
1.41 [1.01, 1.98]
2.43 [1.61, 3.66]
1.83 [1.07, 3.10]
0.80 [0.59, 1.08]
0.65 [0.44, 0.97]
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1.49 [1.06, 2.09]
2.78 [1.18, 6.55]
1.47 [1.00, 2.16]
1.08 [0.69, 1.70]
1.41 [1.01, 1.98]
2.90 [1.71, 4.91]
2.43 [1.61, 3.66]
1.67 [0.98, 2.86]
0.91 [0.65, 1.27]
1.25 [0.93, 1.68]
1.53 [1.03, 2.28]
8.38 [4.34, 16.16]
1.77 [1.25, 2.50]
04 Role of –899C allele and –1329A allele and ∗429TT genotype in GC onset
 Liu et al. [36] (2006) (–899G>C)
 Liu et al. [36] (2006) (–1329G>A)
 Zhang et al. [31] (2006) (–899G>C)
 Zhang et al. [31] (2006) (–1329G>A)
 Pereira et al. [35] (2006) (–899G>C)
 Hou et al. [55] (2007) (–899G>C)
 Hou et al. [55] (2007) (∗429TT)
 Canzian et al. [53] (2008) (∗429TT)
 Saxena et al. [52] (2008) (–899G>C)
Subtotal (95% CI)
05 Role of –899G>C and –1329A in the progression from AIM to GC
 Liu et al. [36] (2006) (–899G>C)
 Liu et al. [36] (2006) (–1329G>A)
 Pereira et al. [35] (2006) (–899G>C)
Subtotal (95% CI)
02 Role of –1329G>A in GC onset
 Liu et al. [36] (2006)
 Zhang et al. [31] (2006)
Subtotal (95% CI)
03 Role of ∗429T>C in GC onset
 Hou et al. [55] (2007)
 Canzian et al. [53] (2008)
Subtotal (95% CI)
Test for heterogeneity: χ2 = 43.21, df = 4 (P < 0.00001), I2 = 90.7%
Test for overall effect: Z = 1.96 (P = 0.05)
Test for heterogeneity: χ2 = 4.00, df = 1 (P = 0.05), I2 = 75.0%
Test for overall effect: Z = 2.22 (P = 0.03)
Test for heterogeneity: χ2 = 0.65, df = 1 (P = 0.42), I2 = 0%
Test for overall effect: Z = 2.43 (P = 0.02)
Test for heterogeneity: χ2 = 50.06, df = 8 (P < 0.00001), I2 = 84.0%
Test for overall effect: Z = 3.25 (P = 0.001)
Test for heterogeneity: χ2 = 3.59, df = 2 (P = 0.17), I2 = 44.3%
Test for overall effect: Z = 1.98 (P = 0.05)
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Forest plot describing the random effect ORs and 95% CI from studies assessing the association between COX2 functional expected
polymorphisms in gastric carcinogenesis: (01) role of – 899G>C polymorphism in gastric cancer (GC) onset; (02) role of – 1329G>A
polymorphism in GC onset; (03) role of *429T>C polymorphism at GC onset; (04) role of – 899C, –1329A alleles and *429TT genotype pooled
together in GC development and (05) role of – 899G>C and –1329G>A polymorphisms in GC onset in patients with atrophy and/or intestinal
metaplasia (AIM). All analysis followed the dominant genetic model. I2 and P value for w2 of heterogeneity is reported for each group analysis. CI,
confidence interval; OR, odds ratio.
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Role of COX polymorphisms in gastric carcinogenesis
The different roles that COX-1 and COX-2 enzymes
portray, COX-1 associated with housekeeping functions
and COX-2 with inflammation and tumor development
[19], may explain the effort disparity to assess COX1 or
COX2 polymorphisms in gastric and colorectal tumors.
COX-1 enzyme in stomach is involved in the protection
and maintenance of gastric mucosa [19]; therefore it
would be interesting to appraise the involvement of COX1
polymorphisms in the development of gastric lesions,
since it was only assessed in two studies [53,55].
In gastric carcinogenesis, polymorphisms in COX2 gene
seemed to differently influence the genetic susceptibility
according to the type of gastric lesions assessed (AIM or
GC). Despite the publishing of four papers since last year
[52,53,55,57], the restricted number of studies included in
this analysis (n=6) [31,35,36,52,53,55] only allowed us to
draw some remarks and not strong conclusions. Two of the
most studied polymorphisms in the promoter region of
COX2 gene ( – 1329G>A and – 899G>C) seemed to be
associated with susceptibility for gastric cancer onset.
The – 1329A allele was associated with a 1.83-fold
increased risk of gastric cancer in approximately 1800
Asiatic individuals. In the study carried out by Liu et al.
[36], the increased susceptibility was even higher in
individual carriers of – 1329AA genotype positives for
H. pylori infection (OR=3.88; 95% CI: 1.46–10.34) or
smokers (OR=7.02; 95% CI: 2.19–22.48). Furthermore,
although not addressed in the original study, this
polymorphism also seemed to be involved in the
development of gastric cancer in patients with intestinal
metaplasia (OR=1.49; 95% CI: 1.06–2.09). All these
associations can be biologically supported, because the
– 1329A allele creates a core recognition sequence for
the c-MYB nuclear transcription factor resulting in higher
transcription activity of COX2 as it was proved in the
study by Zhang et al. [27]. Further studies focusing
different ethnical population are important to understand
whether this polymorphism behavior is ethnic-specific, as
the only study addressed in adult Caucasians [48] did not
show any impact on gastrointestinal cancer onset. These
should also address several confounding factors like age,
sex, H. pylori infection, and smoking status.
The most studied COX2 genetic variation, – 899G>C,
revealed an increased risk behavior associated with the
development of GC in the normal population (OR=2.02;
95% CI: 1.00–4.10), although strong heterogeneity was
reported that could not be interpreted even after ethnicity
and type of controls stratification. From the study by Liu
et al. [36], we defined individuals with superficial gastritis
and chronic atrophic gastritis as belonging to the nonlesions
control group. This may not be the best approach since
these lesions might already have some resemblances with
malignant tumors, thus explaining the nonassociation result
observed in this individual study. Another study worth
mentioning is the one by Saxena et al. [52] where we
observed a nine-fold increased risk of GC in a Northern
Indian population. This value was significantly higher than
all other ethnical populations addressed, suggesting that
the contribution of genetic polymorphims may be depen-
dent on the population being studied, as well as on several
environmental and dietary factors that influence that
population [72]. The molecular mechanism and the
biological impact of this polymorphism in cancer develop-
ment are surrounded by controversy. First characterized by
Papafili et al. [73] is recognized as functional polymorphism
because the transversion from a guanine (G) to a cytosine
(C) in the promoter region of COX2 gene might inhibit the
binding of the Sp1 positive transcription factor resulting in
a reduction of the promoter activity. In contrast, Szczeklik
et al. [74] reported that monocytes from –899CC genotype
carriers had a 10-fold increase in the production of PG. In
addition, Zhang et al. [27] also observed that heterozygous
individuals seemed to have a higher COX2 mRNA
expression although not being statistically significant. The
latter results could be explained as the – 899C allele,
besides eliminating a Sp1 recognition binding site, also
creates and E2F homology binding region, based on
bioinformatic programmes, that could lead to a higher
transcription activity [27,74]. All of these findings suggest
that different cell types under different physiological
conditions could determine the –899G>C behavior by
the binding of specific nuclear proteins to the promoter
region [31]. Therefore, further functional studies in gastric
tumors are required to elucidate the molecular mechanism
involving the – 899C allele in gastric carcinogenesis. Unlike
most of the SNPs addressed, the *429T>C COX2 SNP
seemed to play a protective role in both AIM and GC
development. When pooling all these three polymorphisms
with functional impact on the genetic susceptibility,
according to the risk-associated genotypes, increasing the
number of studies involved, we observed a nearly two-fold
increased risk of gastric cancer onset. Although this
warrants further studies, future investigations should focus
on the combined influence, haplotype analysis of the
– 1329G>A, – 899G>C, and *429T>C COX2 poly-
morphisms. Besides playing a role in gastric cancer onset in
normal adults without expected gastric lesions, the
– 899G>C and – 1329G>A SNPs (pooled together) also
showed a gene–disease interaction in patients with AIM. If
confirmed by further researches, these polymorphims could
allow the identification of higher-risk individuals for gastric
cancer development that may beneficiate from chemopre-
ventive and/or follow-up strategies.
Role of COX polymorphisms in colorectal
carcinogenesis
We can safely say that CRC is one of the most studied
models for unraveling the role of COX enzymes in several
key steps of carcinogenesis [75]. Nowadays, it is well
established that COX-2 plays a pivotal role in early
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colorectal carcinogenesis and that the use of NSAIDs,
like aspirin, is associated with decreased risk for adenoma
and CRC onset and recurrence [76–79].
All the polymorphisms in COX1 gene were investigated in
over 1000 individuals. Only the L15_L16del had any
impact on the genetic susceptibility presenting a strong
increased risk trend for colorectal adenoma onset in
approximately 1200 Caucasians in a hospital-based study
carried out by Ulrich et al. [37]. Curiously, this increased
susceptibility is even more evident in nonregular users
(OR=8.58; 95% CI: 1.07–68.94) and annulled in regular
users of NSAIDs (OR=1.08; 95% CI: 0.24–4.87),
confirming that at least part of the anti-inflammatory
tumor protective effects of NSAIDs are because of COX
inhibition [16]. The remaining polymorphisms expected
to have an impact on COX-1 function, following the
sequence homology-based software programmes predic-
tions [68,69], did not show any association. An interesting
heterogeneity was detected among the two Caucasian
studies addressing the L237M polymorphism [47,48]
revealing opposing estimates. Owing to the restricted
number of studies we did not have the capacity to
scrutinize the characteristic that could explain this
heterogeneity, as they diverge in several features (demo-
graphic origin, study design, number of participants). We
will have to wait for further studies to unravel the true
meaning of this SNP in CRC development.
COX-2 is the inducible isoform of COX enzymes [19].
Unlike COX-1 that is constitutively expressed in most
tissues, COX-2 expression is mainly regulated at tran-
scription level, although posttranscriptional level regula-
tion (COX2 mRNA stability) also seems to influence
COX-2 expression [80,81]. COX2 promoter region has
several recognition sites for nuclear proteins, including
Sp1, c-MYB, NF-kB, AP1, TATA [80]. Therefore, it is
not surprising that eight of the fourteen COX2
polymorphisms analyzed for colorectal lesions onset
belong to the promoter region ( – 1462_ – 1461delTG,
– 1423A>G, – 1329G>A, – 899G>C, – 798A>G,
– 646C>T, – 196C>G, – 125T>G), one to the
intronic region (IVS5 – 275T>G), two to the coding
regions (V102V and V511A) and three to the 30 untrans-
lated region (*429T>C, *1806A>G, *2291G>A).
Seven COX2 polymorphisms, – 1329G>A, – 899G>C,
IVS5–275T>G, V102V, V511A, *429T>C and
*1806A>G, were investigated in both adenoma and CRC
susceptibility, and all of them, except for the
IVS5–275T>G and V511A, seemed to have a histological
type-dependent behavior.
The V511A polymorphism, identified only in African–
Americans, revealed a nonsignificant histological-type
independent protection for colorectal tumors. This lack
of association was possibly due to the low frequency of
511A variant (5%). The in vitro functional characterization
of this polymorphism, that leads to an amino acid change
close to COX-2 active site, did not revealed any allele
differences in the enzyme kinetic parameters (Vma´x and
Km) or stability for arachidonic acid utilization [42]
Nevertheless, this absence of functional differences
between alleles could be limited by conditions in vitro,
as mentioned by Lin et al. [42].
The pooled analysis for the – 899G>C COX2 polymorph-
ism revealed an increased risk association for CRC
development in Asiatic adults, although this was
not noticed in all individual studies [43,51]. Never-
theless, these studies had a low number of participants
(B350) and as the frequency of this polymorphism is
very low in Asiatic populations (2 to 8%), the lack of
association may represent low statistical power and
confidence level. Likewise, the – 1329G>A genetic
variation also revealed an increased risk of CRC, although
it was considered only in the study by Tan et al. [44]
which gathered a total of 2300 Asiatic individuals
following a population-based design ensuring a statisti-
cally significant result. In Caucasians, we did not have
enough statistical power to detect any association for
either polymorphism. Both polymorphims seemed to
have the same increased risk behavior, independent of
the tumor locations, but only associated with the more
severe forms of gastrointestinal lesions (GC and CRC).
In contrast, the *429T>C and V102V COX2 polymorph-
isms seemed to influence the development of colorectal
lesions in early stages of carcinogenesis. The *429T>C
SNP, associated with protection for GC development,
in colorectal lesions exposed a 1.25-fold increased risk
of adenoma onset in Caucasians, suggesting an organ-
specific involvement. The thymine (T) to cytosine (C)
exchange in an AU-rich elements region, known to
influence mRNA degradation [81], could enhance the
stability of mRNA transcripts that could ultimately lead
to an increased PG production [39,82]. This biologic
assumption seems to support our outcome in colon, but
as, so far, no study has functionally characterized this
SNP we can only wait for future evidences. Such a clear
association for adenoma development was not detected
but instead a protective trend was noticed with the
synonymous V102V polymorphism. Further and larger
studies are necessary to elucidate this relationship.
The low-frequency *1806G allele identified in the 30
untranslated region of exon 10 is believed to have an
impact on mRNA COX2 stability through the addition of
some poly-A tail to the mRNA, generating a longer and
more stable mRNA [45]. Conflicting results were
observed between the two individual studies [45,48]
carried out with this polymorphism. Owing to the limited
number of studies we were not able to identify the source
of heterogeneity, although they only seemed to diverge in
one feature. The study by Cox et al. [45] had a hospital-
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based design and in contrast the study by Siezen et al.
[48] followed a population-based one. Before any remarks
could be drawn, further larger epidemiological studies,
also as functional tests, are recommended to elucidate
the nature of *1806G allele in CRC.
A systematic review can be a resourceful tool in detecting
an association that could otherwise remain masked in the
studies of a small number participants [83], especially in
those evaluating rare allele frequency polymorphisms.
Nevertheless, these results should be interpreted bearing
in mind the limitations encountered in this analysis.
Firstly, the elevated number of COX polymorphisms
addressed and the lack of genotype frequency informa-
tion for each one in each of the studies did not allow the
estimation of the best genetic model of inheritance to
follow. Therefore, we assumed the dominant model for
every SNP. For some polymorphisms this model might not
be the most suitable to allow a clear assessment of the
gene-disease interaction [83]. Secondly, for most poly-
morphisms we were not able to address the sources of
heterogeneity when detected among studies, and to
perform subgroup stratifications analysis, because of the
limited number of published studies. Thirdly, in at least
one study there was a clear age gap between cases and
controls. The control group was younger than the
patients, meaning that possibly there are participants
that could develop cancer before reaching the median age
of cases in the control group. Fourthly, several studies did
not confirm the absence of lesions in the control group
by any technique and several others did not mention
the method of choice. The last two drawbacks could
ultimately lead to an underestimation of the overall
polymorphism effect. Finally, this systematic review was
based on unadjusted data, as the genotype information
stratified for the main confounding variables was not
available in the original papers and also the confounding
factors addressed across the different studies were
variable. The adjusted estimates could give more precise
and strong associations, as they reduce the impact of
possible confounding factors.
In future studies several requirements should be fulfilled,
concerning not only the study design but also the
reporting of data: a sample size estimation based on the
genotype distribution should be carried out, especially for
low-frequency alleles; the inclusion and exclusion criteria
ought to be stated clearly in the reporting manuscript;
the control group should represent the same source
populations as cases and the main characteristics, age, and
sex, should be matched between the two groups; to
ensure the correct classification, all participants should be
screened for possible gastric or colorectal lesions; this
information alongside the validated technique applied
should be facilitated when reporting the study; the
selection of participants as well as the genotyping
examination should be performed by blind personnel;
and finally, potential confounders like ethnicity, H. pylori
status (for gastric lesions), diet, NSAID use and lifestyle
habits should be managed by subgroup analysis.
We may conclude that, although further research is
needed, there are apparently consistent results (Table 6),
both laboratory and observational, in COX2 polymorph-
isms that may help to select a group of patients at higher
risk of gastric cancer ( – 899G>C, – 1329G>A, and
*429T>C). This seems to be true among those with
atrophic chronic gastritis or intestinal metaplasia
( – 899G>C and – 1329G>A). Furthermore, in sporadic
colon adenoma (V102V, V511A and *429T>G) and
cancer ( – 1329G>A, – 899G>C, V511A) COX2 poly-
morphisms may help in defining a genetic profile of risk.
If confirmed in future studies such as cohort studies or
Table 6 COX polymorphisms expected impact based on
bioinformatics predictive programs /functional studies (rows) and
observed estimates (OR) on current study (columns)
Gastric
carcinogenesis
Colorectal
carcinogenesis
COX polymorphisms AIM
Gastric
cancer
Colorectal
adenoma
Colorectal
cancer
Funcional
COX1
R8W 2 2
P17L 2
L237M 2 2 2 a
COX2
–1423A>G mmm 2
–1329G>A 2 mmm 2 mmm
–899G>C 2 mmm 2 mmmb
IVS5–275T>G 2 2 2 2
*429T>C kk kkk mmmc 2
*1806A>G 2 a
Nonfunctional
COX2
–1462_ –1461delTG k
–798A>G 2
V102V m a kk m
V511A kd kkd
Unknown
COX1
IVS7+14delA 2 2
IVS7–45T>C 2 2
L15 – L16del mm
V481I 2 m 2
Q41Q 2 2
G213G 2 2
COX2
–646C>T 2
–196C>G 2
–125T>G 2
IVS7+111T>C 2
G587R k 2
*2291G>A mm
*2430C>T mmm
aHeterogeneity detected among studies.
bIn Asiatic populations.
cExcluding the study by Gunter et al. [41] that has a C allele distribution very
different from the other populations.
dIn African–American individuals.
AIM, atrophy and/or intestinal metaplasia; CI, confidence interval; OR, odds ratio;
2, no association; k, trend, kk, strong trend, kkk, statistical association
(P<0.05) for protection. Protection is defined as the 95% CI for OR<1;
m, trend, mm, strong trend, mmm, statistical association (P<0.05) for risk. Risk
is defined as the 95% CI for OR>1.
COX polymorphisms in gastrointestinal tumors Pereira et al. 89
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
else (e.g., cost-effectiveness analysis), these genetic
profiles may enable clinicians to select individuals for
early diagnosis strategies, diverse management schedules
such as the follow-up of patients with intestinal
metaplasia in the stomach or patients with earlier colonic
adenoma (by anticipating follow-up examinations), or
even to propose selective COX-2 inhibitors or nonspecific
COX inhibitors in patients with precancerous lesions.
Supplementary data
Supplementary tables are available at The European Journal of
Gastroenterology & Hepatology (online at http://www.eurojgh.com).
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*1806A>G 
(3618A>G; 9850) 
rs4648298 
 
9850 
 
g.8026A>G 
 
- 
May have some effect on the addition of 
some poly-A tail to the mRNA, or can 
cause a later poly-A site to be used, 
creating a longer, and possibly more 
stable species of mRNA
45
 
Unknown 
*2291G>A (10335) rs689469 10335 
g.8511G>A 
 
- 
Downstream of the last polyadenylation 
site
45
 
Unknown 
*2430C>T rs689470 10474 g.8650C>T - Unknown Unknown 
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CHAPTER IB: COX-2 POLYMORPHISMS AND 
COLORECTAL CANCER RISK: A STRATEGY FOR 
CHEMOPREVENTION
Original article 1
COX-2 polymorphisms and colorectal cancer risk: a strategy
for chemoprevention
Carina Pereiraa,c, Pedro Pimentel-Nunesb,d, Catarina Branda˜ob,
Luı´s Moreira-Diasb, Rui Medeirosa,f and Ma´rio Dinis-Ribeirob,e
Objective COX-2, the inducible isoenzyme, was found
to be overexpressed in approximately 85% of colorectal
adenocarcinomas, contributing to key steps in tumor
development. COX-2 polymorphisms that might modify the
levels of protein expression would be anticipated to have
a substantial influence on disease phenotype. Therefore,
we sought to understand the role of three COX-2
polymorphisms ( – 1195A>G, – 765G>C, and 8473T>C)
in colorectal cancer (CRC) onset.
Material and methods We conducted a hospital-based
case–control study involving 117 consecutively enrolled
CRC patients and 256 healthy individuals without any
clinical evidence of cancer. The COX-2 polymorphisms’
genotypes were characterized by PCR-restriction fragment
length polymorphism or real-time PCR techniques.
Results The –1195A>G polymorphism was associated
with a 1.73-fold increased predisposition to CRC onset.
In a stratified analysis, men and ever-smokers carrying
–1195G allele (AG+GG) had an increased risk for
CRC development (odds ratio: 2.58; 95% confidence
intraval: 1.29–5.15 and odds ratio: 10.3; 95% confidence
intraval: 3.37–31.2, respectively). More interestingly, men
ever-smokers carrying –1195G allele appeared to have a
nine-fold increased risk for CRC onset (95% CI: 2.94–27.6).
No difference in the genotype’s distribution was noticed
between cases and controls for the remaining two
polymorphisms.
Conclusion The –1195A>G COX-2 polymorphism
seems to modulate the genetic susceptibility for CRC
onset, especially in men ever-smokers. This genetically
based higher-risk group definition may help shift the
balance between risk and benefits for the use of COX-2
inhibitors in chemoprevention that is currently hampered
by the adverse gastrointestinal and cardiovascular
side-effects. Eur J Gastroenterol Hepatol 00:000–000c 2010
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Introduction
In developed countries, colorectal cancer (CRC) is the
second most widespread malignancy with a lifetime risk
of 5%, mainly imputed to the ‘westernized lifestyle’ [1–3].
Traditional nonsteroidal anti-inflammatory drugs, such
as aspirin, are thought to exert their chemopreven-
tive actions mainly by targeting cyclooxygenase (COX)
enzymes [4]. COX-1 is constitutively expressed in a
wide range of organs and responsible for tissue homeo-
stasis. Although normally undetectable in physiological
conditions, COX-2 is induced under inflammatory and
tumor promotion stimuli, being overexpressed in appro-
ximately 50% of adenomas and 85% of colon adeno-
carcinomas [5].
In an original observational study, Chan et al. [6] observed
that aspirin’s preventive role was effective only in the
subgroup of colon cancers overexpressing COX-2 in a
dose and treatment duration dependent manner. Hence,
the future challenge lies in the identification of indivi-
duals who will express higher levels of COX-2, probably
through the interaction between the genetic background
and environmental exposure [7].
The involvement of COX-2 genetic variations in colo-
rectal tumor development has been proposed [8]. The
– 1195A>G (rs689466) and – 765G>C (rs20417) poly-
morphisms, identified in gene’s promoter region, are
expected to modulate COX-2 expression by altering the
recognition binding site for specific nuclear proteins, thus
influencing the genetic susceptibility for CRC onset
[9,10]. In contrast, the 8473T>C (rs5275) polymorph-
ism in an AU-rich elements region (30UTR) might
contribute to cancer development by influencing COX-2
mRNA stability [11–13]. In this study, we sought to
evaluate the influence of COX-2 functional polymorph-
isms in the development of CRC. We also aimed to
investigate possible interactions between these genetic
variations and environmental factors in CRC onset.Supplemental digital content is available for this directly from the author.
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Material and methods
Study population
This hospital-based case–control study included 373
participants: 117 histologically confirmed CRC patients
and 256 cancer-free controls from the northern region
of Portugal recruited at the Portuguese Institute of
Oncology, Porto. The method of sampling for cases and
controls can be observed in Fig. 1. Eligible cases included
all patients with a newly diagnosed CRC between January
2002 and September 2007 selected from a colonoscopy
database from the Gastroenterology department, aged
50–75 years, without a previous history of inflammatory
bowel diseases or hereditary syndromes and who were
scheduled for a follow-up observation at our institution
between March and May 2008 (n=384). Controls were
healthy individuals without any clinical evidence of CRC
selected from a DNA database of more than 1000 blood
donors consecutively recruited at our institute between
July 2005 and October 2007. All the individuals between
50 and 75 years of age were included (n=307).
Overall, the participation rate for the interviewed indivi-
duals meeting the cases’ inclusion criteria (n=166) was
90% (n=150). We were unable to obtain blood samples
from all the included cases by the time frame of this
study, but the distribution of known risk factors for
CRC [age, sex, body mass index (BMI) and smoking
behavior] did not deviate between the genotyped group
(n=117) and the included population. In the control
group, DNA samples were available only from 256 (83%)
participants to allow the genotype characterization of all
COX-2 polymorphisms.
Written informed consent was obtained from all partici-
pants before their inclusion in the study, according to
the Declaration of Helsinki. Furthermore, this research
was approved by the Ethics Committee of the Portuguese
Institute of Oncology, Porto. The methods for data col-
lection and variables definition can be seen in Supple-
mentary data 1.
Sample DNA extraction
Blood samples were collected with a standard venipunc-
ture technique using EDTA-containing tubes. Genomic
DNA was extracted from peripheral blood leukocytes,
using the QIAamp DNA Blood Mini Kit (Qiagen, Madrid,
Spain) following the manufacturer’s instructions.
COX-2 polymorphisms genotyping
PCR-based restriction fragment length polymorphism
technique was used to characterize the different geno-
types of –1195A>G and –765G>C COX-2 polymorphisms
as described earlier [10,14]. Briefly, the PCRs were
performed using a specific pair of primers (Metabion,
Martinsried, Deutschland) to amplify the DNA frag-
ments containing the – 1195A>G (F50-CCCTGAGA
CACTACCCATGAT-30 and R50-GCCCTTCATAGGAGA
TACTGG-30) and – 765G>C (F50-ATTCTGGCCATC
GCCGCTTC-30 and R50-CTCCTTGTTTCTTGGAAA
GAGACG-30) COX-2 polymorphisms. Afterwards, the
amplified fragments were digested with 1U of PvuII and
Bsh1236I restriction endonucleases (Fermentas, Vilnius,
Lithuania) allowing the genotype characterization of
– 1195A>G (AA: 273 bp; GG:220+53bp; AG:273+
Fig. 1
Northern portuguese population
Colonoscopy database
(2002 − 2007)
Inclusion criteria:
> 50 and < 75 years;
Without previous history of IBD and
hereditary syndromes;
With follow-up at our institute
between March and May 2008.
No data collection was possible (w/o
interview, n= 218; w/o blood samples,
n= 33)
n= 384
n= 117 n= 256
n= 307
Exclusion criteria:Exclusion criteria:
Patients w/o blood samples
(n= 51)
Selection of cases Selection of controls
Refused to participate (n= 16)
> 1000 blood donors
(2005 − 2007)
Inclusion criteria:
> 50 and < 75 years;
Methods of sampling for cases and controls. IBD, inflammatory bowel disease; w/o, without.
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220+53bp) and – 765G>C (GG:134+23bp; CC:
157 bp: GC:157+134+23bp) COX-2 polymorphisms,
correspondingly.
For quality control, (i) negative controls were included
in every PCR reaction; (ii) the genotype interpreta-
tion was independently performed by two experienced
researchers. There was no discrepancy between results;
(iii) a second PCR-restriction fragment length poly-
morphism analysis was randomly repeated in 10% of all
samples for each polymorphism. The 8473T>C poly-
morphism was genotyped through an allelic discrimina-
tion analysis on a ABI Prism 7300 Real-Time PCR System
(Applied Biosystems, Foster City, California, USA) using
the following validated TaqMan SNP genotyping assay
(Applied Biosystems): C___7550203_10. Cases with
undetermined genotype even after a second round were
excluded. Likewise, in each 96-well plate, negative
controls were included and 10% of genotyped samples
were randomly selected for a second analysis.
Statistical analysis
The Hardy–Weinberg equilibrium was tested by the
Pearson’s goodness-of-fit test to compare the observed
versus the expected genotype frequencies.
Data analysis was performed using the computer software
Statistical Package for Social Sciences-SPSS (SPSS Inc.,
Chicago, Illinois, USA) for Windows (version 15.0). Chi-
square analysis was used to compare categorical variables,
using a 5% level of significance. Statistical differences
between mean values were evaluated by applying the
Mann–Whitney test.
Multivariate logistic regression analysis was used to
estimate odds ratio (OR) and its 95% confidence interval
(CI) as a measure of the association between variant
allele carriers and the risk for the development of CRC.
The potential confounding variables such as age, sex,
BMI, and smoking habits were addressed either by being
included as covariates in the multivariate analysis and/or
through data stratification.
Homozygotes for the allele with the highest frequency
were used as the reference group for each OR estimation.
Variant allele carriers were defined as the heterozygous
and minor allele homozygous genotype carriers pooled
together (dominant model).
Results
Participants’ description
The characteristics of the study population are sum-
marized in Table 1. Cases were significantly older than
controls with a median age of 61 years (50–75) [vs. 55
years in controls (50–65), P<0.001].
There were no significant differences in the distribution
of sex, BMI, and smoking habits between both groups.
Males represented 63% of either population (P=0.995),
and 82% of cases were overweight (vs.76% in controls,
P=0.243).
Genotype frequencies and risk estimates
Genotype frequency of each COX-2 polymorphism
according to disease status is displayed in Table 2. The
genotypic distribution of all three single nucleotide
polymorphisms (SNPs) in the control group was in
agreement with the Hardy–Weinberg equilibrium princi-
ples (PZ 0.05) and the frequencies for the – 1195G,
– 765C, and 8473C alleles were 16.6, 18.9, and 32.4%,
respectively. No significant differences in genotype
distribution were noticed for the COX-2 genetic variations
addressed, although, the heterozygous – 1195AG geno-
type was over-represented in cases (36.8 vs. 28.5%,
P=0.094). Furthermore, the G allele carriers showed
an increased risk trend for CRC onset (OR: 1.50; 95% CI:
0.955–2.371, P=0.078) that reaches significance level in
a multivariate analysis addressing potential confounders
for CRC (age, sex, BMI and smoking habits) (OR: 1.74;
95% CI: 1.011–2.975, P=0.045).
Table 1 Description of participants
Cases
(n= 117)
Controls
(n= 256) P value
Demographics
Age (years)
Mean (SD) 62 (4.1) 56 (6.9)
Median (min–max) 61 (50–65) 55 (50–75) < 0.001d
Sex, n (%)
Male 74 (63.2) 162 (63.3) 0.995
Female 43 (36.8) 94 (36.7)
Lifestyle behaviorsb
BMI (kg/m2)
Mean (SD) 28 (4.0) 28 (3.6)
Median (min–max) 28 (20–43) 27 (21–40) 0.643d
BMI category, n (%)a
< 25 21 (18.3) 40 (24.1) 0.243
Z25 94 (81.7) 126 (75.9)
Smoking status, n (%)
Never-smokers 68 (58.1) 104 (65.4) 0.217
Ever-smokers 49 (41.9) 55 (34.6)
UPY 37 (31–43) 23 (18–28) 0.002
Tumor characteristicsc
Tumor location, n (%)
Recto 44 (37.6) —
Colon 73 (62.4) —
Stage, n (%)
I–II 57 (48.7) —
III–IV 60 (51.3) —
Grade, n (%)
Low/Intermediate 88 (75.2) —
High 5 (4.3) —
Undefined 24 (20.5) —
Synchronous tumors, n (%)
Yes 7 (6.0) —
No 110 (94.0) —
BMI, body mass index; UPY, unit packs (day) years.
aCategorization based on the cutoff defined by WHO for overweight people [15].
bThe numbers may not add up, as we were unable to gather this information for all
participants, namely in the control group.
cFor synchronous tumors the most advanced lesion was the one considered in
tumors’ characterization.
dP value was estimated using the non-parametric Mann–Whitney test.
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Table 2 Genotype frequencies among cases and controls and univariate and multivariate OR (95% CI) estimation on the role
of COX-2 polymorphisms in colorectal cancer onset
Univariate analysis Multivariate analysis
Polymorphism Cases Controls OR 95% CI P value Na aOR 95% CI P value
– 1195A > G
AA 70 (59.8) 177 (69.1) 1.00 Reference — 1.00 Reference —
AG 43 (36.8) 73 (28.5) 1.489 0.933–2.377 0.094 267 1.673 0.964-2.903 0.067
GG 4 (3.4) 6 (2.3) 1.686 0.462–6.155 0.425 187 3.170 0.468-21.48 0.237
G carriers 47 (40.2) 79 (30.9) 1.504 0.955–2.371 0.078 272 1.735 1.011-2.975 0.045
–765G > C
GG 77 (65.8) 166 (64.8) 1.00 Reference — 1.00 Reference —
GC 38 (32.5) 83 (32.4) 0.987 0.617–1.578 0.956 265 0.862 0.500-1.486 0.592
CC 2 (1.7) 7 (2.7) 0.616 0.125–3.034 0.548 179 0.359 0.060-2.161 0.263
C carriers 40 (34.2) 90 (35.2) 0.958 0.605–1.518 0.856 272 0.812 0.477-1.383 0.444
8473T > C
TT 54 (47.0) 118 (46.1) 1.00 Reference — 1.00 Reference —
TC 51 (44.3) 114 (44.5) 0.978 0.616–1.550 0.923 248 0.869 0.510-1.480 0.604
CC 10 (8.7) 24 (9.4) 0.910 0.407–2.036 0.819 147 0.858 0.314-2.347 0.766
C carriers 61 (53.0) 138 (53.9) 0.966 0.621–1.501 0.878 270 0.874 0.525-1.457 0.606
aOR, adjusted odds ratio for age, sex, body mass index, and smoking status; CI, confidence interval; OR, odds ratio.
aTotal number of participants included in the multivariate analysis.
Table 3. aOR (95% CI), under the dominant model, for the influence of COX-2 polymorphims in colorectal cancer onset stratified
for age, sex, BMI, and smoking status
COX-2 polymorphisms
Stratification
– 1195A > G (G carriers vs. AA) –765G > C (C carriers vs. GG) 8473T > C (C carriers vs. TT)
N aOR 95% CI P value aOR 95% CI P value aOR 95% CI P value
Age (years)a
< 57 125 1.423 0.604–3.353 0.419 1.577 0.688–3.617 0.282 1.336 0.577–3.093 0.499
Z57 147 1.933 0.946-3.952 0.071 0.552 0.270–1.131 0.104 0.736 0.376–1.438 0.369
Sex
Female 97 0.632 0.243–1.643 0.346 0.923 0.345–2.467 0.872 0.623 0.252–1.541 0.306
Male 175 2.579 1.290–5.154 0.007 0.854 0.441–1.651 0.638 1.060 0.559–2.011 0.585
BMI (kg/m2)
< 25 57 2.479 0.686–8.956 0.166 0.366 0.106–1.270 0.113 0.549 0.160–1.884 0.341
Z25 215 1.608 0.881–2.934 0.122 0.959 0.525–1.750 0.892 0.959 0.543–1.695 0.886
Smoking status
Never-smokers 169 0.612 0.296–1.264 0.185 1.003 0.488–2.062 0.994 0.904 0.460–1.775 0.769
Ever-smokers 103 10.267 3.374–31.239 < 0.001 0.789 0.340–1.829 0.581 0.958 0.417–2.205 0.920
aOR, adjusted odds ratio for age, sex, body mass index, and smoking status; CI, confidence interval.
aCategorization defined by the overall median age.
Table 4 Measurement of the interaction between sex, smoking status, and –1195A>G COX-2 polymorphism in the development
and time to diagnosis of colorectal cancer
Risk estimate Age at diagnosis
Cases n (%) Controls n (%) aOR 95% CI P value Median 95% CI P value
Females
Never-smokers
AA 27 (65.9) 28 (58.3) 1.00 Reference — 63 (61–65) 0.341
G carriers 14 (34.1) 20 (41.7) 0.48 0.177–1.325 0.158 64 (61–67)
Ever-smokers
AA 1 (50.0) 9 (100) 1.00 Reference — — — —
G carriers 1 (50.0) 0 (0) — — — — — —
Males
Never-smokers
AA 20 (74.1) 38 (67.9) 1.00 Reference — 64 (62–66) 0.462
G carriers 7 (25.9) 18 (32.1) 0.71 0.239–2.096 0.533 69 (54–84)
Ever-smokers
AA 22 (46.8) 40 (87.0) 1.00 Reference — 69 (65–73) < 0.001
G carriers 25 (53.2) 6 (13.0) 9.02 2.940–27.64 < 0.001 62 (58–66)
Risk model
Nota 92 (78.6) 153 (96.2) 1.00 Reference — 64 (62–66) 0.011
Male ever-smokers G allele carriers 25 (21.4) 6 (3.8) 7.75 2.918–20.58 < 0.001 62 (58–66)
aOR, adjusted odds ratio for age; CI, confidence interval.
aNot ‘Male ever-smokers G allele carriers’.
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Gene–environment interaction
Upon a stratified analysis, we observed a measurable
interaction between the – 1195G allele and sex (OR:
2.58; 95% CI: 1.290–5.154, P=0.007 in males) or
smoking habits although we were only able to gather
information about the smoking status in 62% of controls
(OR: 10.27; 95% CI: 3.374–31.24, P<0.001 in ever-
smokers) (Table 3). More interestingly, the susceptibility
for CRC seemed to be modulated by the presence of
the G allele particularly in male ever-smokers (OR:
9.01; 95% CI: 2.940–27.64, P<0.001). When evaluating
these interactions on the time to diagnosis of CRC, we
observed that the waiting time was remarkably lower,
once again, in men G allele carriers who ever smoked
(62 vs. 69 years, P<0.001) (Table 4). Afterwards, a risk
model for CRC was defined considering these individuals
and then tested by comparing them with all other partici-
pants, and as observed in the bottom of Table 4, a nearly
eight-fold higher predisposition for CRC was detected
albeit only 31 individuals were included in this model. No
association was observed for the remaining two SNPs
in the categorized analysis. In addition, no difference in
genotype distribution was observed, considering the
clinicopathological variables (data not shown).
Discussion
Although the regular use of nonsteroidal anti-inflamma-
tory drugs in cancer prevention is currently jeopardized
by the adverse gastrointestinal (GI) complication [16],
the anti-inflammatory and antitumor protective effects
of their use in CRC prevention, through inhibition of
COX-2, are undeniable and consistently observed in
several epidemiological and clinical trials [17–19].
In this case–control study, we assessed the role of
– 1195A>G, – 765G>C, and 8473T>C polymorph-
isms, expected to modulate COX-2 expression, in CRC
development not disregarding a possible gene–environment
interaction.
As recently reviewed, the – 765G>C polymorphism
was earlier associated with a higher CRC predisposition in
Asiatic populations [8]. We failed to show an asso-
ciation between this polymorphism and CRC risk in our
population, which is in agreement with a previous study
developed in Caucasians [20]. In contrast, Hoff et al. [21]
in a larger study observed an increased risk for CRC
development in individuals carrying the GG genotype
in a Dutch population. The dual and antagonic influence
that this polymorphism seems to play in tumor develop-
ment could have a biological reasoning, as the presence
of allele C in COX-2 promoter region in one instance
eliminates the recognition binding site for the Sp1 posi-
tive transcription factor leading to a 30% reduction in
promoter’s activity in vitro [9]. In contrast, it also creates
an E2F homology binding region that could lead to a
higher transcription activity [10]. In fact, the – 765CC
genotype was associated with a 10-fold enhanced
production of PG, compared with the homozygous
– 765GG [22], thus supporting the observed increased
susceptibility to several GI malignancies.
Given its location in the 30UTR of COX-2 gene, the
8473T>C polymorphism is a potential candidate to
modulate the genetic predisposition for CRC. The
thymine (T) to cytosine (C) exchange in an AU-rich
elements region, known to control mRNA stability
and degradation of several other early intermediate genes
encoding inflammatory mediators whose mRNA is very
unstable [23], could enhance the mRNA transcripts’
stability and ultimately lead to an increased prostaglan-
dins production. In the GI tract, the 8473C allele has
been associated with a 1.25-fold increased susceptibility
for colorectal adenoma and paradoxically with a protective
effect for gastric cancer, compared with 8473GG geno-
type [8]. Overall, the involvement of this SNP in CRC,
however, could not be shown in this study, which is in
agreement with the already published studies [20,24,25].
These findings seem to suggest that the 8473T>C poly-
morphism is more important in early stages of colorectal
tumor formation but not so relevant in the progression
from adenomatous polyps to malignant tumors.
When focusing on – 1195A>G COX-2 polymorphism, we
observed an over-representation of AG and GG geno-
types in the group of cases that translated into a 1.7-fold
increased predisposition to CRC onset in G allele carriers
upon a multivariate analysis. Our results were rather
unexpected, although a recently published study invol-
ving familial adenomatous polyposis patients also re-
ported an increased risk association between – 1195GG
genotype and CRC onset [26]. Furthermore, when we
assessed possible gene–environment interactions, we
observed a positive association between – 1195AG/GG
genotypes and CRC in males and in ever-active smokers
and more interestingly a nine-fold increased predisposi-
tion in male ever-smokers. The lack of association in
females might be attributable to the small sample size of
this group, as only 11% (n=11) of women were current or
former smokers. These associations have raised some
controversy. In a previous functional study developed
by Zhang et al. [10], a higher transcriptional activity
and increased COX-2 mRNA expression that translated
in a significantly higher risk for esophageal cancer
in – 1195AA genotype carriers was reported [10]. In
addition, the AA genotype was further associated with a
higher genetic predisposition for the development of
gastric and colorectal adenocarcinomas in Asiatic popula-
tions [27–29]. These contradictory associations seem
to suggest the involvement of other factors that can
modulate this polymorphism behavior. In fact, tobacco
smoke has been implicated in the colorectal carcinogen-
esis [30,31] and COX-2 overexpression is suggested as
one of the smoke-induced pathways involved in tumor
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development [32,33]. Tobacco contains more than 60
identified carcinogens and even though some, such as,
nicotine and benzo[a]pyrene, were shown to trigger
COX-2 expression through b-adrenoceptors and ERK1/2
pathways, respectively, the pathogenesis of smoking-
related CRC is still understudied [33,34]. Hence,
it is possible that other smoke-induced pathways may
interact with – 1195G allele containing promoter region
leading to a differential COX-2 expression that only
future in vitro studies will elucidate. Considering that
COX-2-derived PGE-2 is implicated in key steps of
tumor development including inhibition of apoptosis,
stimulation of angiogenesis, tumor proliferation, and
immunosupression [35], it is plausible that functional
polymorphisms in COX-2 gene might influence the time
to onset for CRC by modulating COX-2 expression and
thus the exposure to PGE-2-induced proneoplastic
effects. In fact, we observed that the diagnosis of CRC
was anticipated by 7 years in male cases carriers of
– 1195G allele who ever consumed tobacco, once again
reinforcing the role of this COX-2 SNP in colorectal
neoplasia.
These findings represent a preliminary study and as such
there are some drawbacks that need to be considered
in their interpretation. A major limitation is the missing
information on BMI and smoking status in the control
group, thus explaining the wider 95% CI observed in the
gene–environment interaction analysis. We also cannot
exclude selection bias as only 43% of eligible cases were
interviewed and informed of this study, mostly explained
by the work overload of the clinicians. The sample size
of our population, especially the case group, could be
insufficient to detect low-magnitude associations and
to allow conclusive findings in the stratified analysis.
Although we imposed the same age-restriction criteria,
we noticed that CRC patients were significantly older
than controls. Therefore, we included age as a covariate in
the multivariate analysis.
A clearer understanding on CRC etiology through the
identification of risk factors might allow a better
definition of risk models that are more likely to benefit
from preventive strategies. Chan et al. [6] reported that
the chemopreventive effects of regular use of aspirin in
CRC development were exclusively effective in COX-2
overexpressing tumors. In this study, we observed that
male ever-smokers carrying at least one – 1195G allele
had not only a higher genetic predisposition but also were
expected to develop CRC at an earlier age, suggesting
that this SNP may help predict individuals expected
to be exposed to higher levels of COX-2 and thus
susceptible to be defined as a risk model for CRC
development as observed in this study.
Further research is needed to determine whether
this specific subgroup of ‘higher-risk’ individuals would
benefit from the use of COX-2 inhibitors by shifting
the balance between costs and benefits that is currently
overshadowed by the adverse GI and cardiovascular
side-effects.
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Considering the findings from the studies enclosed in the previous Chapter I, the 
purpose with this thesis was to asses the influence of genetic polymorphisms in 
key genes in PGE2 pathway (COX-2/HPGD/ABCC4/SLCO2A1) on the 
susceptibility for the development and recurrence of colorectal tumors that may 
help identify individuals at higher risk for colorectal lesions that may benefit from 
targetting screening or be selected for chemopreventive strategies. 
Therefore, our aims were: 
 To functionally characterize the role of -1195A>G (rs699466) polymorphism 
in COX-2 promoter region on gene´s transcriptional activity in CRC cell 
lines; 
 To assess the influence of genetic variants in COX-
2/HPGD/ABCC4/SLCO2A1 genes and possible gene-environment and 
gene-gene interactions in colorectal cancer development. 
 To assess the involvement of polymorphisms in COX-
2/HPGD/ABCC4/SLCO2A1 genes on the risk for development of early 
stages colorectal lesions and metachronous adenomas and on the time for 
recurrence. 
 To evaluate the influence of polymorphisms proven to influence genetic 
susceptibility on COX-2/HPGD/ABCC4/SLCO2A1  mRNA expression. 
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CHAPTER III: THE -1195G ALLELE INCREASES THE 
TRANSCRIPTIONALACTIVITY OF CYCLOOXYGENASE-2 GENE 
(COX-2) IN COLON CANCER CELL LINES 
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The 1195G Allele Increases the Transcriptional
Activity of Cyclooxygenase-2 Gene (COX-2) in
Colon Cancer Cell Lines
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Up-regulation of cyclooxygenase-2 (COX-2) is an early and key event in human colorectal carcinogenesis (CRC).
Nevertheless, the molecular mechanisms leading to this over-expression are largely unknown. We previously reported an
association between the 1195G allele and higher predisposition for CRC in a Caucasian population. The biological
explanation for the involvement of this polymorphism in CRC remains elusive. We aimed to functionally characterize the
inﬂuence of the 1195A>G promoter region polymorphism on COX-2 transcription activity in colon cancer cell lines.
Luciferase reporter assays were performed to assess whether the 1195A/G alleles inﬂuenced COX-2 transcription. The
COX-2 promoter's region containing either the1195A or1195G alleles was cloned into pGL3-basic reporter vector. The
reporter vectors were transiently co-transfected with the pGL4.73 control plasmid to HCT-116 and HCA-7 colon cancer cell
lines. The levels of reporter gene expression driven by the 1195G allele-containing COX-2 promoter were signiﬁcantly
higher in both colon cancer cell lines. A 2.2-fold increase in promoter activity was observed in the HCT-116 cell line
(P < 0.001), and this over-expression was even more noticeable in the HCA-7 COX-2 expressing cell line with a threefold
higher transcriptional activity (P ¼ 0.001). The 1195G allele appeared to enhance COX-2 transcription, providing a
molecular basis underlying the increased susceptibility for CRC and potentially a new mechanism for COX-2
overexpression. © 2013 Wiley Periodicals, Inc.
Key words: colorectal cancer; genetic susceptibility; cyclooxygenase-2 polymorphism; luciferase assays
INTRODUCTION
Prostaglandin-endoperoxide synthase-2 (PTGS2),
most commonly known as cyclooxygenase-2 (COX-
2), is considered to be a biomarker of colorectal
carcinogenesis, being normally undetectable under
physiological conditions and increasingly over-ex-
pressed with progression from colorectal adenomas
(50%) to CRC (85%) [1]. COX-2-derived prostaglandin
E2 (PGE2) up-regulation is implicated in key steps of
carcinogenesis by stimulating cell proliferation, an-
giogenesis, invasiveness and cellmigration, inhibiting
apoptosis and modulating immunosuppression [2].
COX-2 gene expression can be controlled by post-
transcriptional mechanisms regulating mRNA stabili-
ty and protein translation, especially at adenylate-
and uridylate (AU)-rich elements (ARE) by ARE-
binding proteins (HuR, TTP, etc.) or microRNAs
(miR-16 andmiR-101) [3]. Nevertheless, and although
not fully elucidated, the regulation at transcriptional
level is also known to be a major mechanism
underlying COX-2 up-regulation, through the bind-
ing of transcription factors (TF) such as NF-kB, C/EBP,
CREB, AP-2, and Sp-1 to several cis-acting regulatory
elements at COX-2 promoter [4,5].
In fact, the COX-2 gene has been shown to be
genetically polymorphic, particularly in the 5´ un-
translated region, which may lead to differential
COX-2 expression [6]. Over the last decade a body of
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evidence has emerged implicating the involvement of
polymorphisms in the COX-2 promoter in cancer
development, although some heterogeneity is no-
ticed among published studies [6,7]. Our group has
previously reported not only an increased susceptibil-
ity but also a 7-yrs anticipation of CRC development
forG allele carriers of the1195A>GCOX-2promoter
region polymorphism [8]. These results are in agree-
ment with the increased-risk trend observed for
colonic adenoma onset associated with the
1195GG genotype in Japanese and Dutch popula-
tions [9,10]. However, earlier studies in an Asiatic
population implicated the 1195AA genotype as a
risk marker for digestive cancers development (gas-
tric, oesophageal, and colorectal) [11–13]. The con-
troversial evidence arising from both epidemiological
and experimental studies addressing the functional
repercussion of this polymorphism on COX-2 expres-
sion in different models suggests that different path-
waysmight be activated dependingon cell type, tissue
or pathological conditions [12,14]. So far, the biolog-
ical explanation of the 1195A>G polymorphism in
colon carcinogenesis remains elusive. Therefore, with
this in vitro study we aimed to functionally charac-
terize the influence of the 1195A>G promoter
region polymorphism on COX-2 transcription activi-
ty in colon cancer cell lines.
MATERIALS AND METHODS
Cell Lines Culture
The human colon cancer cell lines HCT116 and
HCA-7 were purchased from the European Collection
Cell Cultures (ECACC) as they derive from colon
carcinoma tissues and had previous COX-2 expres-
sion data available. They were cultured in a humidi-
fied, 5% CO2 incubator at 378C in McCoy’s 5A with
GlutaMAX and Dulbecco’s modified Eagle medium
(DMEM)withGlutaMAX, respectively, supplemented
with 10% heat-inactivated fetal bovine serum, Peni-
cillin (50 U/ml), and Streptomycin (0.05 mg/ml). All
reagents were acquired fromGibco (Life Technologies
Corporation, Carlsbad, CA).
Reporter Plasmids Constructs
A1706 bpDNA fragment from theCOX-2 promoter
region containing the 1195A allele was amplified
with following primers: F: 5’ AATATGACTAGAG-
GAGGAGAAAGG 3’ and R: 5’ GGAAGCT-
TAGGCTTTGCTGTCTGAG 3’, which included a
HindIII restriction site (underlined sequence) and
sub-cloned in the pCR2.1-TOPO vector using the
TOPO TA Cloning kit (Invitrogen, Life Technologies
Corporation).
The 1195G allele was obtained by site-directed
mutagenesis using the QuikChangeR II Site-Directed
Mutagenesis Kit (Stratagene, Agilent Technologies,
Inc, Santa Clara, CA) and confirmed by polymerase
chain reaction-restriction fragment length polymor-
phisms (PCR-RFLP; Figure 1). To ensure their authen-
ticity and exclude mis-incorporations during the
mutagenesis both plasmids were sequenced using
the ABI PRISMR 310 Genetic Analyzer (Applied
Biosystems, Life Technologies Corporation).
The pCR2.1-TOPO vector plus inserts were then
double digested with KpnI and HindIII restriction
enzymes (New England Biolabs, Ipswich, MA) and the
inserts cloned into an appropriate double digested
pGL3-basic vector (Promega, Madison, WI), encoding
the firefly luciferase protein as reporter. The ligation
was obtained after a 148C overnight incubation with
T4 ligase using a 3:1 inserts to vector ratio (Promega)
and confirmedby PCRwith intragenic primers used to
characterize the 1195A>G polymorphism [12].
Transient Transfection and Measurement of Luciferase
Activity
The HCT116 and HCA-7 cell lines were seeded in
96-well plates (6  104 and 1  105 cells/well, respec-
tively) and grown to 9095% confluency. After a 24 h
incubation the cells were transfected using the Lip-
ofectamine 2000 transfection reagent (Invitrogen,
Life Technologies Corporation) following manufac-
turer’s instructions. Briefly, 200 ng of reporter plas-
mids was co-transfected with 1.33 ng of pGL4.73
vector (Promega) to HCT116 and HCA-7 cells to
normalize transfection efficiency. The promoter
activity was quantified using the Dual-Glo Luciferase
Assay System (Promega) 24 h after transfection. Cell
viability was assessed by staining the trypsinized cells
with 0.4% trypan blue (Gibco, Life Technologies
Corporation) and counting the viable cells in a
Neubauer chamber. Over 90% cell viability was
observed when measuring Luciferase activity.
Statistical Analysis
Fold increase was measured by defining the activity
of1195A allele-containing plasmid as 1. Data shows
the means fold increase þ SD from two independent
transfection experiments performed in triplicate. The
unpaired t-test was used to assess the difference
between promoters’ activity, with a significance value
of P < 0.05.
RESULTS
We evaluated the effect of the different alleles of
1195A>G polymorphism in COX-2 transcriptional
activity by transiently transfecting luciferase reporter
vector containing either allele to HCT116 and HCA-7
colon cancer cell lines.
The promoter activity of COX-2 showed an allele-
specific behaviour. The levels of reporter gene
expression driven by the 1195G allele-containing
COX-2 promoter were significantly higher in both
colon cancer cell lines. A 2.2-fold increase in promoter
activity was observed in comparison to the 1195A
allele-containing counterparts in the HCT-116 cell
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line (P < 0.001) that was even more noticeable in the
HCA-7 COX-2 expressing cell line (threefold higher
transcriptional activity for those with 1195G allele,
P ¼ 0.001).
DISCUSSION
Up-regulation of cyclooxygenase-2 (COX-2) is an
early and key oncogenic event in human colorectal
carcinogenesis [1]. Nevertheless, themolecularmech-
anisms leading to this over-expression are largely
unknown.
Earlier epidemiological studies have implicated the
1195A>G COX-2 polymorphism in colorectal can-
cer development [8,13]. Although it is one of themost
studied polymorphisms in the COX-2 gene, its
biological role in CRC remains elusive.
With this experimental study, we demonstrated
that COX-2 promoter containing the 1195G allele
leads to a higher transcription activity in contrast
with the 1195A allele in colorectal cancer cell lines.
The difference in promoter activity between the
HCT116 and HCA-7 cell lines may reflect the
molecular heterogeneity observed among colon
tumors. While the HCA-7 cell line constitutively
expresses high levels of COX-2, the HCT-116 lacks
this protein expression [15].
The COX-2 gene has a promoter region rich in cis-
acting regulatory elements and a complex network of
pathways and nuclear proteins involved in its
transcription regulation [4,5]. Hence, it is biologically
plausible that the 1195AG substitution might
modify the recognition binding sites or influence
the binding affinity of specific TF, as observed with a
previous genetic polymorphism in COX-2 promoter
[16]. Zhang et al. [12], initially showed that the
presence of 1195A allele creates a recognition
binding site for the c-myb TF that led to a four- to
sixfold increase in promoter’s activity in HeLa cells,
which was further reproduced in a gastric cancer cell
line (AGS) particularly when stimulated with homo-
genated tissue infected with Helicobacter pylori [11].
This behaviour was further corroborated by the
enhanced expression of COX-2 mRNA in oesophageal
tissues [12]. On the other hand, Sakaki et al. [15]. using
human hepatoma cell lines (HepG2 and Huh-7)
reported a higher transcriptional activity in cells
transfected with 1195G allele-containing promoter
than theoneswith1195Aallele. These results suggest
that this polymorphism in COX-2 promoter region
might have a histological/cell-dependent behavior,
possibly modulated by the activation of pathways and
nuclear proteins specific to each disease model.
This report is thefirst study to evaluate the influence
of 1195A>G polymorphism on COX-2 promoter
activity in colon carcinogenesis. A bioinformatics
analysis using the DS Gene software (version 1.1,
Accelrys Inc., Cambridge, UK), predicted that, besides
eliminating a c-myb binding site, the 1195A>G
substitution also creates an E-box motif, frequently
found in genes that are highly expressed in colon [17].
The E-box motif is recognized by several TFs, namely,
the upstream stimulator factor 1 (USF1), previously
shown to positively regulate the transcription of
several genes involved in colon cancer development
[18–20]. Thismight provide additional clues for future
functional studies to unravel the molecular mecha-
nism leading to the increased promoter activity in the
presence of the 1195G allele in colon cancer lines
and higher susceptibility for CRC development.
In conclusion, with this experimental study we
demonstrated that the1195G allele increasesCOX-2
transcription, providing a biological reasoning un-
derlying the higher susceptibility previously reported
for CRC and potentially a newmechanism for COX-2
overexpression that could be investigated further in
future studies.
ACKNOWLEDGMENTS
This studywas supported by research grants from the
Portuguese Society of Gastroenterology and the Portu-
guese Institute of Oncology of Porto. Furthermore,
Figure 1. Conﬁrmation of subcloning of 1195A and 1195G
allele-containing COX-2 promoter in pCR2.1-TOPO vector. (A) Colony-
PCR with T7 promoter and M13 reverse primers to screen the colonies
for the desired plasmid. C1: positive colony (1.8 kb fragment); C2C4,
false positive; Cþ, positive control (0.8 kb band); (B) Map restriction of
pCR2.1-TOPO plus insert to conﬁrm its authenticity using: (1) KpnI and
HindIII restriction enzymes: 3.8 kb þ 1.5 kb þ 160 bp þ 10 pb; (2)
KpnI and SacI: 4.8 kb þ 600 bp þ 200 bp þ 6 bp; (3) KpnI: 5.5 kb
þ 160 bp; and (4) SacI: 4.8 kb þ 845 bp; (C) Identiﬁcation of colonies
transformed with the mutated allele (1195G allele) after site-directed
mutagenesis (Stratagene, Agilent Technologies, Inc) through PCR-RFLP.
C1: 1195A allele (undigested fragment, 1.8 kb); C2C8: 1195G
allele (the G allele is recognized by PvuII restriction enzyme (New
England Biolabs, Ipswich, MA) creating a 1.3 kb þ 0.5 kb fragments)
[12].
1195A>G POLYMORPHISM INCREASES COX-2 TRANSCRIPTIONAL ACTIVITY 3
Molecular Carcinogenesis
C.P. is a recipient of a PhD grant (SFRH/BD/64805/
2009) from FCT—Fundac¸a˜o para a Cieˆncia e Tecnolo-
gia, co-financed by European Social Funds (ESF) under
Human Potential Operation Programme (POPH) from
National Strategic Reference Framework (NSRF) and
had an allowance for supplemental training by the
Portuguese League Against Cancer—regional Centre of
the North.
We also acknowledge Dr. Paula Paulo for the help
provided during the sequencing of plasmids.
REFERENCES
1. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach
S, DuBois RN. Up-regulation of cyclooxygenase 2 gene
expression in human colorectal adenomas and adenocarcino-
mas. Gastroenterology 1994;107:1183–1188.
2. Wang D, Mann JR, Dubois RN. The role of prostaglandins and
other eicosanoids in the gastrointestinal tract. Gastroenterol-
ogy 2005;128:1445–1461.
3. Dixon DA, Blanco FF, Bruno A, Patrignani P. Chapter 2:
Mechanistic aspects of COX-2 expression in colorectal
neoplasia. Recent Results Cancer Res 2013;191:37–37.
4. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of
the human cyclo-oxygenase-2 gene. Biochem J
1994;302:723–727.
5. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O.
Characterization of the human gene (PTGS2) encoding
prostaglandin-endoperoxide synthase 2. Eur J Biochem
1994;221:889–897.
6. Pereira C, Medeiros R, Pereira C. Cyclooxygenase poly-
morphisms in gastric and colorectal carcinogenesis: Are
conclusive results available? Eur J Gastroenterol Hepatol
2009;21:76–91.
7. Dong J, Dai J, Zhang M, Hu Z, Shen HJ. Potentially functional
COX-2 1195G>A polymorphism increases the risk of
digestive system cancers: A meta-analysis. Gastroenterol
Hepatol 2010;25:1042–1050.
8. Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L,
Medeiros R, Dinis-Ribeiro M. COX-2 polymorphisms and
colorectal cancer risk: A strategy for chemoprevention. Eur J
Gastroenterol Hepatol 2010;22:607–613.
9. Ueda N,Maehara Y, TajimaO, Tabata S,Wakabayashi K, Kono
S. Genetic polymorphisms of cyclooxygenase-2 and colorectal
adenoma risk: The Self Defense Forces Health Study. Cancer
Sci 2008;99:576–581.
10. Peters WH, te Morsche RH, Roelofs HM, Mathus-Vliegen EM,
Berhout M, Nagengest FM. COX-2 polymorphisms in patients
with familial adenomatous polyposis. Oncol Res 2009;17:
347–351.
11. Liu F, Pan K, Zhang X. et al. Genetic variants in cyclooxygenase-
2: Expression and risk of gastric cancer and its precursors in a
Chinese population. Gastroenterology 2006;130:1975–1984.
12. Zhang X, Miao X, Tan W. et al. Identiﬁcation of functional
genetic variants in cyclooxygenase-2 and their associationwith
risk of esophageal cancer. Gastroenterology 2005;129:
565–576.
13. Tan W, Wu J, Zhang X. et al. Associations of functional
polymorphisms in cyclooxygenase-2 and platelet 12-lipoxyge-
nase with risk of occurrence and advanced disease status of
colorectal cancer. Carcinogenesis 2007;28:1197–1201.
14. Sakaki M, Makino R, Hiroishi K. et al. Cyclooxygenase-2 gene
promoter polymorphisms affect susceptibility to hepatitis C
virus infection and disease progression. Hepatol Res
2010;40:1219–1226.
15. Sheng H, Shao J, Kirkland SC. et al. Inhibition of human colon
cancer cell growth by selective inhibition of cyclooxygenase-2.
J Clin Invest 1997;99:2254–2259.
16. Zhao D, Xu D, Zhang X. et al. Interaction of cyclooxygenase-2
variants and smoking in pancreatic cancer: A possible role of
nucleophosmin. Gastroenterology 2009;136:1659–1668.
17. Suzuki Y, Tsunoda T, Sese J. et al. Identiﬁcation and
characterization of the potential promoter regions of 1031
kinds of human genes. Genome Res 2001;11:677–684.
18. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of
UGT1A1 and HNF1 transcription factor gene expression
by DNA methylation in colon cancer cells. BMC Mol Biol
2010; 11.
19. Ansorge N, Jüttner S, Cramer T, Schmidt WE, Höcker M,
Schmitz F. An upstream CRE-E-box element is essential for
gastrin-dependent activation of the cyclooxygenase-2 gene in
human colon cancer cells. Regul Pept 2007;144:25–33.
20. Jaiswal AS, Narayan S. Upstream stimulating factor-1 (USF1)
and USF2 bind to and activate the promoter of the
adenomatous polyposis coli (APC) tumor suppressor gene. J
Cell Biochem 2001;81:262–277.
4 PEREIRA ET AL.
Molecular Carcinogenesis
  
  
91 
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Abstract
The pro-carcinogenic effects of prostaglandin E2 (PGE2) in colonic mucosa are not only regulated by the rates between
Cyclooxygenase-2 (COX-2) biosynthesis and 15-Hydroxyprostaglandin Dehydrogenase (15-PGDH)-dependent degradation
but also the steady-state levels of PGE2 in extracellular microenvironment, maintained by key specific prostaglandin
transporters, the Multidrug Resistance Protein (MRP4) (efflux carrier) and Prostaglandin Transporter (PGT) (influx carrier). To
understand the contribution of genetic variability in genes coding for COX-2/15-PGDH/MRP4/PGT proteins in CRC
development, we conducted a hospital-based case-control study involving 246 CRC patients and 480 cancer-free controls. A
total of 51 tagSNPs were characterized using the Sequenom platform through multiplexed amplification followed by mass-
spectrometric product separation or allelic discrimination using real-time PCR. Seven tagSNPs were implicated in CRC
development: the rs689466 in COX-2 gene, the rs1346271 and rs1426945 in 15-PGDH, the rs6439448 and rs7616492 in PGT
and rs1751051 and rs1751031 in MRP4 coding genes. Upon a stratified analysis a measurable gene-environment interaction
was noticed between rs689466 and smoking habits, with individuals ever-smokers carriers of rs689466 GG homozygous
genotype having a nearly 6-fold increased susceptibility for CRC onset (95%CI: 1.49–22.42, P= 0.011). Furthermore, the
multifactor dimensionality reduction (MDR) analysis identified an overall four-factor best gene-gene interactive model,
including the rs1426945, rs6439448, rs1751051 and rs1751031 polymorphisms. This model had the highest cross-validation
consistency (10/10, P,0.0001) and an accuracy of 0.6957 and was further associated with a 5-fold increased risk for CRC
development (95%CI: 3.89–7.02, P,0.0001). In conclusion, specific low penetrance genes in the pro-carcinogenic PGE2
pathway appear to modulate the genetic susceptibility for CRC development. A clearer understanding on CRC etiology
through the identification of biomarkers of colorectal carcinogenesis might allow a better definition of risk models that are
more likely to benefit from targeted preventive strategies to reduce CRC burden.
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Introduction
Colorectal cancer (CRC) is the most widespread malignancy in
developed regions, accounting for over 13% of all diagnosed cases
(728.550 cases) and 11% of all cancer-related deaths in 2008
(320.279 deaths) [1]. The burden of CRC is increasing as a
reflection of population growth and aging, also as, an increased
adoption of cancer-associated ‘‘westernized’’ lifestyle [2]. So, the
implementation of population-based CRC screening guidelines
focusing on the detection and removal of precancerous lesions is
highly recommended for a successful decrease in CRC incidence
rates [3]. Unfortunately, the compliance rates are far from the
desirable and considerably lower than those reported for other
recommended preventive strategies [4], which compromises the
efficacy of these approaches in CRC prevention. This might
provide reasoning not only for targeted screening but also the
pursuit for alternative and/or complementary strategies, namely
the use of chemoprevention to significantly reduce this cancer
burden.
One group of compounds with extensive data supporting their
preventive role in cancer onset include the nonsteroidal anti-
inflammatory drugs (NSAIDs), shown to reduce the relative risk of
developing CRC by 40–50%, mainly by targeting the cyclooxy-
genase-2 (COX-2) enzyme [5–7].
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COX-2 is an immediate-early response gene, previously shown
to be up-regulated in 40–50% of colorectal adenomas and 85% of
CRC, leading to the extracellular microenvironment accumula-
tion of prostaglandins (PGs) [8]. COX-2-derived PGE2, the major
PG produced in colorectal tumors, plays a key contribution to the
hallmarks of cancer, by stimulating cell proliferation, invasiveness
and migration, enhancing angiogenesis, evading apoptosis and
modulating the antitumor immune response [9]. COX-2 has a
physiologic antagonist in 15-hydroxyprostaglandin dehydrogenase
(15-PGDH) that catabolizes PGE2 to an inactive keto compound
[10]. 15-PGDH is highly expressed in normal mucosa and one of
the most down-regulated genes in colorectal tumors, being a
potent in vivo suppressor of colon neoplasia by decreasing the
catabolism of PGE2 [11,12]. Furthermore, low 15-PGDH levels
are associated with resistance to COX-2 selective inhibitor
Celecoxib chemopreventive effects in colorectal tumors develop-
ment, reinforcing the impact of loss of 15-PGDH expression in
colorectal carcinogenesis [13]. Notwithstanding, the biologic
effects of the COX-2/PGE2 pathway are not only regulated by
the rates between COX-2 biosynthesis and 15-PGDH-dependent
degradation but also the steady-state levels of PGE2 in extracel-
lular microenvironment, regulated by key specific prostaglandin
transporters [14,15]. The multidrug resistance-associated protein 4
(MRP4) is responsible for exporting PGE2 into the extracellular
milieu, where a plethora of pathways will be activated through
binding to specific G-protein couple receptors [14]. On the other
hand, the active uptake back into the cytoplasm, where PGE2 will
be inactivated by 15-HPGD, is carried-out by prostaglandin
transporter (PGT) [15]. In fact, Holla and colleagues [16] reported
that PGT and MRP4 mRNA levels are inversely regulated in
human CRC, with PGT expression being downregulated and
MRP4 overexpressed in CRC tissues and cell lines leading to
higher levels of PGE2 extracellularly thus upregulating the effects
of COX-2/PGE2 pathway.
A decade ago the release of the first human genome draft
allowed a deeper knowledge on the architecture and function of
the human genome, highlighting the relevance of common genetic
variations on disease genesis. In CRC, family history is a well-
established etiologic factor, shedding some clues for the involve-
ment of low penetrance genes in its oncogenesis [17].
The COX-2 gene is genetically polymorphic and was the target
of several genetic association studies, implicating the involvement
of three polymorphism in COX-2 gene on colorectal tumors
development (rs20417, rs699466 and rs5275, also known as
2765G.C, 21195A.G and 8473T.C, respectively), although
not always consistently [18]. In a preliminary study, we reported
an increased susceptibility for CRC development in G allele
carriers of the rs689466A.G polymorphism in COX-2 promoter’s
[19].
Hoeft and colleagues [20] firstly identified two tagging single
nucleotide polymorphisms (tagSNPs), the rs8752 and rs2612656 in
HPGD gene, coding for the 15-PGDH protein, as increased
susceptibility markers for CRC development. More recently,
Thompson and colleagues [21] observed a 40% increased risk
associated with the rs2555639 SNP located at 17.74 kb upstream
of the 59UTR of HPGD gene that was further validated in the
replication set.
With the exception of a two-phase case-control study in a
Spanish population [22] no previous study inquired the role of
common genetic variants in MRP4 and PGT coding genes (ATP-
Binding Cassette Sub-Family C Member 4 (ABCC4) and solute carrier
organic anion transporter family, member 2A1 (SLCO2A1), respectively) in
CRC genesis. Neither addressed the combined effect of SNPs in
these four genes with pivotal roles in modulating the levels of
PGE2 extracellularly. So, in this case-control study we explored
the associations of 51 common genetic variations in COX-2/
HPGD/ABCC4/SLCO2A1 PGE2 pathway genes with CRC onset.
Materials and Methods
Sample Size Estimation
We estimated that the sample size required to detect an Odds
Ratio (OR) equal or superior to 1.70 is 200 patients and 400
controls (2:1 ratio) to achieve a statistical power of 80%, with a
significance level of 5%, for polymorphisms with a frequency
superior to 15%. (Epi Info version 6, Centers for Disease Control,
Atlanta, Georgia). Considering that r2, used to select the tagSNPs,
is inversely related to the magnitude by which the sample size must
be increased in a study design, for a r2 of 0.8 we needed to increase
our sample size by 25%.
Study Population
This non-matched hospital-based case-control study included
726 participants: 246 histologically confirmed CRC patients and
480 cancer-free controls, from the northern region of Portugal and
recruited at the Instituto Portugueˆs de Oncologia do Porto (IPO-Porto).
Written informed consent was obtained from all recruited
participants before their inclusion in the study, according to the
Declaration of Helsinki. This research project was approved by the
Ethics Committee of the IPO-Porto (ref. 0084/08) and Comissa˜o
Nacional de Protecc¸a˜o de Dados (ref. 6619/2011) that is the Portuguese
Data Protection Authority.
Control group. In this group, individuals between 50 and 75
years of age, without any clinical evidence of CRC or other
oncologic malignancy were randomly recruited from the blood
donor’s service at IPO-Porto between July 2005 and February
2008.
CRC patients group. Patients with histologically confirmed
CRC newly diagnosed between January 2002 and September
2007 were enrolled in this study. These patients were selected from
a colonoscopy database from the Gastroenterology Department,
aged 50 to 75 years, without previous history of inflammatory
bowel disease or hereditary syndromes and who were scheduled
for a follow-up consult at Servic¸o de Gastrenterologia or Unidade de
Digestivos at IPO Porto between March and May 2008.
Two hundred and forty seven CRC patients were included out
of the 387 expected to be recruited. During the recruitment or
afterwards by telephone interview patients were asked to recall
their lifestyle habits (smoking behavior, BMI, etc) in the previous
year of CRC diagnosis. Medical records were reviewed to extract
the clinicopathological variables (stage, tumor grade, presence of
synchronous and metachronous lesions) and to exclude misclas-
sification bias.
Sample Collection and Biological Processing
Blood samples were collected using standard venipuncture
technique with EDTA containing tubes. DNA was extracted from
peripheral blood leukocytes using the QIAamp DNA Blood Mini
Kit (Qiagen, Hilden, Germany), following the manufacturer’s
instructions.
For patients unable to provide a blood sample, the DNA was
extracted from formalin fixed paraffin embedded (FFPE) blocks
from the Pathology Department at our institute. Two to four
10 mm thickness section were used in each extraction depending
on the size of tissue area (1.5–3 cm2). Briefly, the CRC tissue
specimens from each glass slide were scraped, using a clean razor
blade, into a 1,5-ml microcentrifuge tube. The samples were
deparaffinised in xylene for 10 minutes, at room temperature,
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followed by centrifugation at 14.000 g–16.000 g for 3 minutes.
The tissue pellets were then rehydrated with 1 ml of absolute
ethanol, followed by centrifugation at 14.000 g–16.000 g for 3
minutes and the supernatant was discarded. This step was
repeated twice. Then, the tube was maintained open for 15
minutes to evaporate any remaining ethanol. Further steps of
DNA isolation were performed using the GRS Genomic DNA Kit
– Tissue, in accordance with the manufacturer’s protocol (GRiSP,
Porto, Portugal).
DNA was quantified using the NanoDrop 1000 Spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE, USA) and
stored at 220uC until genotype examination. The DNA quality
was determined by measuring the optical density (OD) 260/280
ratio.
Validation of DNA Genotyping Extracted from FFPE
Samples
To assess whether DNA isolated from FFPE sections is reliable
for retrospective genotyping we compared the genotypes of 20
somatic DNAs extracted from FFPE specimens to germline DNAs
isolated from fresh peripheral blood from the same patients. The
genotypes were highly concordant (100%).
Polymorphisms Selection
Using a tagSNP approach, the genetic variants were retrieved
from a set of common SNPs in the Caucasian population of
HapMap project (CEU). The Genome Variation Server (version
7.00) was used to recover tagSNPs capturing variations (1) with a
minor allele frequency equal or superior to 15%; (2) within the
coding region of the genes plus 2 Kb upstream and downstream
and (3) with a r2 superior to 0.8. A total of 140 tagSNPs were
captured: 6, 15, 31 and 88 tagSNPs in COX-2, HPGD, SLCO2A1
and ABCC4 genes, respectively. We further selected SNPs with
high likelihood of genotyping success using the Sequenom
platform, (Sequenom, San Diego, CA). Briefly, tagSNPs were
prioritized as follows: first, all non-singletons tagSNPs or singletons
with expected functional repercussion (FuncPred software) were
tested. TagSNPs with low genotyping scores were replaced with
representative variants; and finally the non-significant singletons
were included in the array design. A total of 55 SNPs were
successfully converted to the Sequenom platform.
Furthermore, we also included polymorphisms that were
previously associated with colorectal tumors development and
had a minor allele frequency equal or superior to 15% that failed
to converted to the Sequenom platform: rs20417, rs689466 and
rs5275 in COX-2 and rs2612656 and rs2555639 in HPGD genes.
Genotype Characterization
TagSNP genotyping was performed using MassARRAY iPLEX
Gold technology (Sequenom, San Diego, CA) based on multi-
plexed amplification followed by mass-spectrometric product
separation. This technique was carried-out by the Unidade de
Geno´mica/Servic¸o de Genotipagem do Instituto Gulbenkian de Cieˆncia.
All polymorphisms not included in the tagSNPs analysis were
characterized through allelic discrimination (Real-Time Polymer-
ase Chain Reaction) using validated TaqManH SNP genotyping
assays (C___2517145_20, C___7550203_10, C___15909858_20,
C___16038735_10 for the rs689466, rs5275, rs2612656 and
rs2555639, respectively) with the exception of the polymorphism
2765G.C (rs20417) which was custom designed (Applied
Biosystems, Foster City, California USA). Allelic discrimination
was performed by measuring end-point fluorescence using ABI
PRISM Sequence Detection System (Applied Biosystems, Foster
City, California USA).
Quality Control
Genotypes were excluded from the analysis if any of the
following criteria was applied: call rate inferior to 0.90; concor-
dance rate inferior to 0.95 and Hardy-Weinberg equilibrium
(HWE) with P,0.05. Blank templates were included in each 96
and 384-well plates to ensure contamination-free results. Two
researchers performed the genotype interpretation independently
and five to ten percent of all samples were randomly selected and
re-submitted to a new genetic characterization to confirm the
genotypes.
Statistical Analysis
For genetic distribution analysis, the Hardy–Weinberg equilib-
rium was tested by the Pearson’s goodness-of-fit test to compare
the observed versus the expected genotype distribution among the
control population.
Data analysis was performed using the computer software IBM
Statistical Package for Social Sciences-SPSS (IBM Corp., Armonk,
New York, USA) for Macintosh (version 19.0). Chi-square analysis
was used to compare categorical variables, using a 5% level of
significance. Non-parametric tests were used to compare mean
values. Odds ratio (OR) and its 95% confidence interval (CI) were
calculated as a measure of the association between the genetic
variants and the risk for the development of CRC. Covariates
proven to differ between group populations were included in the
logistic regression analysis. Gene-environment interaction analysis
were carried-out by stratifying data considering the gender,
smoking habits and body mass index (BMI). Additionally, a
bootstrap resampling was used to investigate the stability of risk
estimates (1000 replications). Furthermore, the false positive report
probability (FPRP) was used to confirm the noteworthiness of
significant findings, according to the study by Wacholder and
colleagues [23]. The FPRP threshold was set at 0.5 under an
assigned prior probability ranging from 0.01 to 0.25 to detect an
OR of 1.5.
Haplotype analysis was performed at a gene level using the
SNPStats software (www. http://bioinfo.iconcologia.net/SNPstats).
The haplotype frequencies were estimated using the implementa-
tion of the EM algorithm coded into the haplo.stats package. The
most frequent haplotype was automatically selected as the reference
category. For the HPGD, SLCO2A1 and ABCC4 genes the haplotype
blocks were constructed considering the most meaningful polymor-
phisms.
The open-source multifactor dimensionality reduction (MDR)
software (version 3.0.2) (www.epistasis.org) was used to assess
potential gene-gene interactions between SNPs with statistical
significant impact on CRC genetic susceptibility. The fitness of an
MDR model was estimated by determining the testing accuracy
and its cross-validation consistency (CVC). Using a 10-fold cross-
validation method the data was divided into 10 sets, in which 9
subsets were training sets and one subset was a test set. Hence, the
CVC is a measure of the number of times of 10 divisions of the
dataset the best model was extracted. The single best model
normally has the maximal testing accuracy and CVC. Statistical
significance was evaluated using a 1000-fold permutation test to
compare observed testing accuracies with those expected under
the null hypothesis of null association. Permutation testing
corrected for multiple testing by repeating the entire analysis on
1000 datasets that were consistent with the null hypothesis.
Genetic Variability in PGE2 Pathway Genes and CRC
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Results
Description of Study Population
The characteristics of the study population are summarized in
Table 1. Cases were significantly older than controls with a
median age of 63 years (50–75) (vs. 58 years in controls (50–69),
P,0.001). Males were overrepresented in both groups (60.1% vs
65.4% in cases and controls, respectively, P= 0.159) and nearly
77% of participants were overweight (P= 0.955). The majority of
participants had also never smoked in either category (37.4% in
cases and 39.7% in controls, P= 0.636).
Genotype Frequencies and Risk Estimates
Three SNPs and four samples were excluded from the analysis
due to genotyping failure and four SNPs were dropped because
their frequencies deviated from HWE (P,0.05). A total of 51
SNPs were included in the risk estimate analysis. The mean
genotype call and concordance rates were 99.02% and 99.3%,
respectively. The description of selected SNPs is displayed in Table
S1.
Overall seven genetic polymorphisms across the four genes were
implicated in colorectal carcinogenesis, as can be observed in
Table 2. The AG and GG genotypes of the rs689466 polymor-
phism in COX-2 gene were overrepresented in the group of cases
leading to an increased risk for CRC more noticeable for
homozygous GG although this was not statistically significant in
the multivariate analysis (OR = 2.01; 95%CI:0.93–4.35,
P= 0.076). The rs1346271 and rs1426945 SNPs in HPGD gene
were associated with a 32% and 44% decreased risk for CRC
onset (95%CI:0.47–0.96, P= 0.029 and 95%CI:0.34–0.93,
P= 0.026, for the GC and AA homozygous carriers of the
rs1346271 and rs1426945 polymorphisms, respectively). Out of
the fifteen genetic variations analyzed in the SLCO2A1 gene only
the rs6439448 and rs7616492 polymorphisms influenced the
Table 1. Description of participants.
Cases Controls
(n = 246) (n = 480) P value
Demographics
Age (years)
Mean (SD) 63 (7.2) 58 (4.9) ,0.001
Median (min–max) 63 (50–75) 58 (50–69)
Sex, n (%)
Male 146 (60.1) 314 (65.4) 0.159
Female 97 (39.9) 166 (34.6)
Lifestyle behavior
BMI (Kg/m2)
Mean (SD) 28 (4.2) 28 (3.6) 0.510
Median (min–max) 28 (20–43) 27 (20–41)
BMI category, n (%)#
,25 34 (23.4) 48 (23.2) 0.955
$25 111 (76.6) 159 (76.8)
Smoking status, n (%)
Never-smokers 92 (62.6) 219 (60.3) 0.636
Ever-smokers* 55 (37.4) 144 (39.7)
Tumor characteristics
Tumor location, n (%)
Rectum 127 (52.3) –
Colon 116 (47.7) –
Stage, n (%)
I–II 121 (52.6) –
III–IV 109 (47.4) –
Grade, n (%)
Low grade 135 (95.7) –
High grade 6 (2.4) –
Synchronous tumors, n (%)
Yes 14 (5.5) –
No 224 (88.2) –
BMI, body mass index;
#Categorization based on the cutoff defined by the world Health Organization for overweight people;
*Never- and former-smokers pooled together; For synchronous tumors the most advanced lesions was the one considered in the tumors’ characterization.
doi:10.1371/journal.pone.0092000.t001
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susceptibility for CRC. Individuals carriers of the rs6439448
heterozygous AG genotype presented an OR of 0.68
(95%CI:0.47–0.99, P= 0.047). On the other hand, a two-fold
increased predisposition was noticed for individuals carrying both
copies of the A allele of rs7616492 polymorphism (95%CI:1.27–
3.32, P= 0.003). Focusing on ABCC4 gene, a 1.76 enhanced
susceptibility was observed with the AA genotype of rs1751051
SNP and a protection was evident for AG genotype carriers of
rs1751031 polymorphism (OR = 0.68; 95%CI:0.47–0.97,
P= 0.032). The bootstrap analysis supported our results (Table 2).
The genotypes distribution of all included SNPs is reported in
Table S2.
The FPRP analysis revealed that the unadjusted significant
associations observed in Table 2, retained their significance
(FPRP#0.5) when a prior probability equal or superior to 0.10
was considered, with the exception of the rs689466 polymorphism
(GG vs AA) that presented an FPRP of 0.690, suggesting possible
bias in this positive finding (data not shown).
Gene-environment Interaction Analysis
Upon a stratified analysis we observed, that with the exception
of rs6439448 and rs1751051 polymorphisms in SLCO2A1 and
ABCC4 gene, respectively all other variants appear to have a sex-
dependent behavior particularly relevant in male carriers of GG
genotype of COX-2 rs689466 SNP (OR = 3.3; 95%CI:1.23–9.09,
P= 0.018) and AA homozygous for the rs1426945 polymorphism
in HPGD gene (OR = 0.38; 95%CI:0.20–0.74, P= 0.004), as
reported in Table 3.
Furthermore, a nearly 6-fold increased risk was observed in
ever-smokers carrying the GG genotype for the COX-2 rs689466
polymorphism (95%CI:1.49–22.42, P= 0.011 vs OR = 0.63;
95%CI:0.13–3.08, P= 0.56 in never-smokers). In contrast, the
ABCC4 rs1751051 AA genotype seemed to lead to a higher
susceptibility in individuals who never smoked (OR = 2.32;
95%CI:1.05–5.13, P= 0.037). The rs7616492 homozygous AA
genotype of SLCO2A1 gene played opposing roles when consid-
ering the interaction with BMI (OR = 0.06; 95%CI:0.01–0.69,
P= 0.023 and OR = 2.18; 95%CI:1.00–4.77, P= 0.051 for indi-
viduals with BMI ,25 and overweight (BMI$25 kg/m2),
respectively).
Haplotype Analysis
Four common haplotypes were described for COX-2 gene, as
can be observed in Table 4. The most frequent haplotype, the
AGT, was present in 52% of controls and used as the reference
one. The block containing the rs689466 G allele, GGT, was
associated with a 51% increased susceptibility consistent with the
individual SNP analysis (95%CI:1.10–2.06, P= 0.010). Although
we did not noticed any influence of rs5275 C allele in CRC risk
independently, carriers of AGC haplotype had a 1.53–fold higher
predisposition for CRC (95%CI:1.13–2.19, P= 0.008). The
AGAC haplotype of HPGD gene was the most common (30%)
out of the five blocks. An enhanced risk was observed for
Individuals carrying the blocks, AGGC and ACGC, containing
the rs1426945 G (OR = 1.70; 95%CI:1.22–2.37, P= 0.002 and
OR = 1.60; 95%CI:1.04–2.44, P= 0.031, respectively). Coherent-
ly, the opposing rs1426945 AA genotype conferred a 40% risk
reduction in the SNP analysis. The haplotype TAGAAC of
SLCO2A1 gene containing the decreased risk associated rs6439448
A allele and rs7616492 G allele led to a nearly 50% protection for
CRC development compared with individuals carrying the
TCAAAC reference block. The only common haplotype encom-
passing the rs1751051 A allele of ABCC4 gene (AATTA) increased
the susceptibility for CRC onset by over two-folds in contrast with
the TATTA most frequent haplotype. No block contained the
rs1751031 G allele.
Gene-gene Interaction Analysis
An exhaustive MDR analysis was carried-out to evaluate all
possible combinations of rs689466, rs1346271, rs1426945,
rs6439448, rs7616492, rs1751051 and rs1751031 polymorphisms
proven to be associated with CRC onset in the individual SNP
analysis. As shown in Table 5, we observed the highest CVC (10/
10) and accuracy (0.6957) in the four-factor interaction model,
which shows an interaction between rs1426945 HPGD polymor-
phism, rs6439448 SLCO2A1 SNP and rs1751051 and rs1751031
polymorphisms in ABCC4 gene. This gene-gene interaction was
associated with a 5-fold increased risk for CRC development
(95%CI:3.89–7.02, P,0.0001).
Discussion
Early screening and follow-up of individuals previously diag-
nosed with colorectal adenomas is the cornerstone of CRC
prevention [3]. Nevertheless, the compliance rates in countries
with implemented population-based CRC screening guidelines are
far from the desirable for a successful impact in CRC incidence
[4]. Although the regular use of NSAIDs has been consistently
effective in the primary prevention of colorectal tumors its use is
currently compromised by the onset of serious gastrointestinal side
effects in average-risk population [24]. So, the challenge falls in the
identification of biomarkers that could target higher-risk popula-
tions for colorectal screening and/or chemopreventive strategies.
In this case-control study we assessed the involvement of 51
tagSNPs in four genes (COX-2/HPGD/SLCO2A1/ABCC4) with key
roles in PGE2 pathway in CRC development. Our results indicate
that seven genetic polymorphisms are implicated in colorectal
carcinogenesis: the rs689466A.G in COX-2, the rs1346271G.C
and rs1426945G.A in HPGD, the rs6439448C.A and
rs7616492G.A in SLCO2A1 and the rs1751051T.A and
rs1751031A.G in ABCC4 gene.
The rs689466A.G in COX-2 gene had a synergetic effect in
CRC oncogenesis that increased with allele dosage, further
reinforcing its causative role in cancer development. The GG
homozygous genotype enhanced the susceptibility for CRC onset
by 2-fold and appeared to have a sex and smoking habits
dependent behavior, with ever-smokers having a nearly 6-fold
increased genetic predisposition for CRC. These data follow our
previous observations from a preliminary study [19]. Furthermore,
two haplotypes containing either the rs689466G (GGT) or the
rs5275C alleles (AGC) led to a 50% increase on the risk for CRC.
The lack of consistency observed between epidemiological studies
addressing the rs689466A.G SNP in different ethnic back-
grounds or cancer models appears to suggest that not only
population stratification and lifestyle habits might modulate this
polymorphism behavior but also its influence might be cell, tissue
and pathological condition-dependent [19,25–29]. In fact, in a
recently published study we reported that this polymorphism
located at 21195 nucleotides upstream exon 1 increases COX-2
transcriptional activity in two colon cancer cell lines [30]. This was
also noticeable in human hepatoma cell lines [31] but antagonizes
the increased promoter activity observed for the rs689466 A allele
in gastric cancer cell lines [25]. COX-2 overexpression is
suggested as one of the smoke-induced pathways involved in
carcinogenesis [32,33]. Tobacco contains more than 60 identified
carcinogens and even though some, such as, nicotine and
benzo[a]pyrene, were shown to trigger COX-2 expression through
b-adrenoceptors and ERK1/2 pathways, respectively, the patho-
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Table 3. Risk estimates for the involvement of polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes in colorectal cancer onset
stratified by sex, smoking habits and body mass index.
Gene n aOR 95%CI P value Pbootstrap
COX-2
rs689466 (AAvsGG)
Sex
Female 180 0.89 0.25–3.23 0.862 0.840
Male 313 3.34 1.23–9.09 0.018 0.004
Smoking habits
Never-smokers 213 0.63 0.13–3.08 0.564 0.429
Ever-smokers* 142 5.77 1.49–22.42 0.011 0.004
BMI (kg/m2)#
,25 59 3.63 0.20–64.59 0.381 0.071
$25 182 2.41 0.72–8.07 0.154 0.123
HPGD
rs1346271 (GGvsGC)
Sex
Female 214 0.42 0.23–0.78 0.005 0.007
Male 401 0.86 0.55–1.33 0.487 0.500
Smoking habits
Never-smokers 271 0.88 0.51–1.51 0.644 0.613
Ever-smokers* 171 0.62 0.30–1.27 0.190 0.183
BMI (kg/m2)#
,25 69 0.57 0.19–1.69 0.312 0.312
$25 234 0.69 0.40–1.19 0.185 0.186
rs1426945 (GGvsAA)
Sex
Female 140 1.20 0.52–2.79 0.672 0.677
Male 211 0.38 0.20–0.74 0.004 0.006
Smoking habits
Never-smokers 168 1.02 0.50–2.08 0.966 0.969
Ever-smokers* 101 0.83 0.31–2.21 0.705 0.730
BMI (kg/m2)#
,25 42 1.07 0.28–4.12 0.922 0.932
$25 135 1.29 0.59–2.86 0.525 0.563
SLCO2A1
rs6439448 (CCvsCA)
Sex
Female 253 0.72 0.39–1.33 0.292 0.314
Male 433 0.66 0.41–1.07 0.094 0.082
Smoking habits
Never-smokers 302 0.72 0.41–1.28 0.269 0.265
Ever-smokers* 185 0.64 0.29–1.41 0.272 0.277
BMI (kg/m2)#
,25 79 1.04 0.34–3.13 0.95 0.947
$25 258 0.75 0.42–1.34 0.34 0.312
rs7616492 (GGvsAA)
Sex
Female 135 1.60 0.72–3.58 0.250 0.254
Male 260 2.35 1.28–4.28 0.005 0.008
Smoking habits
Never-smokers 163 1.48 0.64–3.27 0.37 0.382
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genesis of smoking related CRC is still understudied [34]. Further
functional studies are needed to elucidate the nature of this gene-
environment interaction.
The rs5275T.C polymorphism, set at 8473 base pairs from
exon 1 was previously associated with an increased risk for
colorectal adenoma and here with a higher susceptibility for CRC
in the context of the AGC haplotype (vs AGT) [18]. This T-to-C
substitution in the 39UTR was proven to contribute to COX-2
overexpression by disrupting the miR-542-3p:mRNA interaction
and thus decreasing COX-2 mRNA decay [35].
As already mentioned, COX-2 has a predominant role in the
synthesis of the pro-carcinogenic PGE2 bioactive lipid and the
main molecular target of NSAIDs. In fact Chan and colleagues
[36] noticed that aspirin’s preventive role was exclusively effective
in the subgroup of colon cancers overexpressing COX-2 enzyme.
So, the genetic variability in COX-2 gene may help predict
individuals at higher risk and expected to be exposed to higher
levels of COX-2.
The expression and activity of 15-PGDH is repressed in
colorectal cancer and Apcmin mouse adenomas, leading to a
decrease in PGE2 catabolism, local tissue accumulation of PGE2
and resistance to Celecoxib chemoprevention in colon tumors
[11,13].
We were not able to reproduce in our population the
associations reported in previous studies [20,21,37]. This could
be attributed to population stratification involving differences in
genetic ancestry as the study developed by Hoeft and colleagues
[20] involved participants from 10 different European countries or
these variants could be in linkage disequilibrium with a causative
SNP with a lower allele frequency (,15%) thus limiting our
statistical power to detect a true association. Nevertheless, we
observed for the first time that the rs1346271G.C and
rs1426945G.A tagSNPs in HPGD gene were associated with a
decrease risk for CRC development. Both of these genetic
variations are located in the 59UTR of HPGD gene altering the
transcription factors binding sites as predicted by the SNPinfo
software (www.snpinfo.niehs.nih.gov) that ultimately could lead to
a differential expression of 15-PGDH. Remarkably, inherited
mutations in HPGD gene are linked to the development of primary
hypertrophic osteoarthropathy (PHO), thus reinforcing the impact
that the genetic variability in HPGD might portray in disease
development by disrupting the normal 15-HPGD levels or activity
[38].
To the best of our knowledge this is the first study addressing the
involvement of these specific genetic polymorphisms in SLCO2A1
and ABCC4 genes, coding for the PGT and MRP4 specific
prostaglandin transporters, in disease development. The efflux-
Table 3. Cont.
Gene n aOR 95%CI P value Pbootstrap
Ever-smokers* 119 1.27 0.51–3.19 0.60 0.628
BMI (kg/m2)#
,25 50 0.06 0.006–0.69 0.023 0.012
$25 142 2.18 1.00–4.77 0.051 0.050
ABCC4
rs1751051 (TTvsAA)
Sex
Female 151 2.20 0.83–5.81 0.111 0.151
Male 269 1.70 0.91–3.16 0.096 0.100
Smoking habits
Never-smokers 179 2.32 1.05–5.13 0.037 0.033
Ever-smokers* 114 1.26 0.44–3.57 0.665 0.681
BMI (kg/m2)#
,25 46 3.57 0.39–32.52 0.260 0.114
$25 157 1.82 0.86–3.89 0.120 0.145
rs1751031 (AAvsAG)
Sex
Female 249 0.51 0.28–0.94 0.030 0.031
Male 437 0.78 0.49–1.22 0.269 0.269
Smoking habits
Never-smokers 301 0.69 0.39–1.21 0.196 0.203
Ever-smokers* 193 0.76 0.38–1.52 0.439 0.454
BMI (kg/m2)#
,25 80 0.52 0.19–1.45 0.213 0.255
$25 261 0.76 0.44–1.31 0.324 0.351
aOdds ratio (OR) adjusted for age (categorical variable, using the global median age of 60 years as cutoff); CI, confidence interval; BMI, body mass index; #Categorization
based on the cutoff defined by the world Health Organization for overweight people;
*Never- and former-smokers pooled together.
Statistical significant results are at bold.
doi:10.1371/journal.pone.0092000.t003
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dominated flow of PGE2 in neoplastic tumors, due to an increased
in COX-2 and MRP4 and repressed expression of 15-HPGD and
PGT is associated with high levels of PGE2 in the extracellular
milieu culminating in the activation of a plethora of pathways that
potentiate tumor development [8,11,16]. The rs6839448C.A and
rs7617492G.A tagSNPs in SLCO2A1 were implicated in colo-
rectal carcinogenesis Furthermore, individuals carrying the
haplotype containing both the A and G alleles of rs6839448 and
rs7617492 tagSNPs (TAGAAC), respectively, had a nearly 50%
protection for CRC. Although, the rs6439448 is not expected to
be functional it tags two SNPs with predicted impact on PGT
expression: the rs2370512T.A located in the 39UTR that could
affect the binding of microRNAs and stability of mRNA and the
nonsynonymous rs34550074G.A SNP at codon 396 that codes
for two different amino acids (Alanine.Threonine) with potential
repercussion on protein structure and function.
Focusing on ABCC4 gene, two tagSNPs influenced the genetic
susceptibility for the development of CRC (rs1751051 and
rs1751031), although none of the SNPs in the LD blocks tagged
by these two SNPs could explain the altered risk for cancer
development.
Table 4. Haplotype frequencies between patients and controls and risk estimates for their involvement in colorectal cancer
development.
Gene/Haplotype % Cases % Controls aOR 95%CI P
COX-2J
A-G-T 44.9 52.4 1 Reference –
G-G-T 21.9 17.3 1.51 1.10–2.06 0.010
A-G-C 18.3 13.4 1.57 1.13–2.19 0.008
A-C-C 10.3 15.1 0.82 0.56–1.20 0.310
HPGD*
A-G-A-C 23.8 30.5 1 Reference –
A-G-G-C 25.4 17.8 1.70 1.22–2.37 0.002
A-C-G-T 17.9 20.1 1.12 0.77–1.62 0.550
A-C-G-C 12.8 10.8 1.60 1.04–2.44 0.031
G-G-A-C 6.4 8.0 1.05 0.57–1.92 0.880
SLCO2A1£
T-C-A-A-A-C 25.7 26.1 1 Reference –
T-A-G-A-A-C 8.3 12.7 0.54 0.33–0.82 0.012
C-C-G-A-A-C 9.6 10.6 0.86 0.54–1.36 0.520
T-C-G-A-A-C 6.8 9.0 0.75 0.44–1.25 0.270
T-C-G-A-G-C 6.5 8.7 0.68 0.40–1.15 0.150
ABCC4¥
T-A-T-T-A 10.9 12.0 1 Reference –
T-A-T-C-A 7.9 12.0 1.07 0.49–2.34 0.860
T-G-T-T-A 7.8 10.1 1.13 0.57–2.24 0.740
A-A-T-T-A 11.6 7.5 2.28 1.12–4.67 0.024
T-G-C-T-A 8.5 4.0 1.58 0.67–3.68 0.290
T-G-C-C-A 4.5 6.4 0.88 0.40–1.96 0.760
aOdds ratio (OR) adjusted for age (categorical variable, using the global median age of 60 years as cutoff); CI, confidence interval.
JSNPs order: rs689466-rs20417-rs5275.
*SNPs order: rs2612656-rs1346271-rs1426945-rs12500316.
£SNPs order: rs4241362-rs6439448-rs7616492-rs7625035-rs1131598-rs10935090.
¥SNPs order: rs1751051-rs2274403-rs1678405-rs1678396-rs1751031.
doi:10.1371/journal.pone.0092000.t004
Table 5. MDR analysis for the colorectal cancer risk prediction.
Best model CV accuracy CV consistency OR 95%CI P
rs1346271, rs1426945 0.6113 10/10 2.53 1.91–3.35 ,0.0001
rs1426945,rs6439448, rs1751031 0.6376 6/10 3.19 2.39–4.28 ,0.0001
rs1426945,rs6439448, rs1751051, rs1751031 0.6957 10/10 5.23 3.89–7.02 ,0.0001
MDR, multifactor dimensionality reduction; CV, cross-validation; OR, odds ratio; CI, confidence interval.
doi:10.1371/journal.pone.0092000.t005
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Common diseases have proven to be much more challenging to
understand, as they are thought to arise due to the synergetic effect
of many different susceptibility DNA variants interacting with
environmental factors. Although, we have noticed some interac-
tions between the aforementioned tagSNPs and demographic/
lifestyle habits, the lack of complete characterization of the study
population, decreased the statistical power and the scarcity of
studies inquiring the influence of those environmental factors
specifically in these key players in PGE2 pathway have compro-
mised the interpretation of those associations. Furthermore, we
used the data-mining analytical approach, MDR, to enhance the
likelihood of identifying gene-gene interactions and a strong
interaction between four SNPs in HPGD, SCO2A1 and ABCC4
genes reinforcing the data from single–locus analysis and lending
further support to the involvement of genetic susceptibility
biomarkers in colorectal carcinogenesis.
There are a few limitations that should be considered. First, this
study has a case-control design, so we could not rule out selection
bias, although if this was the case our results would tend to have
strong associations; or recall bias that could decrease the accuracy
of collected data. Second, our sample size allowed us to detect
strong associations in the overall analysis for frequent polymor-
phisms, so we cannot exclude the influence of rarer SNPs or with
more modest influences in the PTGS2/HPGD/SLCO2A1/ABCC4
genes in CRC development. Furthermore, and although we
employed statistical strategies to assess the robustness of associa-
tions, namely the use of bootstrap resampling, an independent and
larger data set is needed to corroborate our findings and allow a
more comprehensive understanding of the gene-environment
interactions.
In conclusion, we observed that seven tagSNPs in key genes
regulating the procarcinogenic-PGE2 levels in tumor microenvi-
ronment were implicated in CRC development. Particularly, the
COX-2 rs689466GG genotype in ever-smokers and a gene-gene
interaction involving the rs1426945 HPGD polymorphism,
rs6439448 SLCO2A1 SNP and rs1751051 and rs1751031 poly-
morphisms in ABCC4 gene. A clearer understanding on CRC
etiology through the identification of risk biomarkers might allow a
better definition of risk models that are more likely to benefit from
targeted preventive strategies.
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Table S1. Characterization of genetic polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes and quality control results 
Gene tagSNP 
Other SNPs on 
the block 
Genotype call 
rate 
Genotype 
concordance rate 
HWE 
Passed quality 
check? 
COX-2 
rs689466 Candidate gene 0.98  0.97 0.901 Yes 
rs20417 Candidate gene 0.98 0.96 0.998 Yes 
rs5275 Candidate gene 0.97 1.00 0.999 Yes 
HPGD 
rs2555639 Candidate gene 0.98 1.00 0.989 Yes 
rs1346271 singleton 1.00 1.00 0.167 Yes 
rs2555632 rs3101255 1.00 1.00 0.681 Yes 
rs2303520 rs13127058 0.99 1.00 0.633 Yes 
rs1863642 rs2612659 0.99 1.00 0.474 Yes 
rs1426945 rs3756273 1.00 0.97 0.976 Yes 
rs12500316 
rs1863641 
0.99 1.00 0.508 Yes 
rs11722919 
rs8752 
rs1426947 
1.00 1.00 0.948 Yes 
rs2612658 
rs11133041 
rs11724251 
rs2612656 
rs1816204 
0.92 0.96 0.917 Yes 
rs3857075 
SLCO2A1 
rs4241362 
rs4241361 
0.99 1.00 0.756 Yes 
rs4634113 
rs6804798 
rs9828294 
rs9855403 
rs9874493 
rs9882333 
rs11720811 
rs764392 
rs4327389 
0.98 1.00 0.550 Yes 
rs4854777 
rs5013525 
rs7646298 
rs7646473 
rs12695600 
rs6439448 
rs2370512 
0.99 0.97 0.979 Yes 
rs3923835 
rs3923835 
rs4854768 
rs4854769 
rs34550074 
rs9821091 
rs7630191 
1.00 1.00 0.651 Yes 
rs9841380 
rs6439450 
rs7617777 
rs9834727 
rs9820625 
rs9836830 
1.00 1.00 0.948 Yes 
rs9917636 
rs11709172 
rs13083175 
rs9834412 
rs4854785 
0.98 1.00 0.951 
Yes 
rs13067921 
rs4241365 rs7653639 0.99 1.00 0.923 Yes 
rs4331673 rs11720843 1.00 1.00 0.994 Yes 
rs4854784 rs7636169 0.98 0.97 0.871 Yes 
rs7340717 rs7340718 0.98 1.00 0.600 Yes 
rs7616492 rs10935089 0.99 1.00 0.938 Yes 
rs7625035 rs9822027 1.00 1.00 0.455 Yes 
rs1131598 Singleton 1.00 1.00 0.441 Yes 
rs10935090 Singleton 0.99 1.00 0.815 Yes 
rs11915399 Singleton 0.99 1.00 0.998 Yes 
 
 
 
 
ABCC4 
 
 
rs4148422 rs17300935 1.00 0.95 0.006   No 
rs9524821 [rs9516532] 0.99 1.00 0.604 Yes 
rs3782958 
rs4148515 
0.99 1.00 0.931 Yes 
rs10508023 
rs869951 
rs871052 
1.00 1.00 0.854 Yes 
rs8001444 
rs4771912 rs7981095 0.99 0.97 0.936 Yes 
rs4148421 
rs9524864 
0.98 1.00 0.998 Yes rs9524873 
rs10508017 
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Gene tagSNP 
Other SNPs on 
the block 
Genotype call 
rate 
Genotype 
concordance rate 
HWE 
Passed quality 
check? 
ABCC4 
 
rs8002180 
rs4148424 
1.00 1.00 0.694 Yes 
rs4771910 
rs7317112 
rs7322318 
rs8001475 
rs9584288 
rs9590228 
rs9590222 rs12100301 0.95 1.00 <0.001 No 
rs2127295 
rs2698243 
0.99 0.97 0.657 Yes 
rs1564355 
rs1617785 
rs1630807 
rs1678363 
rs1678394 
rs1729748 
rs2766481 
rs3825415 
rs6650282 
rs1751051 [rs1751050] 0.99 1.00 0.999 Yes 
rs9590220 
rs9590216 
1.00 0.96 0.018 No 
rs17235152 
rs2892715 rs9561814 1.00 1.00 0.473 Yes 
rs2892713 rs12865305 1.00 1.00 0.313 Yes 
rs4612933 
rs899494 
1.00 1.00 0.936 Yes 
rs899495 
rs899496 
rs1678403 
rs1824911 
rs1824913 
rs1926657 
rs3782965 
rs4148465 
rs4148469 
rs4303338 
rs4334136 
rs4505186 
rs4773854 
rs4773855 
rs7325019 
rs7333234 
rs7335147 
rs7983336 
rs7987653 
rs7988494 
rs9524831 
rs9524833 
rs9524845 
rs9524856 
rs12870204 
rs4148437 
rs9556466 
99.3 1.00 0.665 Yes 
rs2892716 
rs4148436 
rs4148446 
rs10508018 
rs12867485 
rs9561811 
0 - - No 
rs17189481 
rs1611822 rs1751015 1.00 1.00 0.969 Yes 
rs1678386 rs9516530 1.00 1.00 0.818 Yes 
rs2274403 
rs3864997 
1.00 0.97 0.862 Yes 
rs4148481 
rs17268122 rs17268163  0.93 0.96 0.027 No 
rs1751027 
rs1564351 
1.00 1.00 0.396 Yes 
rs4148487 
rs17189390 
rs17268170 
rs4148476 
rs4773843 
1.00 1.00 0.280 Yes 
rs9524822 
rs1678374 rs1751025 0.99 1.00 0.964 Yes 
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Gene tagSNP 
Other SNPs on 
the block 
Genotype call 
rate 
Genotype 
concordance rate 
HWE 
Passed quality 
check? 
       
ABCC4 
rs1678405 
rs2793821 
0.99 1.00 0.722 Yes rs6492768 
rs7330933 
rs1678396 rs2766482 1.00 1.00 0.537 Yes 
rs1628382 
rs4148527 
0.27 1.00 - No rs8001657 
rs12584534 
rs1678354 rs1751059 0 - - No 
rs1751031 
rs931111 
1.00 1.00 0.372 Yes 
rs1189444 
rs1189451 
rs1189452 
rs1729747 
rs2619312 
rs5016378 
rs7993878 
rs9302040 
1.00 0.97 0.346 Yes 
rs9302042 
rs9302043 
rs9556455 
rs9561768 
rs9561769 
rs9590168 
rs10219913 
rs6492763 rs10508024 0.99 0.97 0.520 Yes 
rs3742106 
rs4148544 
0.99 1.00 0.987 Yes 
rs4148549 
rs4148551 
rs7330196 
rs9302039 
rs9524769 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal cancer onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95%CI P value aOR 95%CI P value 
COX-2         
rs689466         
   AA 143 (58.8) 323 (68.4) 1.00 Reference - 1.00 Reference - 
AG 85 (35.0) 133 (28.2) 1.44 1.03-2.02 0.032 1.53 1.08-2.17 0.018 
GG 15 (6.2) 16 (3.4) 2.12 1.02-4.40 0.040 2.02 0.93-4.39 0.076 
rs20417         
GG 179 (74.9) 328 (69.3) 1.00 Reference - 1.00 Reference - 
GC 55 (23.0) 132 (27.9) 0.76 0.53-1.10 0.145 0.80 0.55-1.16 0.390 
CC 5 (2.1) 13 (2.7) 0.71 0.25-2.01 0.511 0,64 0.22-1.90  
s5275         
TT 122 (50.8) 235 (50.9) 1.00 Reference - 1.00 Reference - 
TC 89 (37.1) 189 (40.9) 0.91 0.65-1.27 0.567 0.93  0.66-1.32 0.390 
CC 29 (12.1) 38 (8.2) 1.47 0.86-2.50 0.153 1.39 0.80-2.41  
HPGD         
rs2555629         
TT 111 (46.1) 216 (45.6) 1.00 Reference - 1.00 Reference - 
TC 101 (41.9) 209 (44.1) 0.94 0.68-1.31 0.715 0.99 0.70-1.40 0.960 
CC 29 (12.0) 49 (10.3) 1.15 0.69-1.92 0.589 1.07 0.63-1.83  
rs2612656         
AA 160 (72.7) 295 (65.6) 1.00 Reference - 1.00 Reference - 
AG 47 (21.4) 137 (30.4) 0.63 0.43-0.93 0.019 0.71 0.48-1.05 0.110 
GG 13 (5.9) 18 (4.0) 1.33 0.64-2.79 0.446 1.48 0.69-3.18  
rs8752         
TT 91 (37.1) 197 (41.2) 1.00 reference - 1.00 Reference - 
TC 112 (45.7) 219 (45.8) 1.11 0.79-1.55 0.553 1.16 0.82-1.65 0.398 
CC 42 (17.1) 62 (13.0) 1.47 0.92-2.33 0.105 1.61 0.98-2.62 0.059 
rs1346271         
GG 104 (42.4) 174 (36.2) 1.00 reference - 1.00 Reference - 
GC 97 (39.6) 246 (51.2) 0.66 0.47-0.92 0.016 0.68 0.47-0.96 0.029 
CC 44 (18.0) 60 (12.5) 1.23 0.78-1.94 0.382 1.34 0.83-2.17 0.231 
rs2555632         
TT 143 (58.4) 284 (59.3) 1.00 reference - 1.00 Reference - 
TC 88 (35.9) 174 (36.3) 1.00 0.72-1.39 0.979 1.14 0.81-1.60 0.470 
CC 14 (5.7) 21 (4.4) 1.32 0.65-2.68 0.434 1.44 0.69-3.00 0.331 
rs2303520         
GG 167 (69.3) 342 (71.4) 1.00 reference - 1.00 Reference - 
GA 66 (27.4) 123 (25.7) 1.10 0.77-1.56 0.599 1.09 0.76-1.58 0.641 
AA 8 (3.3) 14 (2.9) 1.17 0.48-2.84 0.728 1.30 0.52-3.28 0.576 
rs1863642         
GG 126 (52.3) 231 (48.1) 1.00 reference - 1.00 Reference - 
GT 96 (39.8) 212 (44.2) 0.83 0.60-1.15 0.261 0.81 0.58-1.14 0.233 
TT 19 (7.9) 37 (7.7) 0.94 0.52-1.71 0.842 0.94 0.51-1.76 0.854 
rs1426945         
GG 110 (44.7) 169 (35.3) 1.00 reference - 1.00 Reference - 
GA 108 (43.9) 233 (48.6) 0.71 0.51-0.99 0.044 0.70 0.50-1.00 0.050 
AA 28 (11.4) 77 (16.1) 0.56 0.34-0.92 0.020 0.56 0.34-0.93 0.026 
rs12500316         
CC 150 (62.0) 262 (54.7) 1.00 reference - 1.00 Reference - 
CT 78 (32.2) 191 (39.9) 0.71 0.51-0.99 0.045 0.73 0.52-1.03 0.071 
TT 14 (5.8) 26 (5.4) 0.94 0.48-1.86 0.860 1.01 0.50-2.08 0.972 
SLCO2A1         
rs4241362         
TT 152 (63.3) 333 (69.5) 1.00 reference - 1.00 Reference - 
TC 73 (30.4) 130 (27.1) 1.23 0.87-1.74 0.239 1.14 0.79-1.63 0.487 
CC 15 (6.2) 16 (3.3) 2.05 0.99-4.26 0.049 1.82 0.84-3.94 0.130 
rs7646392          
CC 92 (38.8) 175 (36.5) 1.00 reference - 1.00 Reference - 
CT 97 (40.9) 220 (45.8) 0.84 0.59-1.19 0.321 0.97 0.67-1.40 0.869 
TT 48 (20.3) 85 (17.7) 1.07 0.70-1.66 0.747 1.28 0.81-2.04 0.286 
rs6439448         
CC 174 (72.2) 320 (66.7) 1.00 reference - 1.00 Reference - 
CA 56 (23.2) 143 (29.8) 0.72 0.50-1.03 0.073 0.68 0.47-1.00 0.047 
AA 11 (4.6) 17 (3.5) 1.19 0.54-2.60 0.662 0.93 0.39-2.20 0.869 
         
         
 110 
Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal cancer onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95%CI P value aOR 95%CI P value 
rs9821091         
GG 110 (44.5) 180 (37.6) 1.00 reference - 1.00 Reference - 
GA 105 (42.5) 235 (49.1) 0.73 0.52-1.02 0.063 0.79 0.56-1.12 0.181 
AA 32 (13.0) 64 (13.4) 0.82 0.50-1.33 0.418 0.86 0.52-1.43 0.561 
rs9820625         
AA 77 (31.3) 141 (29.4) 1.00 reference - 1.00 Reference - 
AC 110 (44.7) 232 (48.3) 0.87 0.61-1.24 0.440 1.00 0.69-1.46 0.998 
CC 59 (24.0) 107 (22.3) 1.01 0.66-1.54 0.964 1.14 0.73-1.78 0.574 
rs9834412         
CC 140 (59.6) 270 (56.1) 1.00 reference - 1.00 Reference - 
CA 76 (32.3) 179 (37.2) 0.82 0.58-1.15 0.245 0.78 0.55-1.11 0.170 
AA 19 (8.1) 32 (6.7) 1.14 0.63-2.09 0.660 1.13 0.60-2.11 0.707 
rs4241365         
TT 156 (64.5) 282 (58.9) 1.00 reference - 1.00 Reference - 
TC 72 (29.8) 169 (35.3) 0.77 0.55-1.08 0.130 0.82 0.57-1.16 0.255 
CC 14 (5.8) 28 (5.8) 0.90 0.46-1.77 0.768 1.05 0.52-2.13 0.888 
rs4331673         
CC 153 (62.4) 332 (69.2) 1.00 reference - 1.00 Reference - 
CA 84 (34.3) 134 (27.9) 1.36 0.98-1.90 0.070 1.30 0.92-1.84 0.145 
AA 8 (3.3) 14 (2.9) 1.24 0.51-3.02 0.635 1.22 0.48-3.06 0.679 
rs4854784         
GG 106 (45.1) 215 (44.9) 1.00 reference - 1.00 Reference - 
GA 97 (41.3) 208 (43.4) 0.95 0.68-1.32 0.745 1.00 0.70-1.41 0.989 
AA 32 (13.6) 56 (11.7) 1.16 0.71-1.90 0.557 1.35 0.80-2.28 0.255 
rs7340717         
GG 105 (44.5) 204 (42.5) 1.00 reference - 1.00 Reference - 
GT 90 (38.1) 210 (43.8) 0.83 0.59-1.17 0.293 0.83 0.58-1.18 0.299 
TT 41 (17.4) 66 (13.8) 1.21 0.76-1.90 0.418 0.99 0.61-1.60 0.952 
rs7616492         
GG 89 (37.1) 202 (42.1) 1.00 reference - 1.00 Reference - 
GA 103 (42.9) 216 (45.0) 1.08 0.77-1.52 0.651 1.18 0.82-1.69 0.373 
AA 48 (20.0) 62 (12.9) 1.76 1.12-2.76 0.014 2.05 1.27-3.32 0.003 
rs7625035         
AA 139 (57.0) 278 (57.9) 1.00 reference - 1.00 Reference - 
AG 85 (34.8) 181 (37.7) 0.94 0.68-1.30 0.708 0.92 0.65-1.29 0.619 
GG 20 (8.2) 21 (4.4) 1.91 1.00-3.63 0.047 1.60 0.82-3.12 0.168 
rs1131598         
AA 136 (55.7) 274 (5.1) 1.00 reference - 1.00 Reference - 
AG 88 (36.1) 184 (38.3) 0.96 0.70-1.34 0.824 0.90 0.64-1.27 0.563 
GG 20 (8.2) 22 (4.6) 1.83 0.97-3.47 0.061 1.79 0.92-3.50 0.087 
rs10935090         
CC 180 (74.4) 382 (79.7) 1.00 reference - 1.00 Reference - 
CT 54 (22.3) 90 (18.8) 1.27 0.87-1.86 0.213 1.28 0.86-1.90 0.222 
TT 8 (3.3) 7 (1.5) 2.42 0.87-6.79 0.082 2.33 0.80-6.83 0.123 
rs11915399         
CC 173 (70.0) 328 (68.5) 1.00 reference - 1.00 Reference - 
CT 66 (26.7) 137 (28.6) 0.91 0.65-1.29 0.608 0.99 0.69-1.42 0.953 
TT 8 (3.2) 14 (2.9) 1.08 0.45-2.63 0.860 1.11 0.44-2.79 0.832 
ABCC4         
rs9524821         
GG 92 (37.9) 205 (42.8) 1.00 reference - 1.00 Reference - 
GA 116 (47.7) 209 (43.6) 1.24 0.88-1.73 0.213 1.30 0.91-1.84 0.145 
AA 35 (14.4) 65 (13.6) 1.20 0.74-1.94 0.456 1.18 0.70-1.98 0.534 
rs3782958         
GG 173 (70.9) 336 (70.1) 1.00 reference - 1.00 Reference - 
GC 62 (25.4) 129 (26.9) 0.93 0.66-1.33 0.700 0.89 0.62-1.29 0.894 
CC 9 (3.7) 14 (2.9) 1.25 0.53-2.94 0.611 1.15 0.48-2.78 0.755 
rs869951         
GG 101 (41.1) 171 (35.6) 1.00 reference - 1.00 Reference - 
GC 103 (41.9) 226 (47.1) 0.77 0.55-1.08 0.133 0.75 0.53-1.07 0.120 
CC 42 (17.1) 83 (17.3) 0.86 0.55-1.34 0.496 0.88 0.56-1.40 0.600 
rs4771912         
AA 189 (79.4) 359 (74.6) 1.00 reference - 1.00 Reference - 
AG 48 (20.2) 112 (23.3) 0.81 0.56-1.19 0.290 0.80 0.54-1.19 0.275 
GG 1 (0.4) 10 (2.1) 0.19 0.02-1.50 0.078 0.17 0.02-1.38 0.097 
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SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95%CI P value aOR 95%CI P value 
rs4148421         
GG 71 (30.1) 134 (28.0) 1.00 reference - 1.00 Reference - 
GA 111 (47.0) 238 (49.7) 0.88 0.61-1.27 0.494 0.84 0.57-1.24 0.381 
AA 54 (22.9) 107 (22.3) 0.95 0.62-1.47 0.827 1.02 0.64-1.61 0.939 
rs8002180         
TT 124 (50.6) 248 (51.8) 1.00 reference - 1.00 Reference - 
TC 97 (39.6) 188 (39.2) 1.03 0.74-1.43 0.850 0.98 0.70-1.38 0.909 
CC 24 (9.8) 43 (9.0) 1.12 0.65-1.92 0.692 1.03 0.58-1.84 0.913 
rs2127295         
GG 70 (28.8) 137 (28.7) 1.00 reference - 1.00 Reference - 
GA 130 (53.5) 247 (51.7) 1.03 0.72-1.47 0.871 1.00 0.69-1.45 0.998 
AA 43 (17.7) 94 (19.7) 0.90 0.56-1.42 0.639 0.85 0.52-1.38 0.508 
rs1751051         
TT 112 (46.5) 234 (48.8) 1.00 reference - 1.00 Reference - 
TA 91 (37.8) 202 (42.1) 0.94 0.67-1.32 0.723 1.06 0.74-1.50 0.764 
AA 38 (15.8) 44 (9.2) 1.80 1.11-2.94 0.017 1.76 1.04-2.95 0.034 
rs2892715         
GG 103 (42.0) 173 (36.0) 1.00 reference - 1.00 Reference - 
GA 100 (40.8) 220 (45.7) 0.76 0.54-1.07 0.119 0.74 0.52-1.06 0.102 
AA 42 (17.1) 88 (18.3) 0.80 0.52-1.25 0.326 0.82 0.52-1.30 0.406 
rs2892713         
CC 169 (68.7) 337 (70.4) 1.00 reference - 1.00 Reference - 
CT 66 (26.8) 124 (25.9) 1.06 0.75-1.51 0.740 1.13 0.78-1.63 0.514 
TT 11 (4.5) 18 (3.8) 1.22 0.56-2.64 0.615 1.25 0.56-2.81 0.582 
rs4612933         
CC 160 (65.8) 315 (65.5) 1.00 reference - 1.00 Reference - 
CT 71 (29.2) 148 (30.8) 0.94 0.67-1.33 0.743 0.95 0.66-1.36 0.777 
TT 12 (4.9) 18 (3.7) 1.31 0.62-2.79 0.479 1.31 0.59-2.90 0.510 
rs4148437         
TT 107 (44.0) 194 (40.4) 1.00 reference - 1.00 Reference - 
TC 104 (42.8) 215 (44.8) 0.88 0.63-1.22 0.439 0.80 0.56-1-13 0.201 
CC 32 (13.2) 71 (14.8) 0.82 0.51-1.32 0.409 0.81 0.50-1.33 0.406 
rs1611822         
CC 77 (31.4) 182 (37.9) 1.00 reference - 1.00 Reference - 
CT 126 (51.4) 225 (46.9) 1.32 0.94-1.87 0.110 1.44 0.89-2.07 0.060 
TT 42 (17.1) 73 (15.2) 1.36 0.86-2.16 0.193 1.38 0.85-2.22 0.190 
rs1678386         
AA 124 (50.6) 243 (50.6) 1.00 reference - 1.00 Reference - 
AC 90 (36.7) 193 (40.2) 0.91 0.66-1.27 0.593 0.90 0.64-1.27 0.541 
CC 31 (12.7) 44 (9.2) 1.38 0.83-2.30 0.212 1.33 0.77-2.30 0.304 
rs2274403         
AA 74 (30.2) 120 (25.0) 1.00 reference - 1.00 Reference - 
AG 122 (49.8) 234 (48.8) 0.84 0.59-1.22 0.365 0.90 0.61-1.32 0.594 
GG 49 (20.0) 126 (26.2) 0.63 0.41-0.98 0.039 0.66 0.42-1.03 0.067 
rs1751027         
AA 202 (82.1) 402 (83.8) 1.00 reference - 1.00 Reference - 
AG 40 (16.3) 77 (16.0) 1.03 0.68-1.57 0.876 1.13 0.73-1.75 0.588 
GG 4 (1.6) 1 (0.2) 7.96 0.88-71.69 0.047 6.11 0.65-57.40 0.113 
rs4148476         
TT 181 (74.2) 339 (70.6) 1.00 reference - 1.00 Reference - 
TG 56 (23.0) 123 (25.6) 0.85 0.59-1.23 0.390 0.89 0.61-1.31 0.559 
GG 7 (2.9) 18 (3.8) 0.73 0.30-1.78 0.484 0.76 0.30-1.92 0.565 
rs1678374         
TT 90 (37.0) 164 (34.2) 1.00 reference - 1.00 Reference - 
TC 118 (48.6) 235 (49.1) 0.92 0.65-1.28 0.608 1.02 0.71-1.45 0.931 
CC 35 (14.4) 80 (16.7) 0.80 0.50-1.28 0.347 0.77 0.48-1.26 0.303 
rs1678405         
TT 116 (48.5) 199 (41.4) 1.00 reference - 1.00 Reference - 
TC 103 (43.1) 227 (47.2) 0.78 0.56-1.08 0.132 0.75 0.54-1.06 0.104 
CC 20 (8.4) 55 (11.4) 0.62 0.36-1.09 0.097 0.56 0.31-1.01 0.056 
rs1678396         
TT 94 (38.2) 147 (30.6) 1.00 reference - 1.00 Reference - 
TC 105 (42.7) 248 (51.7) 0.66 0.47-0.94 0.019 0.73 0.50-1.04 0.084 
CC 47 (19.1) 85 (17.7) 0.86 0.56-1.34 0.518 0.88 0.56-1.40 0.590 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal cancer onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95%CI P value aOR 95%CI P value 
rs1751031         
AA 165 (67.1) 299 (62.3) 1.00 reference - 1.00 Reference - 
AG 66 (26.8) 166 (34.6) 0.72 0.51-1.02 0.060 0.68 0.47-0.97 0.032 
GG 15 (6.1) 15 (3.1) 1.81 0.86-3.80 0.111 1.67 0.77-3.63 0.194 
rs7993878         
GG 190 (77.2) 361 (75.1) 1.00 reference - 1.00 Reference - 
GA 47 (19.1) 107 (22.2) 0.84 0.57-1.23 0.357 0.77 0.52-1.15 0.204 
AA 9 (3.7) 13 (2.7) 1.32 0.55-3.13 0.535 1.26 0.49-3.23 0.634 
rs6492763         
TT 89 (37.2) 168 (35.0) 1.00 reference - 1.00 Reference - 
TC 108 (45.2) 242 (50.4) 0.84 0.60-1.19 0.327 0.80 0.56-1.14 0.220 
CC 42 (17.6) 70 (14.6) 1.13 0.71-1.80 0.596 0.99 0.61-1.61 0.971 
rs3742106         
AA 86 (35.4) 166 (34.6) 1.00 reference - 1.00 Reference - 
AC 117 (48.1) 234 (48.8) 0.97 0.68-1.36 0.839 1.00 0.70-1.43 0.992 
CC 40 (16.5) 80 (16.7) 0.96 0.61-1.53 0.880 1.06 0.65-1.71 0.823 
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; aOR, adjusted OR for age, gender and smoking habits 
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ABSTRACT 
Objective: To evaluate the influence of the genetic variability in COX-
2/HPGD/SLCO2A1/ABCC4 prostaglandin E2 (PGE2) pathway genes on the 
development and recurrence of colorectal adenomatous polyps. 
Design: A hospital-based case-control study was conducted gathering 480 
unscreened individuals and 195 patients with personal history of adenomas. A 
total of 43 tagSNPs were characterized using the Sequenom platform or real-time 
PCR. 
Results: Ten tagSNPs were identified as susceptibility biomarkers for the 
development of adenomas: rs689466 in COX-2, rs2555639, rs1346271, 
rs1863642 and rs12500316 in HPGD, rs6439448 and rs1131598 in SLCO2A1 and 
rs9524821, rs1751051 and rs1678405 in ABCC4 genes. The haplotype 
encompassing the rs9524821 and rs1751051 SNPs in ABCC4 conferred a 3.9 
enhanced risk for adenomas onset (95%CI:2.28-6.65, P<0.001). Furthermore, the 
best four-locus gene-gene interaction model included the rs1346271, rs186342 
and rs12500316 SNPs in HPGD and rs1678405 in ABCC4 genes and was 
associated with a 13-fold increased susceptibility (95%CI:3.84-46.3, P<0.001, 
cross-validation (CV) accuracy: 0.78 and CV consistency: 8/10). Interesting, in 
high-risk patients the rs1678405 ABCC4 SNP had a lower hazard ratio (HR) and 
half the crude risk for adenoma recurrence at 36 months, when comparing with the 
overall high-risk patients (7% vs 14%). 
Conclusion: Genetic polymorphisms in the COX-2/PGE2 pathway appear to 
contribute to the development of colorectal adenomas and influence the interval 
time to adenomas recurrence. The improvement of current risk models through the 
inclusion of genetic biomarkers might provide a better balance between benefits 
and drawbacks of post-polypectomy surveillance or even target individuals to 
complementary chemopreventive strategies. 
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INTRODUCTION 
According to the International Agency for Research on Cancer (IACR), 837.437 
individuals will be diagnosed and 381.188 will die from CRC in 2020, a 13.6% and 
14.4% increase in this cancer burden and mortality from previous estimates [1].  
Colorectal adenomatous polyps are well-characterized CRC precursors [2]. 
Although most adenomas are asymptomatic and do not progress into cancer, the 
majority of CRC will develop through the adenoma-cancer sequence on an 
average of 10-15 years [3]. Over one-third of people will develop at least one 
adenoma in their lifetime [4]. 
CRC screening has been shown to reduce the incidence and CRC mortality 
through the endoscopic detection and removal of the precancerous lesions [5,6]. 
Still, these patients are at increased risk for developing metachronous adenomas 
or even cancer, with the recurrence rate being around 40-50% [7,8]. Despite 
population-based CRC screening being widely recommended in Europe, the 
development of primary prevention strategies is an important goal, considering the 
inherent limitations of colorectal screening and adherence rates [9,10]. 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most widely studied 
pharmacological agent in CRC prevention and its use reduces the occurrence of 
advanced adenomas by 28% and the recurrence by 34%, mainly by targeting the 
cyclooxygenase-2 enzyme (COX-2) [11,12]. 
Deregulation of COX-2 expression, observed in half of adenomatous polyps, leads 
to an increased biosynthesis of prostaglandin E2 (PGE2) [13]. The pleiotropic 
effects of higher levels of PGE2 contribute to key steps of cancer development 
including stimulation of cell proliferation, angiogenesis, invasiveness and migration, 
inhibition of apoptosis and immunosurveillance [14]. The degradation of PG is 
mediated by the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-
PGDH), encoded by the hydroxyprostaglandin dehydrogenase (HPGD) gene, 
which directly counteracts the COX-2 oncogenic PGE2 pathway [15]. Furthermore, 
low levels of rectal 15-PGDH were associated with increased adenoma recurrence 
[16]. The multidrug resistance-associated protein 4 (MRP4) and the prostaglandin 
transporter (PGT), encoded by the ATP-binding cassete sub-family C member 4 
(ABCC4) gene and solute carrier organic anion transporter family, member 2A1 
(SLCO2A1) genes, respectively, are the specific prostaglandin membrane 
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transporters that regulate PGE2 levels in the extracellular microenvironment 
[17,18]. PGT and MRP4 mRNA levels were reported to be inversely regulated in 
human CRC, with PGT expression being repressed and MRP4 up-regulated in 
CRC tissues and cell lines leading to higher levels of PGE2 extracellularly thus 
potentiating the effects of COX-2/PGE2 pathway [19]. 
The genetic background certainly contributes to CRC development. At least 35% 
of CRC cases are attributable to heritability, as reported in a large twin study [20]. 
Considering that the aforementioned genes are not only highly polymorphic but 
their expression span several folds, one could hypothesize that an unbalance in 
PGE2 levels reflecting potential functional polymorphisms might influence 
colorectal carcinogenesis and consequently the genetic susceptibility for the 
development of colorectal precancerous lesions.  
Using a tagSNP approach, our group recently reported the involvement of several 
polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes on CRC development 
[21]. Therefore, with this study we aimed to investigate whether tagSNPs in these 
four genes were also associated with earlier stages of colorectal tumor 
development. To the best of our knowledge this is the first study to evaluate the 
influence of polymorphisms in HPGD, SLCO2A1 and ABCC4 genes in the 
occurrence of colorectal metachronous lesions. 
MATERIAL AND METHODS 
Type of study 
A hospital-based case-control study was design involving a group of unscreened 
individuals and patients diagnosed with colorectal adenomas. These patients were 
further stratified according to the presence of metachronous lesions in a 
retrospective case-cohort study. All individuals were from the northern region of 
Portugal and recruited at the Instituto Português de Oncologia do Porto (IPO-Porto) 
or Centro Hospitalar do Porto (CHP). This project was approved by the Ethics 
Committee at both institutes  (ref. 0084/08 and ref. 080 DEFI/100-CES, 
respectively) and Comissão Nacional de Protecção de Dados (ref. 6619/2011), the 
Portuguese Data Protection Authority. 
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Control group 
Unscreened individuals between 50 and 75 years of age, without any clinical 
evidence of CRC or other oncologic malignancy were randomly recruited from the 
blood donor’s service at IPO-Porto between July 2005 and February 2008. 
Patients group 
Patients diagnosed with one or more adenomas between 1996 and 2008 were 
enrolled in this study after reviewing a colonoscopy database from the 
Gastroenterology departments at IPO-Porto and CHP. The inclusion criteria were: 
(1) age between 50 to 75 years; (2) with a total colonoscopy with good to excellent 
preparation at diagnosis; (3) without history of inflammatory bowel disease or 
family history of colorectal tumors; and (4) without previous diagnose of CRC.  
Adenoma recurrence was defined as the diagnosis of an adenoma after having a 
normal total colonoscopy, with a good to excellent preparation, at least one year 
after the initial diagnosis of adenoma.  
Nearly three thousand individuals had history of adenomas, although only less 
than 10% complied with the inclusion criteria. A total of 256 patients were included 
in this study.  From these we were only able to obtain DNA samples from 195 
patients. No differences were observed between demographic variables, lifestyle 
habits and tumor characteristics between these patients and the overall population 
of patients. 
Sample collection and biological processing 
The DNA was extracted from formalin fixed paraffin embedded (FFPE) blocks from 
the Pathology Departments at both centers, using the GRS Genomic DNA Kit – 
Tissue, in accordance with the manufacturer’s protocol (GRiSP, Porto, Portugal).  
Polymorphisms selection 
The strategy for polymorphisms selection has been described elsewhere [21]. 
Briefly, 55 tagSNPs were included after being retrieved from a set of common 
SNPs in the Caucasian population of HapMap project (CEU) (1) with minor allele 
frequency equal or superior to 0.15; (2) within the coding region of the genes plus 
2Kb upstream and downstream; (3) with a r2 superior to 0.8 and (4) that 
successfully converted to the Sequenom platform. 
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Furthermore, the rs20417, rs689466 and rs5275 polymorphisms in COX-2 and 
rs2612656 and rs2555639 in HPGD genes, that were previously associated with 
colorectal tumors development, were also included [22-24]. 
Genotype characterization 
TagSNPs genotyping was performed using MassARRAY iPLEX Gold technology 
(Sequenom, San Diego, CA) based on multiplexed amplification followed by mass-
spectrometric product separation. This technique was carried-out by the Unidade 
de Genómica/Serviço de Genotipagem do Instituto Gulbenkian de Ciência. 
The rs689466, rs20417, rs5275, rs2612656 and rs2555639 were characterized 
through allelic discrimination (Real-Time Polymerase Chain Reaction) using 
validated TaqMan® SNP genotyping assays (C___2517145_20, 
C___7550203_10, C___15909858_20, C___16038735_10, respectively) with the 
exception of the rs20417 SNP which was custom designed (Applied Biosystems, 
Foster City, California USA). 
Quality control 
Genotypes were excluded from the analysis if any of the following criteria was 
applied: call rate inferior to 0.90; concordance rate inferior to 0.95 and Hardy-
Weinberg equilibrium (HWE) with P<0.05. Blank templates were included in each 
96 and 384-well plates to ensure contamination-free results. Two researchers 
performed the genotype interpretation independently and five to ten percent of all 
samples were randomly selected and re-submitted to a new genetic 
characterization. Furthermore, the use of FFPE samples for SNP genotyping was 
previously validated by comparing the genotypes from 20 DNAs isolated from 
fresh peripheral blood and paired FFPE samples from CRC patients.  
Statistical analysis  
The Hardy–Weinberg equilibrium was tested by the Pearson’s goodness-of-fit test 
to compare the observed versus the expected genotype distribution among the 
control population.  
Data analysis was performed using the computer software IBM Statistical Package 
for Social Sciences-SPSS (IBM Corp., Armonk, New York, USA) for Macintosh 
(version 19.0). Chi-square analysis was used to compare categorical variables, 
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using a 5% level of significance. Non-parametric tests were used to compare 
mean values. Odds ratio (OR) and its 95% confidence interval (CI) were calculated 
as a measure of the association between the genetic variants and the risk for the 
development of CRC. Covariates expected to be involved on colorectal 
carcinogenesis, namely age, gender and smoking habits were included in the 
logistic regression analysis. A bootstrap resampling was used to assess the 
stability of risk estimates (1000 replications). The false positive report probability 
(FPRP) was used to confirm the noteworthiness of significant findings on the 
overall risk for colorectal adenoma development, according to the study by 
Wacholder and colleagues [25]. The FPRP threshold was set at 0.5 under an 
assigned prior probability ranging from 0.01 to 0.10 to detect an OR of 1.5.  
Haplotype analysis was performed at a gene level using the SNPStats software 
(www. http://bioinfo.iconcologia.net/SNPstats). The haplotype frequencies were 
estimated using the implementation of the EM algorithm coded into the haplo.stats 
package. The most frequent haplotype was automatically selected as the 
reference category. After excluding the genetic variations most likely to represent 
false positive findings, all polymorphisms with significant associations were 
included within each gene. 
The open-source multifactor dimensionality reduction (MDR) software (version 
3.0.2) (www.epistasis.org) was used to assess potential gene-gene interactions 
between SNPs with statistical significant impact on colorectal adenoma genetic 
susceptibility. The fitness of an MDR model was estimated by determining the 
testing accuracy and its cross-validation consistency (CVC). Using a 10-fold cross-
validation method the data was divided into 10 sets, in which 9 subsets were 
training sets and one subset was a test set. Hence, the CVC is a measure of the 
number of times of 10 divisions of the dataset the best model was extracted.  
Kaplan-Meier curves were used to evaluate the correlation between the genetic 
variants and time to recurrence; log rank statistical test was used for curves 
comparison.  
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RESULTS 
Study population 
A description of the population understudied is displayed in Table 1 and as can be 
observed patients with history of adenomas were slightly older than controls’ (61 
vs 58, P<0.001). Males and non-smokers were overrepresented in either group 
(57 vs 65%, P=0159 and 72 vs 70%, P=0.075, respectively).  
In over 70% of patients, less than three adenomas (71%) were detected. Most 
were located distally to the splenic flexure (82%) and were larger or equal to 10 
mm in size (64%). Histologically, high-grade dysplasia was described in 33% of 
index adenomatous polyps.  
High-risk patients for adenoma recurrence (adenoma with villous histology or high 
grade dysplasia or ≥ 10 mm in size, or ≥ 3 adenomas) represented 72% of cases’ 
population. The median follow up time was 76 months (22-201) and metachronous 
lesions were identified in 46% of patients with personal history of adenomas. No 
differences were observed between these patients and the ones without adenoma 
recurrence during the follow up period. 
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Table 1. Description of population    
 Controls Adenomas 
P value 
Recurrence 
P value 
 (n=480) (n=195) No Yes 
Demographics 
      
   Age (years)       
     Mean (SD) 58 (4.90) 61 (6.78)  61 (6.64) 61 (6.74)  
     Median (min-max) 58 (50-69) 61 (50-75) <0.001 61 (50-75) 60 (50-
75) 
0.698 
   Gender, n (%)       
     Male 314 (65.4) 110 (57.3)  54 (49.5) 55 (50.5)  
     Female 166 (34.6)  82 (42.7) 0.159 48 (60.0) 32 (40.0) 0.154 
Lifestyle behaviors 
      
   Smoking status, n (%)       
     Never-smokers 219 (60.3) 86 (71.7)  47 (54.7) 39 (45.3)  
     Ever-smokers
£
 144 (39.7) 34 (28.3) 0.075 16 (47.1) 18 (52.9) 0.453 
High-risk patients* 
      
No - 53 (27.9)  27 (54.0) 23 (46.0)  
Yes - 137 (72.1)  74 (53.6) 64 (46.4) 0.963 
Time of follow up (mo) 
      
Mean (SD) - 80.1 (39.5)  - - - 
Median (min-max) - 76 (22-201)  - - - 
Polyps characteristics
#
 
      
   Number of adenomas       
     Mean (SD) - 2.15 (1.69)  1.98 (1.51) 2.38 
(1.87) 
 
     Median (min-max) - 1 (1-10)  1 (1-9) 2 (1-10) 0.119 
     <3 - 133 (70.7)  74 (55.6) 59 (44.4)  
     ≥3 - 55 (29.3)  27 (49.1) 28 (50.9) 0.413 
   Tumor location, n (%)       
     Distal - 155 (82.0)  87 (56.1) 68 (43.9)  
Proximal - 34 (18.0)  15 (44.1) 19 (55.9) 0.203 
   Size, n (%)       
<10 - 67 (35.6)  37 (55.2) 30 (44.8)  
≥10 - 121 (64.4)  65 (53.7) 56 (46.3) 0.843 
   Morphology, n (%)       
Pedunculated - 76 (46.1)  42 (55.3) 34 (44.7)  
Sessile - 89 (53.9)  42 (47.2) 47 (52.8) 0.301 
   Histological Grade, n (%)       
Low-grade dysplasia - 127 (67.2)  67 (52.8) 60 (47.2)  
High-grade dysplasia - 62 (32.8)  35 (56.5) 27 (43.5) 0.632 
   Histological type, n (%)       
Tubular - 30 (46.1)  16 (53.3) 14 (46.7)  
Tubulovillous - 20 (30.8)  14 (70.0) 6 (30.0)  
Villous - 15 (23.1)  9 (60.0) 6 (40.0) 0.446 
   Metachronous adenomas       
No - 102 (54)  - -  
Yes - 87 (46)  - -  
SD, standart deviation; min, minimum; max, maximum; mo, months 
£
Former and current smokers pooled together 
*risk stratification for adenoma recurrence based on the endoscopic findings at baseline colonoscopy. Low-risk patients: 1-2 
tubular adenomas <10 mm in size with low grade dysplasia; High-risk patients: patients with adenomas with villous histology 
or high grade dysplasia or ≥ 10 mm in size, or ≥ 3 adenomas; 
#
the most advanced tumor was considered 
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Risk estimates for colorectal adenoma 
Eight SNPs were excluded from the analysis due to genotyping failure and four 
SNPs were dropped because their frequencies deviated from HWE (P<0.05). A 
total of 43 SNPs were included in the risk estimate analysis. The mean genotype 
call and concordance rates were 0.97. The description of selected SNPs and 
genotype distribution are displayed in Table 1 and Table 2 of supporting 
information, respectively. 
Using the false positive report probability (FPRP), nine polymorphisms retained 
their association with colorectal adenoma development, as observed in Table 2. 
Individuals homozygous for the minor G allele of the rs689466 SNP in COX-2 
gene were overrepresented in the group of cases (10% vs 3%, in controls) leading 
to a 3-fold increased risk for colorectal adenoma (95%CI:1.52-6.86, P=0.002) in 
the multivariate analysis, including age, gender and smoking habits as covariates. 
Following a recessive model, the rs2555639 polymorphism was positively linked 
with the onset of colorectal precancerous lesions (OR=2.48; 95%CI:1.36-4.53, 
P=0.003), whereas the rs1346271, rs1863642 and rs12500316 genetic variants in 
the HPGD gene were associated with a 45-51% protection in carriers of the minor 
alleles (OR=0.55; 95%CI:0.35-0.85, P=0.008, OR=0.55; 95%CI:0.36-0.85, 
P=0.007 and OR=0.49; 95%CI:0.31-0.78, P=0.002 for the rs1346271, rs1863642 
and rs12500316, respectively). Stressing the SLCO2A1 gene, individuals carrying 
the rs6439448G allele presented a 62% decreased risk for colorectal adenomas 
(95%CI:0.22-0.65, P<0.001). Although with a lower influence, the rs1131598 was 
also inversely associated with colorectal adenomas development (OR=0.58; 
95%CI:0.41-0.84, P=0.018). Three out of the 21 polymorphisms in ABCC4 gene 
appeared to have an impact in colorectal carcinogenesis in early stages. The AA 
and CC genotypes of rs9524821 and rs1751051 polymorphisms, more than 
double the susceptibility for colonic precancerous tumors (OR=2.38; 95%CI:1.39-
4.09, P=0.002 and OR=2.75; 95%CI:1.58-4.80, P<0.001). In contrast, a protective 
role was noticed for genotypes carrying the rs1678405C allele SNP was noticed, 
even more in homozygous for the C allele (OR=0.41; 95%CI:0.27-0.63, P<0.001).  
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Table 2. Risk estimates for the involvement of COX-2/HPGD/SLCO2A1/ABCC4 genes in colorectal adenoma 
development  
SNP 
Model of 
inheritance 
aOR 95%CI P value Pbootstrap 
FPRP prior probability 
0.01 0.05 0.1 
COX-2         
rs689466  Recessive 
(AA/AGvsGG) 
3.23 1.52-6.86 0.002 0.001 0.908 0.654 0.472* 
HPGD         
rs2555639  Recessive 
(TT/TCvsCC) 
2.48 1.36-4.53 0.003 0.002 0.859 0.538 0.356* 
rs2612656 Dominant 
(AAvsAG/GG) 
0.47 0.23-0.94 0.033 
0.035 
0.953 0.794 0.646 
 Recessive 
(AA/AGvsGG) 
3.20 1.22-8.41 0.018 
0.009 
0.967 0.848 0.726 
rs8752 Recessive 
(AA/AGvsGG) 
1.94 1.09-3.44 0.023 
0.036 
0.924 0.701 0.526 
rs1346271 Dominant 
(GGvsGC/CC) 
0.55 0.35-0.85 0.008 
0.013 
0.785 0.411 0.249 
rs1863642 Dominant 
(GGvsGT/TT) 
0.55 0.36-0.85 0.007 
0.008 
0.785 0.411 0.249 
rs12500316 Dominant 
(CCvsCT/TT) 
0.49 0.31-0.78 0.002 
0.002 
0.729 0.340 0.196 
SLCO2A1         
rs4241362 Recessive 
(TT/TCvsCC) 
3.90 1.80-8.43 0.001 0.001 0.876 0.575 0.391 
rs6439448 Dominant 
(CCvsCA/AA) 
0.38 0.22-0.65 <0.001 0.002 0.670 0.280 0.156 
rs9821091 Dominant 
(GGvsGA/AA) 
0.62 0.40-0.96 0.033 0.044 0.895 0.621 0.437 
 Recessive 
(GG/GAvsAA) 
1.77 1.02-3.06 0.041 0.048 0.936 0.738 0.571 
rs4241365 Recessive 
(TT/TCvsCC) 
2.60 1.30-5.22 0.007 0.006 0.921 0.692 0.516 
rs7625035 Recessive 
(AA/AGvsGG) 
2.68 1.71-6.11 0.020 0.026 0.957 0.812 0.672 
rs1131598  Dominant 
(AAvsAG/GG) 
0.58 0.41-0.84 0.018 0.052 0.629 0.245 0.133 
rs10935090 Recessive 
(CC/CTvsTT) 
5.18 1.33-20.17 0.018 0.002 0.979 0.901 0.812 
ABCC4         
rs9524821 Recessive 
(GG/GAvsAA) 
2.38 1.39-4.09 0.002 0.003 0.780 0.405 0.244 
rs869951 Dominant 
(GGvsGC/CC) 
0.60 0.39-0.92 0.018 0.019 0.858 0.537 0.354 
rs1751051 Recessive 
(TT/TAvsAA) 
2.75 1.58-4.80 <0.001 0.001 0.691 0.300 0.169 
rs2892713 Recessive 
(CC/CTvsTT) 
2.50 1.12-5.58 0.025 0.006 0.959 0.819 0.682 
rs4612933 Recessive 
(CC/CTvsTT) 
3.03 1.35-6.79 0.007 0.005 0.941 0.754 0.593 
rs4148476 Recessive 
(TT/TGvsGG) 
3.22 1.41-7.36 0.005 0.005 0.940 0.751 0.588 
rs1678405 Dominant 
(TTvsTC/CC) 
0.41 0.27-0.63 <0.001 0.001 0.261 0.064 0.031 
 Recessive 
(TT/TCvsCC) 
0.15 0.04-0.63 0.010 0.010 0.979 0.897 0.805 
rs1751031 Recessive 
(AA/AGvsGG) 
2.99 1.11-8.00 0.030 0.016 0.971 0.867 0.756 
rs7993878 Recessive 
(GG/GAvsAA) 
3.14 1.09-9.01 0.033 0.024 0.975 0.882 0.780 
SNP, single nucleotide polymorphism; FPRP, false positive report probability; Bold for FPRP<0.5; *A prior probability of 0.1 
was assumed for the rs689466 and rs2555369 considering the available epidemiologic and functional data; For all other 
polymorphisms a prior probability of 0.05 was considered.  
aOdds Ratio, Logistic regression (Forward:conditional model) including gender, smoking habits and age (median global age 
of 59 years used as cutoff). CI, confidence interval; Only statistical significant associations are presented (P<0.05); bootstrap 
results are based in 1000 samples. 
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Haplotype analysis for colorectal adenomas 
Since multiple SNPs were addressed within each gene and multiple associations 
were reported, with exception of COX-2 gene, a haplotype analysis was performed. 
The frequencies of derived haplotypes from HPGD, SLCO2A1 and ABCC4 genes 
are presented in Table 3. The most frequent haplotype of the HPGD gene, the 
CGGT, was present in 35% of controls and used as the reference one. The blocks 
containing the rs1250016T allele, TGGT, and the rs1346271C-rs1863642T-
rs2555639C alleles, CCTC, were associated with a high protection, although they 
were detected roughly in 1% of cases (OR=0.05; 95%CI:0.01-0.15, P<0.001 and 
OR=0.06; 95%CI:0.01-0.33, P=0.001, respectively). Consistent with the individual 
SNP analyses, the haplotypes carrying the rs1131598G allele, GC, or rs6439448A 
allele, AA, displayed a protective role for the development of colorectal adenoma 
(vs AC, OR=0.68; 95%CI:0.49-0.95, P=0.024 and OR=0.50; 95%CI:0.33-0.76, 
P=0.001, respectively). No block containing both the minor alleles was present at 
a frequency higher or equal to 5%. Out of the six haplotypes described for the 
ABCC4 gene, the block carrying the rs9524821A and rs1751051A alleles boosted 
even further the susceptibility for colorectal precancerous lesion reported in the 
individual analysis in contrast with the GTT haplotype (OR=3.90; 95%CI: 2.28-6.65, 
P<0.001). 
Gene-gene interaction analysis in colorectal adenoma  
To address possible interactions between the noteworthy SNPs from the main 
analysis, an exhaustive MDR approach was employed and Table 4 summarizes 
the best interactive models obtained. All best models from one to four-locus were 
significant at P≤0.001, and the highest cross-validation consistency was observed 
with the two-factor interaction model (9/10). Nevertheless, the best four-locus 
model achieved the highest testing accuracy of 78% for predicting the 
development of colorectal adenomas, although with a lower cross-validation 
consistency (8/10). This interaction model included the rs1346271, rs1863642 and 
rs12500316 polymorphisms in HPGD gene and rs1678405 in ABCC4 gene and 
was associated with a 13-fold increased adenoma risk (95%CI:3.84-46.3, 
P<0.001). 
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Table 3. Haplotype frequencies between patients and controls and risk estimates for their 
involvement in adenoma development 
Gene / Haplotype % Cases % Controls aOR 95%CI P value 
HPGD*      
C-G-G-T 35.0 28.0 1 Reference - 
C-G-G-C 18.6 10.9 1.04 0.64-1.70 0.87 
C-C-G-T 15.3 9.1 1.11 0.68-1.82 0.67 
T-G-G-T 1.1 12.6 0.05 0.01-0.15 <0.001 
C-C-T-T 0 10.4 - - - 
C-C-T-C 0.8 8.8 0.06 0.01-0.33 0.001 
SLCO2A1
£
      
A-C 71.6 60.8 1 Reference - 
G-C 17.2 20.8 0.68 0.49-0.95 0.024 
A-A 8.4 15.4 0.50 0.33-0.76 0.001 
ABCC4
¥
      
G-T-T 19.8 26.9 1 Reference - 
A-T-T 26.8 19.7 1.85 1.19-2.86 0.006 
G-C-T 15.3 17.0 1.18 0.71-1.98 0.52 
G-T-A 14.3 14.4 1.51 0.89-2.56 0.13 
A-T-A 17.3 3.9 3.90 2.28-6.65 <0.001 
G-C-A 5.7 6.1 0.99 0.46-2.12 0.98 
Bold for P<0.001 
aOdds ratio (OR) adjusted for age (categorical variable, using the global median age of 59 years as cutoff), 
gender and smoking habits: CI, confidence interval
 
*SNPs order: rs12500316-rs1346271-rsrs1863642-rs2555639 
£
SNPs order: rs1131598-rs6439448 
¥
SNPs order: rs9524821-rs1678405-rs1751051 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. MDR analysis for the colorectal adenoma risk prediction 
Best model 
CV 
accuracy 
CV 
consistency 
aOR 95%CI P value 
rs1346271, rs12500316 0.6964 9/10 5.41 1.88-15.5 0.001 
rs1346271, rs1863642, rs12500316 0.7006 6/10 5.51 1.90-15.9 0.001 
rs1346271, rs1863642, rs12500316, 
rs1678405 
0.7816 8/10 13.3 3.84-46.3 <0.001 
Bold for P<0.001 
MDR, Multifactor dimensionality reduction; CV, cross-validation; aOR, Odds ratio adjusted for age, gender 
and smoking habits; CI, confidence interval 
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Risk assessment for the development of colorectal metachronous lesions 
The genetic variability in COX-2 and HPGD genes does not appear to contribute to 
the development of metachronous tumors in patients previously diagnosed with 
colorectal adenomas, as observed in Table 5.  
Two polymorphisms in SLCO2A1 gene were reported to influence the 
susceptibility for colorectal adenomas recurrence. The rs1131598GG homozygous 
genotype was associated with an enhanced risk of 6.3 (95%CI:1.31-30.0, 
P=0.021). On the other hand, individuals carrying the rs7340717T allele had a 56% 
protection for developing metachronous adenomas (95%CI:0.20-0.97, P=0.041). 
Under a dominant model of inheritance, the rs1751031 and rs9524821 
polymorphisms in ABCC4 gene appear to display a protective behavior (OR=0.29; 
95%CI:0.12-0.72, P=0.007 and OR=0.42; 95%CI:0.19-0.93, P=0.033, 
respectively), in contrast with the positive association observed in the presence of 
rs8002180C allele (OR=2.22; 95%CI:1.04-4.76, P=0.041). None of the 
aforementioned SNPs retained their noteworthiness upon the FPRP analysis, 
potentially indicating false positive findings (FPRP>0.5). 
 
 
 
  
 
 
Table 5. Risk estimates for the influence of COX-2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal 
adenoma recurrence 
SNP 
Model of 
inheritance 
aOR 95%CI P value Pbootstrap 
FPRP prior probability 
0.01 0.05 0.1 
SLCO2A1     
    
rs1131598 Recessive 
(AA/AGvsGG) 
6.28 1.31-30.0 0.021 0.019 0.983 0.918 0.841 
rs7340717 Dominant 
(GGvsGT/TT) 
0.44 0.20-0.97 0.041 0.060 0.965 0.840 0.713 
ABCC4         
rs1751031 Dominant 
(AAvsAG/GG) 
0.29 0.12-0.72 0.007 0.015 0.954 0.799 0.653 
rs8002180 Dominant 
(TTvsTC/CC) 
2.22 1.04-4.76 0.041 0.057 0.962 0.831 0.700 
rs9524821 Dominant 
(GGvsGA/AA) 
0.42 0.19-0.93 0.033 0.034 0.961 0.827 0.694 
SNP, single nucleotide polymorphism; FPRP, false positive report probability 
aOdds Ratio: Logistic regression (Forward: conditional method) including smoking habits, risk profile and centre as 
covariates.;  CI, confidence interval; bootstrap results are based in 1000 samples 
Only statistcal significant association are presented (P<0.05) 
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Influence on the time to recurrence and crude risk  
We next, inquired if polymorphisms in these key genes in PGE2 pathway could 
influence not only the time but also the crude risk for adenomas recurrence at 36, 
60 and 120 months, following the recommendations for post-polypectomy 
colonoscopy surveillance (Table 6) [26]. Although no difference was observed on 
the time to adenoma recurrence (112 vs 105 months, P=0.788) or recurrence rate 
(46%, P=0.996) between the high and low-risk patients, 14% of all adenomatous 
polyps recurred at 36 in the high-risk group in contrast to the 2% reported in low-
risk patients. Additionally, nearly 95% (18/19) of metachronous advanced 
adenomas were described in the high-risk group, with 28% and 67% being 
diagnosed at 36 and 60 months (data not shown). 
The contribution of the genetic background appeared to be particularly relevant on 
patients at low-risk. For example, the rs9524821AA genotype not only was 
associated with a nearly three-fold increased susceptibility in the cox regression 
analysis (95%CI:1.07-8.03, P=0.036), but also half of patients carrying this 
genotype had adenoma recurrence at 60 months, considerable higher than the 21% 
noticed in low-risk patients. Similarly, patients’ carriers of rs2274403AA genotype 
had a lower interval until recurrence (85 (29-140) vs 122 (109-135), P=0.011) with 
44% of metachronous tumors developing by 36 months (vs 23% for AG/GG). In 
the high-risk group the genetic polymorphism with potential for influencing current 
guidelines is the rs1678405, for which TT carriers had a lower hazard ratio, with a 
higher time to recurrence (109 (89-129) vs 90 (76-104), P=0.075) and half the 
crude risk for recurrence at 36 months, in comparison with the overall high-risk 
patients (7% vs 14%). 
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Table 6: Influence of genetic variations in COX-2/HPGD/SLCO2A1/ABCC4 on the time to recurrence of colorectal 
adenomas and crude risk of recurrence at 36, 60 and 120 months of follow up. 
 
 
Recurrence, 
% 
aOR 
(95%CI) 
aHR 
(95%CI) 
Time to 
recurrence* 
(min-max) 
Crude risk for 
recurrence, ‰ 
36 
mo 
60 
mo 
120  
mo 
Low-risk individuals 
Global  46   112 (100-124) 2 21 86 
SLCO2A1         
rs9820625 AA/AC 32 10.71  
(1.17-98.24) 
3.33  
(1.22-9.10) 
115 (100-130) 3 16 70 
 CC 80 85 (62-108) 0 29 100 
rs9524821 GG/GA 41 - 2.93 
(1.07-8.03)* 
122 (97-147) 4 16 78 
 AA 43  107 (57-157) 0 48 100 
ABCC4         
rs1678396 TT 50 
- 
0.20 
(0.07-0.60) 
94 (90-98) 0 18 100 
 TC/CC 39 122 (95-149) 3 18 80 
rs2274403 AA 50 
- 
0.26 
(0.08-0.83) 
85 (29-140) 0 44 69 
 AG/GG 39 122 (109-135) 3 23 83 
rs3742106 AA 21 5.36 
(1.25-23.04) 
5.78 
(1.61-20.8) 
135 (77-193) 0 8 72 
 AC/CC 59 105 (84-126) 3 27 92 
rs6492763 TT 73 0.18 
(0.04-0.74) 
0.26 
(0.07-0.91) 
93 (55-130) 6 38 100 
 TC/CC 15 176 (-) 0 7 66 
rs869951 GG/GC 35 
- - 
114 (105-123) 3 17 89 
 CC 75 66 (48-84) 0 50 100 
High-risk individuals 
Global  46   105 (87-123) 14 27 82 
SLCO2A1         
rs1131598 AA/AG 44 
- 
3.23 
(1.49-7.02) 
105 (86-124) 13 23 81 
 GG 73 67 (59-74) 19 59 100 
rs7616492 GG 57 
- - 
94 (78-110) 14 40 94 
 GA/AA 39 121 (98-143) 13 20 74 
rs7340717 GG/GT 44 
- - 
115 (88-142) 12 26 81 
 TT 57 94 (43-145) 26 47 93 
ABCC4         
rs1678405 TT 39 2.09* 
(1.04-4.23) 
1.75* 
(1.05-2.91) 
109 (89-129) 7 22 77 
 TC/CC 57 90 (76-104) 23 35 88 
aOdds Ratio: Logistic regression (Forward: conditional method) including centre as covariate; aHazard Ratio: Cox regression 
(Forward: conditional method) including centre as covariate; CI, confidence interval; min, minimum; max, maximum; mo, month.  
*P>0.05 upon the bootstrap analysis (bootstrap results are based in 1000 samples) 
 
 
DISCUSSION 
Colorectal cancer still remains a major clinical and public health challenge that 
could be averted by applying the current knowledge about CRC prevention and 
improving the adherence to established screening guidelines [5,6].   
The rapid decline on CRC incidence over the past decade has been largely 
attributed to the endoscopic detection and removal of precancerous adenomatous 
polyps and endoscopic follow up of these patients with personal history of 
colorectal adenomas [5]. Nevertheless, not only are the compliance rates far from 
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the desirable, even in countries with implemented population-based CRC 
screening guidelines, also important lesions are missed or incompletely removed 
during colonoscopy [27,28].   
The search for susceptibility biomarkers in colorectal carcinogenesis might reveal 
an important tool to select unscreened individuals to CRC screening or even to 
complementary chemopreventive strategies with NSAIDs by allowing the 
identification of individuals at higher risk for the development of colorectal tumors. 
Currently, NSAIDs use in CRC prevention is hampered by the adverse 
gastrointestinal side effects associated with its regular use in average risk 
populations [29]. 
The efflux-dominated flow of PG during carcinogenesis as a reflection of an 
increased expression of COX-2 and MRP4 and down regulation of 15-PGDH and 
PGT leads to an accumulation of PGE2 in the extracellular milieu culminating in 
the activation of a plethora of pathways that stimulate tumor development [19]. 
In the present study, we addressed the role of 43 tagSNPS in four candidate 
genes (COX-2/HPGD/SLCO2A1/ABCC4) of COX-2/PGE2 pathway on the 
development and recurrence of colorectal adenomatous polyps in a Northern 
Portuguese population. Recently, using the same tagSNPs approach and targeting 
the same pathway we also identified the rs689466A>G polymorphism in COX-2, 
the rs1346271G>C in HPGD, the rs6439448C>A in SLCO2A1 and the 
rs1751051T>A in ABCC4 genes polymorphisms as susceptibility biomarkers for 
CRC, supporting the associations reported here and the role they might portray in 
colorectal carcinogenesis [21].  
The homozygous GG genotype for the rs689466 SNP, also known as -1195A>G 
COX-2 polymorphism, associated presently with a three-fold higher predisposition, 
was previously related with a higher risk for duodenal adenomatosis in patients 
with familial adenomatous polyposis (FAP) [30]. Although representing a 
hereditary syndrome, deregulation of COX-2 expression was observed in normal 
and duodenal adenomas of FAP patients.[31] Furthermore, our group in a earlier 
study, observed a higher transcriptional activity in HCT116 and HCA-7 CRC cell 
lines transfected with COX-2 promoters’ encompassing the rs689466G allele, thus 
providing a biological plausibility for the epidemiologic observations [32].  
Thompson and colleagues [24], first associated the rs2555639T>C SNP located at 
17.74kb upstream the 5’UTR of HPGD gene with a 40% increased risk for CRC in 
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TT homozygous carriers. Surprisingly, in our population this SNP not only appears 
to be more relevant in early stages of colorectal carcinogenesis, but the opposing 
rs2555639CC genotype was the one linked to colorectal adenomas onset. This 
conflicting data, might reflect population stratification involving different genetic 
ancestry, considering that the initial study involved participants from the Kentucky 
Surveillance, Epidemiology and End Results (SEER) registry most likely with 
Northern or Western European ancestry (English, German, Irish ancestry).   
Furthermore, the rs1346271G>C, rs1863642G>T and rs12500316C>T tagSNPs in 
HPGD gene displayed a protective role in colorectal adenoma onset, as reported 
by Edwards and colleagues [33].  Apart from the rs1346271 polymorphism, that 
was previously associated with a reduced risk for CRC and locates in HPGD 
promoter region altering the binding site for nuclear proteins (SNPinfo software), 
no other SNP provides a biological reasoning for the protection observed [21].  
The PGT and MRP4 specific PG membrane transporters are encoded by highly 
polymorphic genes. Still, the study of genetic variants in SLCO2A1 and ABCC4 
genes on the etiology of malignant diseases has been rather neglected [21,34].  
In our population, two polymorphisms in SLCO2A1 gene appeared to modulate the 
susceptibility for colorectal adenoma (rs1131598A>G and rs6439448C>A), 
although it was more noticeable in rs6439448A allele carriers, in whom a 60% 
protection was observed. Biologically, the rs6439448 SNP tags two other 
polymorphisms with predicted impact on PGT expression: the rs2370512T>A 
located in the 3’UTR could affect the binding of microRNAs and stability of mRNA 
and the nonsynonymous rs34550074G>A SNP at codon 396 codes for two 
different amino acids (Ala396Thr) with potential repercussion on protein structure 
and function. Similarly, the rs1131598A>G polymorphism, located at 3’UTR, is 
predicted to influence mRNA stability and thus the PGT protein expression. 
Remarkably, homozygous mutations in HPGD and more recently in SLCO2A1 
gene were identified as causative agents for the development of primary 
hypertrophic osteoarthropathy (PHO) [35,36]. Similarly to neoplastic tumor genesis, 
increased levels of PGE2 play a role in the pathogenesis of PHO, thus reinforcing 
the impact that genetic variability in these genes might portray in disease 
development by disrupting the normal 15-PGDH and PGT levels or activity [36].  
Regarding the ABCC4 gene, three polymorphisms influenced the risk for adenoma 
onset (rs1678405, rs9524821 and rs1751051). More interesting, individuals 
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carrying the haplotype containing both the A alleles for the rs9524821 and 
rs1751051 SNPs had a nearly 4-fold increased susceptibility. The in silico analysis 
did not provide any biological clue for the involvement of these polymorphisms in 
MRP4 expression or function. 
The common disease-common variant (CD-CV) hypothesis predicts that complex 
polygenic diseases develop from the additive or multiplicative effect of low 
penetrance genes [37]. Here, a 13-fold increased predisposition was noticed in the 
multi-locus analysis, supporting the role that common variants portray in colorectal 
carcinogenesis. 
The current post-polypectomy guidelines recommend endoscopic surveillance 
based on risk stratification upon the endoscopic findings at baseline colonoscopy 
[26]. In this study we observed that polymorphisms in the COX-2/PGE2 pathway, 
particularly on the ABCC4 gene, influenced not only the hazard ratio for the 
development of metachronous adenomas, but perhaps more importantly the 
probability for recurrence considering the surveillance intervals currently 
recommended. As an example, the individuals carrying the rs9524821AA 
genotype in the low-risk group presented a nearly three-fold increased hazard ratio 
for adenoma recurrence and nearly half of them developed metachronous lesions 
by 60 months (vs 16%, for G allele carriers). In contrast, the rs1678405TT 
genotype was associated with a 7% recurrence at 36 months in the high-risk group, 
in opposition to C allele carriers (23%). Considering the limited number of 
participants in this study we were not able to specifically assess the influence of 
these SNPs on the risk for the development of advanced colorectal adenomas, but 
assuming an equal distribution among genotypes, this could represent that 
patients carrying the rs1678405TT genotype might benefit from a looser 
surveillance interval. 
These observations should be interpreted with caution considering the several 
drawbacks encountered in this study. Inherent to a retrospective study we cannot 
rule out selection bias, even more considering that our control population was 
represented by unscreened individuals. Nevertheless, if this were true we would 
expect stronger associations; or recall bias that could decrease the availability and 
accuracy of collected data, compromising our ability to estimate possible gene-
environment interactions. Our major limitation certainly falls on the low statistical 
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power (<80%), namely when carrying out the analysis on the recurrence of 
adenomas. Although, the bootstrap analysis reinforced the robustness of the 
associations reported here, further replication studies with larger and independent 
populations are needed to clarify the involvement of these polymorphisms in early 
stages of colorectal carcinogenesis. Furthermore, functional studies evaluating the 
repercussion of the aforementioned SNPs on protein expression/function will allow 
a deeper understanding of their real contribution on cancer development. 
In this study, we observed the involvement of several polymorphisms in COX-
2/HPGD/SLCO2A1/ABCC4 genes in colorectal adenoma development and 
recurrence. Furthermore, the incorporation of genetic variants in current risk 
models might provide a better balance between benefits and drawbacks of post-
polypectomy surveillance.  
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Table S1. Characterization of genetic polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes and quality control results 
Gene tagSNP 
Other SNPs 
on the block 
Genotype call rate  
(controls/ cases) 
Genotype 
concordance 
rate 
HWE 
Passed 
quality 
check? 
COX-2 
rs689466 
Candidate 
gene 
0.98 / 0.95 0.97 0.901 
Yes 
rs20417 
Candidate 
gene 
0.98 / 0.93 0.92 0.998 
No 
rs5275 
Candidate 
gene 
0.96 / 0.95 1.00 0.999 
Yes 
HPGD 
rs2555639 
Candidate 
gene 
0.99 / 0.98 1.00 0.989 
Yes 
rs1346271 singleton 1.00 / 0.91 1.00 0.167 Yes 
rs2555632 rs3101255 1.00 / 0.92 1.00 0.681 Yes 
rs2303520 rs13127058 0.99 / 0.94 1.00 0.633 Yes 
rs1863642 rs2612659 1.00 / 0.96 1.00 0.474 Yes 
rs1426945 rs3756273 1.00 / 0.86 0.97 0.976 No 
rs12500316 
rs1863641 
1.00 / 0.93 1.00 0.508 Yes 
rs11722919 
rs8752 
rs1426947 
1.00 / 0.90 1.00 0.948 Yes 
rs2612658 
rs11133041 
rs11724251 
rs2612656 
rs1816204 
0.94 / 0.91 0.96 0.917 Yes 
rs3857075 
SLCO2A1 
rs4241362 
rs4241361 
1.00 / 0.90 1.00 0.756 Yes 
rs4634113 
rs6804798 
rs9828294 
rs9855403 
rs9874493 
rs9882333 
rs11720811 
rs7646392 
rs4327389 
1.00 / 0.78 1.00 0.550 No 
rs4854777 
rs5013525 
rs7646298 
rs7646473 
rs12695600 
rs6439448 
rs2370512 
0.99 / 0.98 0.97 0.979 Yes 
rs3923835 
rs3923835 
rs4854768 
rs4854769 
rs34550074 
rs9821091 
rs7630191 
1.00 / 0.93 1.00 0.651 Yes 
rs9841380 
rs6439450 
rs7617777 
rs9834727 
rs9820625 
rs9836830 
1.00 / 0.94 1.00 0.948 Yes 
rs9917636 
rs11709172 
rs13083175 
rs9834412 
rs4854785 
1.00 / 0.82 1.00 0.951 No 
rs13067921 
rs4241365 rs7653639 1.00 / 0.94 1.00 0.923 Yes 
rs4331673 rs11720843 1.00 / 0.93 1.00 0.994 Yes 
rs4854784 rs7636169 1.00 / 0.80 0.97 0.871 No 
rs7340717 rs7340718 0.99 / 0.93 1.00 0.600 Yes 
rs7616492 rs10935089 1.00 / 0.98 1.00 0.938 Yes 
rs7625035 rs9822027 1.00 / 0.91 1.00 0.455 Yes 
rs1131598 Singleton 1.00 / 0.96 1.00 0.441 Yes 
rs10935090 Singleton 1.00 / 0.91 1.00 0.815 Yes 
rs11915399 Singleton 1.00 / 0.93 1.00 0.998 Yes 
ABCC4 
rs4148422 rs17300935 0.99 / 0.92 0.95 0.006 No 
rs9524821 [rs9516532] 0.99 / 0.90 1.00 0.604 Yes 
rs3782958 
rs4148515 
1.00 / 0.97 1.00 0.931 Yes 
rs10508023 
rs869951 
rs871052 
1.00 / 0.92 1.00 0.854 Yes 
rs8001444 
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Table S1. Characterization of genetic polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes and quality control results 
Gene tagSNP 
Other SNPs 
on the block 
Genotype call rate  
(controls/ cases) 
Genotype 
concordance 
rate 
HWE 
Passed 
quality 
check? 
ABCC4 
rs4771912 rs7981095 1.00 / 0.95 0.97 0.936 Yes 
rs4148421 
rs9524864 
1.00 / 0.85 1.00 0.998 No rs9524873 
rs10508017 
rs8002180 
rs4148424 
1.00 / 0.97 1.00 0.694 Yes 
rs4771910 
rs7317112 
rs7322318 
rs8001475 
rs9584288 
rs9590228 
rs2127295 
rs2698243 
1.00 / 0.95 0.97 0.657 Yes 
rs1564355 
rs1617785 
rs1630807 
rs1678363 
rs1678394 
rs1729748 
rs2766481 
rs3825415 
rs6650282 
rs1751051 [rs1751050] 1.00 / 0.93 1.00 0.999 Yes 
rs9590220 
rs9590216 
1.00 / 0.90 0.96 0.018 No 
rs17235152 
rs2892715 rs9561814 1.00 / 0.95 1.00 0.473 Yes 
rs2892713 rs12865305 1.00 / 0.95 1.00 0.313 Yes 
rs4612933 
rs899494 
1.00 / 0.93 1.00 0.936 Yes 
rs899495 
rs899496 
rs1678403 
rs1824911 
rs1824913 
rs1926657 
rs3782965 
rs4148465 
rs4148469 
rs4303338 
rs4334136 
rs4505186 
rs4773854 
rs4773855 
rs7325019 
rs7333234 
rs7335147 
rs7983336 
rs7987653 
rs7988494 
rs9524831 
rs9524833 
rs9524845 
rs9524856 
rs12870204 
rs4148437 
rs9556466 
1.00 / 0.90 1.00 0.665 Yes 
rs2892716 
rs4148436 
rs4148446 
rs10508018 
rs1611822 rs1751015 1.00 / 0.96 1.00 0.969 Yes 
rs1678386 rs9516530 1.00 / 0.97 1.00 0.818 Yes 
rs2274403 
rs3864997 
1.00 / 0.95 0.97 0.862 Yes 
rs4148481 
rs17268122 rs17268163  0.97 / 0.65 0.96 0.027 No 
rs1751027 
rs1564351 
 0.99 / 0.95 1.00 0.396 No* 
rs4148487 
rs17189390 
rs17268170 
rs17268122 rs17268163  0.97 / 0.65 0.96 0.027 No 
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Table S1. Characterization of genetic polymorphisms in COX-2/HPGD/SLCO2A1/ABCC4 genes and quality control results 
Gene tagSNP 
Other SNPs 
on the block 
Genotype call rate  
(controls/ cases) 
Genotype 
concordance 
rate 
HWE 
Passed 
quality 
check? 
ABCC4 
rs1751027 
rs1564351 
 0.99 / 0.95 1.00 0.396 No* 
rs4148487 
rs17189390 
rs17268170 
rs4148476 
rs4773843 
1.00 / 0.93 1.00 0.280 Yes 
rs9524822 
rs1678374 rs1751025 1.00 / 0.95 1.00 0.964 Yes 
rs1678405 
rs2793821 
100 / 0.95 1.00 0.722 Yes rs6492768 
rs7330933 
rs1678396 rs2766482 1.00 / 0.92 1.00 0.537 Yes 
rs1678354 rs1751059 0 - - No 
rs1751031 
rs931111 
1.00 / 0.94 1.00 0.372 Yes 
rs1189444 
rs1189451 
rs1189452 
rs1729747 
rs2619312 
rs5016378 
rs7993878 
rs9302040 
1.00 / 0.96 0.97 0.346 Yes 
rs9302042 
rs9302043 
rs9556455 
rs9561768 
rs9561769 
rs9590168 
rs10219913 
rs6492763 rs10508024 1.00 / 0.83 0.97 0.520 No 
rs3742106 
rs4148544 
1.00 / 0.95 1.00 0.987 Yes 
rs4148549 
rs4148551 
rs7330196 
rs9302039 
rs9524769 
* minor allele frequency<0.15 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal adenoma onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value aOR 95% CI P value 
COX-2 
rs689466 
   AA 117 (62.9) 323 (68.4) 1.00 Reference - 1.00 Reference - 
AG 50 (26.9) 133 (28.2) 1.03 0.67-1.60 0.884 - - ns 
GG 19 (10.2) 16 (3.4) 3.25 1.53-6.91 0.001 3.33 1.54-7.16 0.002 
RM - - 3.22 1.53-6.77 0.001 3.23 1.52-6.86 0.002 
rs5275 
TT 95 (51.4) 235 (50.9) 1.00 Reference - 1.00 Reference - 
TC 65 (35.1) 189 (40.9) 0.86 0.58-1.28 0.458 - - ns 
CC 25 (13.5) 38 (8.2) 1.66 0.92-3.01 0.089 - - ns 
RM9 - - 1.78 1.01-3.13 0.045 - - ns 
HPGD 
rs2555639 
TT 93 (48.7) 216 (45.6) 1.00 Reference - 1.00 Reference - 
TC 59 (30.9) 209 (44.1) 0.65 0.43-0.99 0.044 0.48 0.28-0.83 0.008 
CC 39 (20.4) 49 (10.3) 1.83 1.07-3.11 0.025 - - ns 
RM - - 2.21 1.33-3.65 0.002 2.48 1.36-4.53 0.003 
rs2612656 
AA 138 (77.5) 295 (65.6) 1.00 Reference - 1.00 Reference - 
AG 21 (11.8) 137 (30.4) 0.32 0.17-0.63 0.001 0.19 0.068-0.56 0.002 
GG 19 (10.7) 18 (4.0) 2.24 0.99-5.07 0.047 - - ns 
DM - - 0.55 0.32-0.92 0.023 0.47 0.23-0.94 0.033 
RM - - 2.86 1.27-6.41 0.008 3.20 1.22-8.41 0.018 
rs8752 
TT 79 (44.9) 197 (41.2) 1.00 reference - 1.00 Reference - 
TC 57 (32.4) 219 (45.8) 0.66 0.44-0.97 0.034 - - ns 
CC 40 (22.7) 62 (13.0) 1.59 0.99-2.56 0.054 - - ns 
RM - - 1.94 1.25-3.02 0.003 1.94 1.09-3.44 0.023 
rs1346271 
GG 87 (49.2) 174 (36.2) 1.00 reference - 1.00 Reference - 
GC 54 (30.5) 246 (51.2) 0.46 0.31-0.68 <0.001 0.45 0.28-0.74 0.002 
CC 36 (20.3) 60 (12.5) 1.12 0.68-1.85 0.663 - - ns 
DM - - 0.59 0.41-0.84 0.003 0.55 0.35-0.85 0.008 
rs2555632 
TT 124 (68.9) 284 (59.3) 1.00 reference - 1.00 Reference - 
TC 42 (23.3) 174 (36.3) 0.54 0.36-0.81 0.003 0.51 0.30-0.86 0.012 
CC 14 (7.8) 21 (4.4) 1.56 0.77-3.18 0.213 - - ns 
DM - - 0.65 0.45-0.94 0.022 - - ns 
rs2303520 
GG 124 (67.4) 342 (71.4) 1.00 reference - 1.00 Reference - 
GA 45 (24.5) 123 (25.7) 1.00 0.67-1.49 0.999 - - ns 
AA 15 (8.2) 14 (2.9) 2.93 1.37-6.24 0.004 - - ns 
RM - - 2.93 1.38-6.20 0.003 - - ns 
rs1863642 
GG 110 (58.5) 231 (48.1) 1.00 reference - 1.00 Reference - 
GT 56 (29.8) 212 (44.2) 0.56 0.38-0.80 0.002 0.48 0.30-0.76 0.002 
TT 22 (11.7) 37 (7.7) 1.25 0.70-2.22 0.448 - - ns 
DM - - 0.66 0.47-0.92 0.016 0.55 0.36-0.85 0.007 
rs12500316         
CC 122 (67.4) 262 (54.7) 1.00 reference - 1.00 Reference - 
CT 41 (22.7) 191 (39.9) 0.46 0.31-0.69 <0.001 0.44 0.27-0.72 0.001 
TT 18 (9.9) 26 (5.4) 1.49 0.78-2.82 0.221 - - ns 
DM - - 0.59 0.41-0.84 0.003 0.49 0.31-0.78 0.002 
RM - - 1.92 1.02-3.59 0.039 - - ns 
SLCO2A1 
rs4241362 
TT 124 (70.4) 333 (69.5) 1.00 reference - 1.00 Reference - 
TC 28 (15.9) 130 (27.1) 0.58 0.36-0.92 0.019 - - ns 
CC 24 (13.6) 16 (3.3) 3.99 2.04-7.81 <0.001 3.47 1.58-7.58 0.002 
RM - - 4.53 2.33-8.80 <0.001 3.90 1.80-8.43 0.001 
rs6439448 
CC 160 (83.3) 320 (66.7) 1.00 reference - 1.00 Reference - 
CA 21 (10.9) 143 (29.8) 0.29 0.18-0.48 <0.001 0.24 0.12-0.49 <0.001 
AA 11 (5.7) 17 (3.5) 1.29 0.59-2.81 0.527 - - ns 
DM - - 0.40 0.26-0.61 <0.001 0.38 0.22-0.65 <0.0001 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal adenoma onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value aOR 95% CI P value 
rs9821091 
GG 84 (46.2) 180 (37.6) 1.00 reference - 1.00 Reference - 
GA 48 (26.4) 235 (49.1) 0.44 0.29-0.66 <0.001 0.50 0.31-0.81 <0.001 
AA 50 (27.5) 64 (13.4) 1.67 1.07-2.63 0.025 - - ns 
DM - - 0.70 0.50-0.99 0.044 0.62 0.40-0.96 0.033 
RM - - 2.46 1.62-3.73 <0.001 1.77 1.02-3.06 0.041 
rs9820625 
AA 79 (42.9) 141 (29.4) 1.00 reference - 1.00 Reference - 
AC 70 (38.0) 232 (48.3) 0.54 0.36-0.78 0.001 0.60 0.38-0.98 0.040 
CC 35 (19.0) 107 (22.3) 0.58 0.36-0.93 0.023 - - ns 
DM - - 0.55 0.39-0.78 0.001 - - ns 
rs4241365 
TT 108 (59.0) 282 (58.9) 1.00 reference - 1.00 Reference - 
TC 52 (28.4) 169 (35.3) 0.81 0.55-1.18 0.274 - - ns 
CC 23 (12.6) 28 (5.8) 2.14 1.18-3.89 0.011 2.63 1.29-5.37 0.008 
RM - - 2.31 1.29-4.13 0.004 2.60 1.30-5.22 0.007 
rs4331673 
CC 126 (68.1) 332 (69.2) 1.00 reference - 1.00 Reference - 
CA 54 (29.2) 134 (27.9) 1.06 0.73-1.55 0.755 - - ns 
AA 5 (2.7) 14 (2.9) 0.94 0.33-2.67 0.909 - - ns 
rs7340717 
GG 75 (41.2) 204 (42.5) 1.00 reference - 1.00 Reference - 
GT 68 (37.4) 210 (43.8) 0.88 0.60-1.30 0.529 - - ns 
   TT 39 (21.4) 66 (13.8) 1.59 0.99-2.56 0.055 - - ns 
rs7616492 
GG 70 (36.5) 202 (42.1) 1.00 reference - 1.00 Reference - 
GA 80 (41.7) 216 (45.0) 1.07 0.74-1.55 0.727 - - ns 
AA 42 (21.9) 62 (12.9) 1.99 1.23-3.20 0.005 - - ns 
RM - - 1.92 1.24-2.96 0.003 - - ns 
rs7625035 
AA 114 (64.4) 278 (57.9) 1.00 reference - 1.00 Reference - 
AG 48 (27.1) 181 (37.7) 0.65 0.44-0.95 0.026 0.58 0.35-0.94 0.028 
GG 15 (8.5) 21 (4.4) 1.74 0.87-3.50 0.115 - - ns 
RM - - 2.02 1.02-4.02 0.041 2.68 1.17-6.11 0.020 
rs1131598         
AA 128 (68.4) 274 (57.1) 1.00 reference - 1.00 Reference - 
AG 43 (23.0) 184 (38.3) 0.50 0.34-0.74 <0.001 0.50 0.34-0.74 0.007 
GG 16 (8.6) 22 (4.6) 1.55 0.79-3.05 0.201 - - ns 
DM - - 0.61 0.43-0.87 0.003 - - ns 
RM - - 1.94 1.00-3.79 0.048 2.20 1.01-4.80 0.047 
rs10935090 
CC 141 (79.7) 382 (79.7) 1.00 reference - 1.00 Reference - 
CT 27 (15.3) 90 (18.8) 0.81 0.51-1.30 0.388 - - ns 
TT 9 (5.1) 7 (1.5) 3.48 1.27-9.530 0.010 5.68 1.43-22.53 0.013 
RM - - 3.61 1.32-9.85 0.008 5.18 1.33-20.17 0.018 
rs11915399 
CC 129 (71.3) 328 (68.5) 1.00 reference - 1.00 Reference - 
CT 38 (21.0) 137 (28.6) 0.69 0.46-1.05 0.082 - - ns 
TT 14 (7.7) 14 (2.9) 2.50 1.16-5.40 0.016 - - ns 
RM - - 2.75 1.28-5.89 0.007 - - ns 
ABCC4 
rs9524821 
GG 65 (36.9) 205 (42.8) 1.00 reference - 1.00 Reference - 
GA 65 (36.9) 209 (43.6) 0.97 0.65-1.43 0.866 - - ns 
AA 46 (26.1) 65 (13.6) 2.20 1.38-3.52 0.001 2.15 1.18-3.90 0.012 
RM - - 2.24 1.46-3.43 <0.001 2.38 1.39-4.09 0.002 
rs3782958 
GG 135 (71.1) 336 (70.1) 1.00 reference - 1.00 Reference - 
GC 48 (25.3) 129 (26.9) 0.93 0.63-1.36 0.697 - - ns 
CC 7 (3.7) 14 (2.9) 1.24 0.49-3.15 0.644 - - ns 
rs869951 
GG 86 (48.0) 171 (35.6) 1.00 reference - 1.00 Reference - 
GC 67 (37.4) 226 (47.1) 0.59 0.40-0.85 0.005 0.58 0.37-0.93 0.026 
CC 26 (14.5) 83 (17.3) 0.62 0.37-1.03 0.065 - - ns 
DM - - 0.60 0.42-0.84 0.003 0.60 0.39-0.92 0.018 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal adenoma onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value aOR 95% CI P value 
rs4771912         
AA 147 (79.5) 359 (74.6) 1.00 reference - 1.00 Reference - 
AG 29 (15.7) 112 (23.3) 0.63 0.40-0.99 0.044 - - ns 
GG 9 (4.9) 10 (2.1) 2.19 0.87-5.50 0.087 - - ns 
rs8002180 
TT 112 (58.9) 248 (51.8) 1.00 reference - 1.00 Reference - 
TC 60 (31.6) 188 (39.2) 0.71 0.49-1.02 0.063 0.59 0.37-0.94 0.026 
CC 18 (9.5) 43 (9.0) 1.07 0.51-1.68 0.802 - - ns 
rs2127295 
GG 55 (29.7) 137 (28.7) 1.00 reference - 1.00 Reference - 
GA 86 (46.5) 247 (51.7) 0.86 0.58-1.28 0.461 - - ns 
AA 44 (23.8) 94 (19.7) 1.16 0.72-1.86 0.547 - - ns 
rs1751051 
TT 88 (48.6) 234 (48.8) 1.00 reference - 1.00 Reference - 
TA 51 (28.2) 202 (42.1) 0.67 0.45-1.00 0.046 - - ns 
AA 42 (23.2) 44 (9.2) 2.54 1.56-4.14 <0.001 2.24 1.25-4.04 0.007 
RM - - 2.99 1.88-4.76 <0001 2.75 1.58-4.80 <0.001 
rs2892715 
GG 61 (32.8) 173 (36.0) 1.00 reference - 1.00 Reference - 
GA 84 (45.2) 220 (45.7) 1.08 0.74-1.59 0.685 - - ns 
AA 41 (22.0) 88 (18.3) 1.35 0.84-2.17 0.210 - - ns 
rs2892713         
CC 131 (70.4) 337 (70.4) 1.00 reference - 1.00 Reference - 
CT 40 (21.5) 124 (25.9) 0.83 0.55-1.25 0.372 - - ns 
TT 15 (8.1) 18 (3.8) 2.14 1.05-4.38 0.033 2.72 1.22-6.06 0.014 
RM - - 2.25 1.11-4.56 0.022 2.50 1.12-5.58 0.025 
rs4612933 
CC 124 (68.5) 315 (65.5) 1.00 reference - 1.00 Reference - 
CT 41 (22.7) 148 (30.8) 0.70 0.47-1.05 0.084 - - ns 
TT 16 (8.8) 18 (3.7) 2.25 1.11-4.55 0.021 3.10 1.37-7.03 0.007 
RM - - 2.49 1.24-4.99 0.008 3.03 1.35-6.79 0.007 
rs4148437 
TT 78 (44.3) 194 (40.4) 1.00 reference - 1.00 Reference - 
TC 76 (43.2) 215 (44.8) 0.88 0.61-1.28 0.512 - - ns 
CC 22 (12.5) 71 (14.8) 0.78 0.45-1.35 0.376 - - ns 
rs1611822 
CC 66 (35.1) 182 (37.9) 1.00 reference - 1.00 Reference - 
CT 75 (39.9) 225 (46.9) 0.91 0.62-1.34 0.647 - - ns 
TT 47 (25.0) 73 (15.2) 1.77 1.11-2.80 0.015 - - ns 
RM - - 1.85 1.23-2.80 0.003 - - ns 
rs1678386 
AA 111 (58.7) 243 (50.6) 1.00 reference - 1.00 Reference - 
AC 60 (31.7) 193 (40.2) 0.68 0.47-0.98 0.039 - - ns 
CC 18 (9.5) 44 (9.2) 0.90 0.50-1.62 0.715 - - ns 
rs2274403 
AA 55 (30.6) 120 (25.0) 1.00 reference - 1.00 Reference - 
AG 75 (41.7) 234 (48.8) 0.70 0.46-1.06 0.088 - - ns 
GG 50 (27.8) 126 (26.2) 0.87 0.55-1.37 0.537 - - ns 
rs4148476 
TT 126 (69.6) 339 (70.6) 1.00 reference - 1.00 Reference - 
TG 40 (22.1) 123 (25.6) 0.88 0.58-1.32 0.524 0.57 0.32-0.99 0.046 
GG 15 (8.3) 18 (3.8) 2.24 1.10-4.58 0.024 2.81 1.22-6.47 0.015 
RM - - 2.32 1.14-4.71 0.017 3.22 1.41-7.36 0.005 
rs1678374 
TT 82 (44.3) 164 (34.2) 1.00 reference - 1.00 Reference - 
TC 76 (41.1) 235 (49.1) 065 0.45-0.94 0.021 0.62 0.39-0.98 0.042 
CC 27 (14.6) 80 (16.7) 0.68 0.40-1.12 0.131 - - ns 
DM - - 0.66 0.46-0.93 0.017 - - ns 
rs1678405 
TT 111 (59.7) 199 (41.4) 1.00 reference - 1.00 Reference - 
TC 69 (37.1) 227 (47.2) 0.54 0.38-0.77 0.001 0.47 0.30-0.74 0.001 
CC 6 (3.2) 55 (11.4) 0.20 0.08-0.47 <0.001 0.10 0.02-0.45 0.002 
DM - - 0.47 0.34-0.67 <0.001 0.41 0.27-0.63 <0.001 
RM - - 0.26 0.11-0.61 0.001 0.15 0.04-0.63 0.010 
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Table S2. Genotype frequencies among cases and controls and risk estimates for the involvement of COX-
2/HPGD/SLCO2A1/ABCC4 polymorphisms in colorectal adenoma onset 
SNPs rs 
Cases 
n (%) 
Controls 
n (%) 
OR 95% CI P value aOR 95% CI P value 
rs1678396         
TT 66 (36.9) 147 (30.6) 1.00 reference - 1.00 Reference - 
TC 72 (40.2) 248 (51.7) 0.65 0.44-0.96 0.028 - - ns 
CC 41 (22.9) 85 (17.7) 0.75 0.52-1.08 0.116 - - ns 
         
rs1751031         
AA 133 (72.7) 299 (62.3) 1.00 reference - 1.00 Reference - 
AG 35 (19.1) 166 (34.6) 0.47 0.31-0.72 <0.001 0.53 0.32-0.88 <0.001 
GG 15 (8.2) 15 (3.1) 2.24 1.06-4.72 0.030 - - ns 
DM - - 0.62 0.43-0.90 0.012 - - ns 
RM - - 2.76 1.32-5.78 0.005 2.99 1.11-8.00 0.030 
rs7993878         
GG 135 (71.8) 361 (75.1) 1.00 reference - 1.00 Reference - 
GA 38 (20.2) 107 (22.2) 0.95 0.62-1.44 0.809 - - ns 
AA 15 (8.0) 13 (2.7) 3.34 1.53-7.32 0.002 - - ns 
DM - - 3.38 1.55-7.37 0.001 3.14 1.09-9.01 0.033 
rs3742106 
AA 67 (36.2) 166 (34.6) 1.00 reference - 1.00 Reference - 
AC 82 (44.3) 234 (48.8) 0.87 0.59-1.27 0.465 - - ns 
CC 36 (19.5) 80 (16.7) 1.12 0.69-1.81 0.660 - - ns 
aOdds Ratio, Logistic regression (Forward:conditional model) including gender, smoking habits and age (median global age of 59 years used as 
cutoff). CI, confidence interval 
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ABSTRACT 
Deregulation of the COX-2/PGE2 pathway is an early event in colorectal 
carcinogenesis leading to the stimulation of a plethora of oncogenic pathways with 
repercussion on most if not all hallmarks of cancer. Our group has previously 
identified several genetic variants in the COX-2/PGE2 pathway has risk biomarkers 
for the occurence and recurrence of colorectal tumors.  
A functional study was design to assessed the influence of polymorphisms on 
COX-2, HPGD, SLCO2A1 or ABCC4 mRNA levels on colonic tissues from 60 
patients diagnosed with CRC, through Real-time PCR. 
Thirteen out of the 20 genetic variants analysed presented and allelic-specific 
expression profile. The rs689466GG genotype was associated with a 7-fold 
overexpression of COX-2 in CRC tissues (-1.57±0.10 vs-4.42±1.58 for the AA 
genotype, P=0.024). Similarly, the heterozygous genotype for the rs1425945 
polymorphism exhibited a trend for higher levels of HPGD (-1.10±1.41 vs -
2.02±2.18 for the GG homozygous genotype, P=0.163). An approximately 2-fold 
overexpression was reported for AC and CC genotypes of rs9820625 tagSNP 
when compared with the AA homozygous genotype in normal-appearing mucosa 
(-4.96±1.78 and -5.17±1.28 vs -6.08±0.96, respectively). Furthemore,the ABCC4 
levels were progressively lower in rs1678405TC and CC genotypes in malignant 
mucosa (-2.26±1.47 and -3.39±0.92, respectively, vs -1.43±1.18 with the TT 
genotype, P=0.049). 
The present functional study reports the involvement of genetic variants on COX-2, 
HPGD, SLCO2A1 and ABCC4 genes’ expression providing a biological reasoning 
underlying the epidemiological data.  
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INTRODUCTION 
A large number of common low-penetrance genetic variants each exhibiting a 
small influence on the risk are expected to be involved on the occurrence of 
colorectal tumors [1]. Furthermore, studies uncovering the genetic basis of 
variation in gene expression, also known as, expression qualitative trait loci (eQTL) 
have implicated polymorphisms as regulators of the expression of genes with 
considerable variation [2]. 
A large body of epidemiological and functional data as highlighted the central role 
of COX-2/PGE2 pathway in colorectal carcinogenesis [3-7]. Moreover, the 
nonsteroidal anti-inflammatory drugs target the cyclooxygenases (COX) enzymes 
to exert their preventive effects on colorectal tumors development [8].   
COX-2, the inducible isoenzyme, was shown to be up-regulated by 2 to 50-fold in 
human colorectal adenomas and adenocarcinomas [9]. This deregulation 
increases the synthesis of prostaglandin E2 (PGE2) that once carried-out across 
the membrane via the multidrug resistance-associated protein 4 (MRP4) triggers 
several oncogenic signaling pathways that contribute to most of the known 
hallmarks of cancer, including inhibition of apoptosis, stimulation of cell 
proliferation and angiogenesis [10-12]. The first step in PGE2 catabolism requires 
its transport back to the cytoplasm from the extracellular microenvironment by the 
specific PG transporter (PGT), where NAD+-dependent 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) oxidizes PGE2 to yield inactive 15-keto metabolites 
[13]. 
Backlund and colleagues [14] reported a repressed expression and activity of 15-
PGDH in human CRC and ApcMin/+ mouse adenoma resulting in a decreased 
catabolism of PGE2. The down-regulation of 15-PGDH in colorectal tumors was 
corroborated in subsequent studies [15,16]. Further exploring this pathway Holla 
and colleagues [17], showed that PGT expression was also decreased whereas 
the MRP4 was elevated in CRC. In fact, mRNA levels of PGT and MRP4 are 
inversely regulated in human CRC compared to normal mucosa and in intestinal 
adenomas from ApcMin/+ mice [17]. Deregulation of these molecules leads to higher 
levels of PGE2 extracellularly thus potentiating the effects of COX-2/PGE2 pathway 
[12]. 
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Our group previously identified several genetic polymorphisms in the genes coding 
for COX-2, 15-PGDH (HPGD, hydropxyprostaglandin dehydrogenase), PGT 
(ABCC4, ATP-binding cassete sub-family c member 4) and MRP4 proteins 
(SLCO2A1, solute carrier organic anion transporter family, member 2A1) as risk 
markers not only in the development of colorectal cancer (CRC) and early stage 
colorectal tumors but also in the occurrence of metachronous adenomatous polyps 
in a Northern Portuguese population [18,19]. The scarcity of available data 
evaluating the molecular relevance of these polymorphisms, prompted us to 
investigate the functional impact of the genetic variability in COX-2, HPGD, 
SLCO2A1 and ABCC4 on genes’ expression to provide a biological plausibility 
underlying the epidemiological associations [20].  
MATERIAL AND METHODS 
Patient samples 
Sixty patients were selected from a subset of 129 CRC patients from the original 
observational study [18], recruited between 2002 and 2007 at the Portuguese 
Institute of Oncology of Porto, based on the availability of formalin fixed paraffin 
embedded (FFPE) tissues. Only patients not submitted to treatments with 
chemotherapy and/or radiotherapy prior to surgical resection of tumor were 
included. The description of patients is displayed in Table 1.  
In comparison with the entire group, tumors from these CRC patients tended to 
have lower stages (70.6% vs 52.6) and be located preferentially at the colon (61.0 
vs 47.7).  
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Table 1. Description of patients with colorectal cancer 
 CRC mucosa 
(n=39) 
Normal mucosa 
(n=60) 
P value 
Age (years) 
   
Mean (SD) 65 (7.39) 65 (7.19) 0.977 
Median (min-max) 66 (50-75) 66 (50-75)  
Gender, n (%)    
Male 21 (53.8) 36 (60.0) 0.545 
Female 18 (46.2) 24 (40.0)  
Smoking habits, n (%)    
Never-smokers 11 (73.3) 12 (75.0) 0.916 
Ever-smokers 4 (26.7) 4 (25.0)  
Tumor location, n (%) 
   
Rectum 36 (61.0) -  
Colon 23 (39.0) -  
Stage, n (%)    
I-II 24 (70.6) -  
III-IV 10 (29.4) -  
 
Polymorphisms selection and genotyping 
The selection of polymorphisms and the genotype characterization is described 
elsewhere [18]. Briefly, 55 tagSNPs were included in the case-controls studies 
after being retrieved from a set of common SNPs in the Caucasian population of 
HapMap project (minor allele frequency: ≥0.15%; r2<0.8). In this study we only 
addressed the genetic variations that were identified as susceptibility markers for 
the development or recurrence of colorectal tumors in the observational studies 
(Table S1 of supplementary data).  
The tagSNPs genotyping was performed using MassARRAY iPLEX Gold 
technology based on multiplex amplification followed by mass-spectrometric 
product separation (Sequenom, San Diego, CA). The rs689466 in COX-2 gene 
was characterized by Real-Time PCR using validated TaqMan SNP genotyping 
assay (C___2517145_20).  
RNA isolation and quantification 
RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissues using 
the Absolutely RNA FFPE Kit following the manufacture’s instructions (Stratagene, 
La Jolla, CA, USA). The number of 10µm thickness sections used for RNA 
extraction varied from two to four, depending on the size of tumor area. A 3μm 
section was stained with hematoxylin and eosin (H&E) and a histopathological 
characterization was rendered, by a senior pathologist. The enriched tumor cell 
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area were microdissected into a 1.5 ml reaction tube containing 1 ml of 
deparaffinization reagent (d-limonene) by scratching using a sterile single-use 
scapel. Normal colon tissues were prepared from the surgical margins at the edge 
of a colon resection. RNA was quantified using the NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The RNA 
quality was determined by measuring the optical density (OD) 260/280 ratio. 
Reverse transcriptase and mRNA quantification 
Up to 2µg of total RNA was reverse transcribed using the High Capacity cDNA 
Reverse Transcription Kit from Applied Biosystems (Foster City, CA, USA). Briefly, 
in a 20µl reaction mix, 2.0µl of 1X RT buffer, 0.8µl 25X dNTP mix, 2.0µl 10X RT 
random primers and 1.0µl of Multiscribe Reverse Transcriptase were used. The 
amplification conditions were as follows: annealing at 25ºC for 10 min, extension 
at 37ºC for 120 min and RT inactivation at 85ºC for 5 min. All reverse transcriptase 
reactions included two no-template negative controls. Furthermore, the QPCR 
Human Reference Total RNA, included in the RNA extraction kit was included as a 
positive control to monitor the quality of RT reaction. 
Real-time PCR amplification of cDNA was performed in a StepOne Real-Time 
PCR System (Applied Biosystems, Foster City, CA, USA) using 10µl of 2X 
TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA, 
USA), 1µl of Gene Expression Assay and 30 to 40ng of cDNA template. The 
mRNA expression of COX-2, HPGD, SLCO2A1 and ABCC4 genes was measured 
with the gene expression assays Hs00153133_m1, Hs00960586_g1, 
Hs00194554_m1, Hs00988717_m1, respectively (Applied Biosystems). Thermal 
cycling for all assays was 95ºC for 10 min, followed by 50 cycles of 95ºC for 15 
sec and 60ºC for 1 min. Cytokeratin 20 (KRT20) was used as the reference gene 
for normalization and was amplified using the human hydrolysis Probe/Primer 
assay Hs00300643_m1 from Applied Biosystems. KRT20 is a specific marker for 
colonic epithelial mass with previously reported uniform expression by microarray 
across colon tissue biopsies [20,21].  
The endpoint of the qPCR data was the cycle threshold (Ct) determined as the 
average values from two independent real-time PCR reactions. The relative 
expression of mRNA was defined as the difference between Cts of the 
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amplification curves of the target genes and the KRT20 reference gene (-ΔCt).  
The fold difference in expression was determined following the Livak method, also 
known as 2-ΔΔCt [22]. 
Quality control 
All reverse transcriptase reactions included two no-template negative controls. 
Furthermore, the QPCR Human Reference Total RNA included in the RNA 
extraction kit was used as a positive control in the RT reaction. The efficiency of 
the amplification reaction for each Probe/Primer was calculated, also as the limit of 
detection. Efficiency superior to 95% and sensitivity above 20ng was reported for 
all expression assays.  
Data analysis  
Statistical analysis was performed using the computer software IBM® SPSS® 
(Statistical Package for Social Sciences) Statistics version 20.0 for Mac. Student’s 
t-test was used to compare the expression between cancer and normal mucosa. 
The difference in mean tissue expression between the three possible genotypes 
was evaluated using a one-way ANOVA. The non-parametric corresponding 
statistical tests were applied when appropriate.  
RESULTS 
We were able to successfully extract RNA from normal-appearing mucosa in all 60 
cases and CRC tissues from 39 patients.  The mean expression of KRT20 was 
31.17±2.14 with a 1.36-fold variation (lowest to highest), suggesting a good 
stability across samples and lesions. The mean mRNA expression values are 
displayed in Table 2. Overall, the COX-2 gene was found to be overexpressed in 
CRC tumors (-3.99±1.64 vs -5.22±1.67 in normal-appearing mucosa, P=0.001), 
leading to a 2.34-fold increase in mRNA expression, as can be observed in Figure 
1. This increased levels in COX-2 was only evident in males (P<0.001) 
    
Table 2. Mean expression values (-ΔCt) for COX-2, HPGD, SLCO2A1 and ABCC4 stratified by gender and SNPs 
 Normal mucosa CRC 
 N 
Mean expression  
(SD) 
P* value P value 
Fold-
difference** 
N 
Mean expression 
(SD) 
P* value P value 
Fold-
difference** 
COX-2 57 -5.22 (1.67) - - - 37 -3.99 (1.64) - 0.001 2.34 
Gender           
Female 22 -4.54 (1.60) - - - 17 -4.43 (1.44) - 0.821 1.08 
Male 33 -5.73 (1.60) - - - 18 -3.58 (1.67) - <0.001 4.44 
rs689466           
AA 26 -4.99 (1.74) 
0.155 
-  21 -4.42 (1.58) 
0.024 
-  
AG 26 -5.32 (1.58) 0.481 0.80 13 -3,50 (1.40) 0.095 1.89 
GG 3 -6.96 (1.64) 0.073 0.26 2 -1,57 (0.10) 0.021 7.21 
HPGD 60 -1.59 (1.49) - - - 39 -1.64 (1.97) - 0.848 0.96 
Gender           
Females 24 -1.47 (1.07) - - - 18 -1.90 (1.63) - 0.647 0.74 
Males 36 -1.66 (1.76) - - - 20 -1.66 (2.20) - 0.986 1.00 
rs12500316           
CC 38 -1.38 (1.76) 
0.193 
- - 29 -1.69 (1.89) 
0.449 
- - 
CT 14 -1.95 (0.99) 0.087 0.67 4 -0.87 (1.90) 0.423 1.76 
TT 6 -1.79 (0.80) 0.374 0.75 4 -2.70 (3.12) 0.360 0.50 
rs1863642           
GG 32 -1.11 (1.53) 
0.035 
- - 22 -1.66 (1.99) 
0.486 
- - 
GT 21 -2.19 (1.49) 0.015 0.47 12 -1.36 (1.64) 0.656 1.23 
TT 6 -1.90 (0.74) 0.227 0.58 4 -2.76 (3.08) 0.357 0.47 
rs1346271           
GG 29 -1.34 (1.78) 
 
0.582 
- - 21 -2.05 (1.70) 
0.313 
- - 
GC 15 -2.04 (1.11) 0.039 0.62 6 -0.88 (1.42) 0.136 2.27 
CC 16 -1.60 (1.23) 0.148 0.84 12 -1.45 (2.56) 0.428 1.51 
rs1425945           
GG 35 -1.33 (1.50) 
0.319 
- - 25 -2.02 (2.18) - - - 
GA 23 -1.96 (1.81) 0.130 0.65 14 -1.10 (1.41) - 0.163 1.89 
AA 2 -1.79 (0.79) 0.608 0.73 0 - - - - 
rs2555639           
TT 34 -1.33 (1.49) 
0.216 
- - 24 -1.67 (2.26) 
0.482 
- - 
TC 19 -2.03 (1.70) 0.091 0.62 11 -2.16 (1.21) 0.505 0.71 
CC 7 -1.59 (0.84) 0.665 0.84 3 -1.10 (1.19) 0.672 1.48 
C carriers 26 -1.91 (1.52)  0.101 0.67 14 -1.94 (1.24)  0.692 0.83 
           
           
   
Table 2. Mean expression values (-ΔCt) for COX-2, HPGD, SLCO2A1 and ABCC4 stratified by gender and SNPs 
 Normal mucosa  CRC 
 N 
Mean expression  
(SD) 
P* value P value 
Fold-
difference** 
N 
Mean expression 
(SD) 
P* value P value 
Fold-
difference** 
SLCO2A1 58 -5.30 (1.46) - - - 39 -4.26 (1.63) - 0.001 2.06 
Gender           
Males 32 -5.28 (1.56) - - - 20 -4.29 (1.53) - 0.011 1.99 
Females 24 -5.31 (1.40) - - - 18 -4.26 (1.83) - 0.029 2.07 
rs6439448           
CC 39 -5.19 (1.62) 
0.774 
- - 27 -4.32 (1.49) 
0.176 
- - 
CA 11 -5.43 (1.30) 0.598 0.85 8 -4.49 (2.05) 0.790 0.89 
AA 3 -5.20 (0.46) 0.678 0.99 3 -2.51 (1.57) 0.058 3.51 
rs1131598           
AA 29 -5.32 (1.71) 
0.718 
- - 20 -4.16 (2.62) 
0.518 
- - 
AG 21 -5.21 (1.76) 0.510 1.08 11 -4.02 (1.99) 0.830 1.10 
GG 6 -5.38 (0.88) 0.507 0.96 7 -4.91 (1.27) 0.280 0.59 
rs7616492           
GG 19 -5.52 (1.10) 
0.847 
- - 17 -4.52 (1.45) 
0.701 
- - 
GA 25 -5.17 (1.73) 0.731 1.27 13 -4.78 (1.61) 0.210 0.84 
AA 10 -5.11 (1.62) 0.425 1.33 9 -4.34 (2.07) 0.790 1.13 
rs9820625           
AA 14 -6.08 (0.96) 
0.024 
- - 10 -4.31 (2.06) 
0.640 
- - 
AC 24 -4.96 (1.78) 0.032 2.17 17 -4,04 (1.40) 0.681 1.20 
CC 16 -5.17 (1.28) 0.030 1.88 10 -4.68 (1.79) 0.677 0.77 
rs7340717           
GG 28 -5.35 (1.21) 
0.272 
- - 18 -4.15 (1.83) 
0.965 
- - 
GT 17 -5.03 (2.00) 0.515 1.25 13 -4.17 (1.37) 0.973 1 
TT 9 -6.01 (0.74) 0.131 0.63 5 -4.37 (1.48) 0.812 0.86 
ABCC4 60 -3.03 (1.36) - - - 38 -1.74 (1.33) - <0.001 2.44 
Gender           
Males 35 -3.36 (1.41) - - - 20 -1.74 (1.40) - 0.011 2.44 
Females 23 -2.55 (1.23) - - - 18 -1.74 (1.29) - 0.029 1.75 
 rs9524821           
GG 19 -3.05 (1.62) 
0.752 
- - 12 -1.67 (1.43) 
0.603 
- - 
GA 26 -3.09 (1.26) 0.408 0.97 15 -1.32 (1.25) 0.573 1.27 
AA 11 -2.87 (1.45) 0.800 1.13 10 -1.41 (1.43) 0.674 1.20 
           
           
 
 Table 2. Mean expression values (-ΔCt) for COX-2, HPGD, SLCO2A1 and ABCC4 stratified by gender and SNPs 
 Normal mucosa CRC 
 N 
Mean expression  
(SD) 
P* value P value 
Fold-
difference** 
N 
Mean expression 
(SD) 
P* value P value 
Fold-
difference** 
rs1751051           
TT 29 -2.98 (1.13) 
0.138 
- - 22 -1.61 (1.24) 
0.987 
- - 
TA 19 -3.49 (1.75) 0.223 0.70 8 -1.64 (1.19) 0.946 0.98 
AA 7 -2.28 (1.28) 0.163 1.62 6 -1.70 (1.58) 0.877 0.94 
T carriers 48 -3.18 (1.41)  0.118 1.87 30 -1.62 (1.21)  0.694 0.95 
rs1678405           
TT 35 -3.10 (1.30) 
- 
- - 24 -1.43 (1.18) 
0.049 
- - 
TC 19 -2.86 (1.64) 0.380 1.18 10 -2.26 (1.47) 0.900 0.56 
CC 1 - - - 2 -3.39 (0.92) 0.032 0.26 
rs1751031           
AA 40 -2.77 (1.30) 
0.053 
- - 25 -1.60 (1.32) 
0.320 
- - 
AG 12 -3.83 (1.44) 0.019 0.48 6 -1.50 (1.18) 0.859 1.07 
GG 5 -3.46 (1.54) 0.380 0.62 7 -2.43 (1.42) 0.162 0.56 
rs1678396           
TT 25 -2.82 (1.51) 
0.507 
- - 18 -1.63 (1.32) 
0.879 
- - 
TC 21 -3.16 (1.51) 0.449 0.79 12 -1.88 (1.31) 0.607 0.84 
CC 11 -3.37 (0.75) 0.263 0.68 8 -1.78 (1.54) 0.807 0.90 
rs2274403           
AA 19 -3.13 (1.47) 
0.686 
- - 14 -1.84 (1.37) 
0.708 
- - 
AG 25 -3.14 (0.96) 0.965 0.99 15 -1.81 (1.42) 0.958 1.02 
GG 13 -2.74 (1.97) 0.538 1.31 7 -1.33 (1.35) 0.437 1.42 
rs3742106           
AA 24 -3.38 (1.27) 
0.286 
- - 14 -2.21 (1.24) 
0.235 
- - 
AC 29 -2.80 (1.47) 0.133 1.49 20 -1.52 (1.14) 0.101 1.61 
CC 4 -2.70 (1.47) 0.388 1.60 4 -1.22 (2.27) 0.258 1.99 
rs6492763           
TT 28 -2.84 (1.24) 
0.612 
- - 19 -1.66 (1.47) 
0.831 
- - 
TC 20 -3.11 (1.52) 0.504 0.83 10 -1.62 (1.07) 0.937 1.03 
CC 7 -3.82 (1.72) 0.362 0.51 8 -1.98 (1.46) 0.612 0.80 
rs869951           
GG 24 -3.36 (1.52) 
0.335 
- - 14 -2.39 (0.93) 
0.003 
- - 
GC 22 -3.54 (1.34) 0.346 0.88 13 0.74 (1.33) 0.001 8.75 
CC 11 -2.57 (1.17) 0.152 1.73 9 -1.98 (1.21) 0.366 1.33 
C carriers 33 -2.82 (1.28)  0.157 1.45 22 -1.25 (1.40)  0.011 2.20 
SNP, single nucleotide polymorphism; CRC, Colorectal cancer; SD, standart deviation. At bold, statistical significant results 
*calculated using One-way ANOVA or Kruskal-Wallis test, when appropriate;; **calculated using the Livak method (2
-ΔΔCt
) 
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Figure 1. Real-time analysis for COX-2, HPGD, SLCO2A1 and ABCC4 mRNA levels (-ΔCT) in 
normal-appearing mucosa and colorectal cancer (CRC) tissues. The Box plots represent in the 
horizontal bar the mean value for mRNA in each group. The whiskers represent the maximum and 
minimum values of the data. Black dots represent outliers. *P<0.05. 
Although detected at high levels in colonic mucosa, no differences in HPGD 
mRNA expression was noticed (-1.59±1.49 vs -1.64±1.97, P=0.848). Surprisingly, 
a 2-fold increase in SLCO2A1 levels was observed independently of gender (-
5.30±1.46 vs -4.26±1.63 in normal mucosa, P=0.011). Similarly, the ABCC4 gene 
was found at higher levels in CRC (-3.03±1.36 vs -1.74±1.33, P<0.001, 
2.4 folincrease). No gender-specific behavior was noticed.Considering 
the high variance in genes’ levels, we then questioned if the genetic variants could, 
if fact, be determinants of mRNA expression?  
Thirteen out of the twenty polymorphisms analyzed appear to be involved in 
gene´s regulation, some of which with a gender and histological-type dependent 
behavior.  
As can be observed in Figure 2, an increasingly overexpression of COX-2 mRNA 
is observed from genotypes carrying one to both copies of rs689466G allele in 
contrast with the AA homozygous genotype (-3.50±1.40, -1.57±0.10 and -
4.42±1.58, respectively; P=0.024). The rs689466AG and GG genotypes were 
COX-2 HPGD SLCO2A1
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further associated with a nearly 2- and 7-fold increase in COX-2 mRNA expression 
in colorectal neoplasia. This seems particularly relevant in males. The 
heterozygous genotype in males’ tumors led to an increase in mRNA levels by 3-
fold (-2.87±1.34 vs -4.45±1.56 for the AA genotype, P=0.041 in males and -
4.52±0.79 vs -4.40±1.67, for the AG and AA genotypes, respectively, P=0.884 in 
females). Antagonically, in normal-appearing colonic mucosa, the GG genotype 
decreased the expression of COX-2 in comparison with the AA genotype (-
6.96±1.64 vs -4.99±1.74, P=0.073).  
 
 
 
Figure 2. Relative levels of COX-2 mRNA (-ΔCT) considering the genotypes for the rs689466A>G 
polymorphism. The Box plots represent in the horizontal bar the mean value for mRNA in each 
group. The whiskers represent the maximum and minimum values of the data. Black dots 
represent outliers. *P<0.05. 
Similarly, the GC genotype of rs1346271 polymorphism decreased the levels of 
HPGD mRNA in normal-appearing mucosa (-2.04±1.11 vs -1.11±1.53, P=0.039 for 
GG genotype) and was associated with a 2-fold higher expression in CRC mucosa, 
although not statistically significant (-0.88±1.42 vs -2.05±1.70, P=0.136), as 
observed in Figure 3. Three other tagSNPs in HPGD presented an allele-specific 
regulation. In normal-appearing mucosa the GC genotype of rs1863642 and TC 
Only in CRC samples
* *
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heterozygous genotype of rs2555639 polymorphism had a lower mRNA 
expression in opposition with the respective dominant genotypes (-2.19±1.49 vs -
1.11±1.53 for the rs1863642GG genotype, P=0.015; and -2.03±1.70 vs -1.33±1.49 
for the homozygous TT genotype of rs2555639, P=0.091). A trend for a higher 
expression was noticed with the rs1425945GA genotype in malignant mucosa (-
1.10±1.41 vs -2.02±2.18 for GG genotype, P=0.163). 
 
 
 
Figure 3. Relative levels of HPGD mRNA (-ΔCT) considering the genotypes for the rs1346271G>C 
(left side) and rs1863642G>T (right side) polymorphisms. The Box plots represent in the horizontal 
bar the mean value for mRNA in each group. The whiskers represent the maximum and minimum 
values of the data. Black dots represent outliers. *P<0.05; 
#
P=0.136. 
Considering the SLCO2A1 gene, an approximately 2-fold overexpression was 
reported for AC and CC genotypes of rs9820625 tagSNP when compared with the 
AA homozygous genotype in normal-appearing mucosa (-4.96±1.78 and -
5.17±1.28 vs -6.08±0.96, respectively (see Figure 4). Additionally, two trends were 
observed with the rs6439448C>A and rs7340717G>T in CRC tissues and mucosa 
with no observable tumors, respectively. An enhanced expression was evident 
with the AA genotype of rs6439448 (-2.51±1.57 vs -4.32±1.49 for the CC genotype, 
P=0.058) in opposition with the rs73407171TT genotype that downregulated 
SLCO2A1 mRNA levels (-6.01±0.74 vs -5.23±1.54 observed for G allele carriers, 
P=0.107). 
* *
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Figure 4. Relative levels of SLCO2A1 mRNA (-ΔCT) considering the genotypes for the 
rs9820625A>C (left side) and rs6439448C>A (right side) polymorphisms. The Box plots represent 
in the horizontal bar the mean value for mRNA in each group. The whiskers represent the 
maximum and minimum values of the data. Black dots represent outliers. *P<0.05; 
#
P=0.058.  
The mRNA expression of ABCC4 genes was particularly differentiated in the 
rs1678405, rs1751031 and rs869951 tagSNPs. The ABCC4 levels were 
progressively lower in rs1678405TC and CC genotypes in malignant mucosa (-
2.26±1.47 and -3.39±0.92, respectively, vs -1.43±1.18 with the TT genotype, 
P=0.049), as noticed in Table 5. A 50% decrease in mRNA expression was 
noticed with the rs1751031AG genotype in normal-appearing tissues (-3.83±1.44 
vs -2.77±1.30, P=0.019). Furthermore, a nearly 9-fold overexpression was 
observed with the rs869951GC genotype (0.74±1.33 vs -2.39±0.93 for the GG 
genotype, P=0.001).  Furthermore, a higher expression of ABCC4 was observed 
with the rs1751051AA genotype in normal-appearing tissues in contrast with 
genotypes carrying the T allele, although not statistically significant (-2.28±1.28 vs 
-3.18±1.41, respectively, P=0.118). A trend for increased expression was reported 
in the presence of rs3742106C allele (-3.38±1.27 vs -2.79±1.45 for the AA 
genotype, P=0.113 in normal-appearance mucosa and -1.47±1.33 vs -2.21±1.24 
in CRC tissues, P=0.096).   
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Figure 2. Relative levels of ABCC4 mRNA (-ΔCT) considering the genotypes for the rs1678405T>C 
(left side) and rs1751031A>G (right side) polymorphisms. The Box plots represent in the horizontal 
bar the mean value for mRNA in each group. The whiskers represent the maximum and minimum 
values of the data. Black dots represent outliers. *P<0.05. 
DISCUSSION 
Colorectal cancer develops through a multistep process, known as the adenoma-
carcinoma sequence, as a result of the cumulative effects of acquired molecular 
events due to genomic instability and the influence of a large number of low-
penetrance genetic variants each exerting a modest effect on CRC risk [1,23,24]. 
Deregulation of the COX-2/PGE2 pathway is an early event in colorectal 
carcinogenesis leading to the stimulation of a plethora of oncogenic pathways with 
repercussion on most if not all hallmarks of cancer [9,11].  
In this functional study we assessed the influence of a set of polymorphisms 
formerly implicated in colorectal carcinogenesis [18,19] on COX-2, HPGD, 
SLCO2A1 or ABCC4 genes’ expression in colonic tissues. 
Surprisingly, we observed a stable mRNA expression of HPGD from normal-
appearing to malignant mucosa in contrast with previous works. Yan and 
colleagues [25] observed a high expression of HPGD in normal mucosa but that 
for most of colon cancer samples the HPGD mRNA expression was at 
undetectable levels. Considering that we only included tissues with measurable 
* *
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gene expression, we might have an enrichment towards higher mRNA levels in 
CRC samples, potentially explaining the disparities observed with earlier reports. 
Holla and colleagues [17] observed that SLCO2A1 mRNA expression was 
significantly lower in fresh-frozen human colorectal tumor specimens than that 
noticed in matched normal mucosa. We failed to corroborate this finding. In fact, 
we observed a two-fold overexpression in CRC tissues. Nevertheless, and 
similarly to our results, Lejeune and colleagues [26] noticed that PGT expression 
was up-regulated in colonic epithelial cells during inflammation (ulcerative colitis) 
leading to a high-output of PGE2 extracellularly by vectorial transport through the 
epithelium towards lumen.  
Despite these inconsistencies, a significant variation was observed in gene 
expression across all genes (above seven-fold), suggesting the involvement of 
genetic determinants. 
The regulation of mRNA levels by different alleles appears to be dependent on the 
histological context. During colorectal carcinogenesis different pathways are 
activated overtime due to acquired mutations or environmental exposure resulting 
on the release of transcription factors (TF) that can bind to the regulatory regions 
containing the genetic variations, thus leading to an altered gene expression. As 
an example, mutations in adenomatous polyposis coli (APC) gene is associated 
with the earliest stages of colorectal carcinogenesis and shown to increase COX-2 
expression through C/EBP-β [27]. If a specific COX-2 polymorphisms is located 
within the recognition-binding site for that TF a differential expression between 
alleles will be noticed once that pathway is activated. 
The rs689466G>A polymorphism in COX-2 gene was previously associated with 
an increased risk for the development of colorectal cancer and adenomas [18,19]. 
Its role on cancer is controversial. Initial studies in Asian populations identified the 
GG genotype as risk marker for the occurrence of gastrointestinal cancers and a 
higher COX-2 mRNA expression was observed in esophageal tumors [28-30]. In 
CRC cell lines the opposing GG genotype let to an increase in COX-2 
transcriptional activity  [31]. This biological repercussion was further supported in 
the present study, where a 7-fold overexpression was reported in CRC specimens. 
Four genetic variants in HPGD gene had an allele-specific mRNA gene expression 
(rs1863642G>T, rs1346271G>C, rs1426945G>A and rs2555639T>C) that 
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provided the biological reasoning underlying the epidemiological observations, 
with the exception of rs1863642G>T, although for some, the difference was not 
statistically significant probably reflecting limited statistical power. This genetic 
variant, located in an intronic region with no predicted impact on protein 
expression or function, was associated with a decreased in HPGD expression and 
antagonically a protection was reported for the occurrence of colorectal adenomas 
in the presence of T allele. Future studies are needed for a deeper comprehension 
on the influence of this tagSNP or other represented in the LD block on colorectal 
carcinogenesis.  
Looking at the SLCO2A1 gene, the AA genotype of rs6439448C>A polymorphism 
presented a trend for higher mRNA expression in neoplastic sample. Following the 
traditional view on PGT, increased levels of SLCO2A1 will increase the cellular 
intake of PGE2 and subsequent inactivation by 15-PGDH, thus explaining the 
lower risk observed for colorectal tumors. Although this tagSNPs has no 
predictable function repercussion (SNPinfo database) it tags two SNP: the 
rs2370512T>C located in the 3’UTR that could influence mRNA expression and 
stability and the rs34550074G>A at the codon 396 coding for two difference 
aminoacids. 
Five out of the nine tagSNPs that altered the susceptibility for the development 
and recurrence of colorectal tumors influenced the ABCC4 mRNA expression 
levels corroborating their relevance in colorectal carcinogenesis. The 
rs1751031AG genotype was associated with a lower expression in contrast with 
the AA homozygous genotype. That under-expression is expected to hamper the 
efflux-dominated flow decreasing the levels of PGE2 in the extracellular milieu and 
the activation of oncogenic pathways thus explaining the lower risk observed.  
Gene expression studies from FFPE represent an unlimited source for 
translational cancer research. Unfortunately, this type of analysis may be 
problematic considering the potentially low quality of the RNA extracted from 
FFPE [32,33]. To overcome this limitation we selected amplicons under 100bp 
proven to obtain accurate and specific gene expression in Real-Time analysis [32]. 
We also carried-out the reverse transcriptase step with random primers, 
considering that up to 50% of RNA may not contain the poly-A tail intact [33]. 
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Furthermore, we also observed a stable expression of the KRT20 reference gene 
across samples.  
In conclusion, the present functional study reports the involvement of genetic 
variants on COX-2, HPGD, SLCO2A1 and ABCC4 genes’ expression providing a 
biological reasoning underlying the epidemiological data. This further reinforces 
the important role that the genetic background has on the development of 
colorectal tumors. The definition of higher-risk populations might be a useful tool 
for targeted screening and surveillance. Furthermore, Chan and colleagues [34] 
reported that the protective role of aspirin in colorectal carcinogenesis is only 
noticeable in tumors overexpressing COX-2. So, the identification of 
polymorphisms that influence the genes’ levels might be particularly relevant for 
selecting subjects for chemopreventive strategies.  
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Table S1. Description of genetic polymorphisms previously implicated in Colorectal 
carcinogenesis   
Gene / SNP 
Nucleotide 
substitution 
Location 
Previous epidemiological association 
CRC Adenoma 
COX-2 
rs689466 A>G 5’UTR 
Risk 
(AAvsGG) 
Risk 
(AA/AGvsGG) 
HPGD 
rs12500316 C>T Intron  
Protection 
(GGvsGT/TT) 
rs1863642 G>T Intron  
Protection 
(GGvsGT/TT) 
rs1346271 G>C 5’UTR 
Protection 
(GGvsGC) 
Protection 
(GGvsGC/CC) 
rs1426945 G>A 5’UTR 
Protection  
(GGvsAA) 
- 
rs2555639 T>C 5’UTR  
Risk 
(TT/TCvsCC) 
SLCO2A1 
rs6439448* 
C>A 
 
Intron 
Protection 
(CCvsCA) 
Protection 
(CCvsCA/AA) 
rs1131598 A>G 3’UTR  
Protection 
(AAvsAG/GG) 
rs7616492 G/A Intron 
Risk 
(GGvsAA) 
Higher interval
# 
(GGvsGA/AA) 
rs9820625 A>C Intron  
Risk 
(AA/ACvsCC) 
rs7340717 G>T Intron  
Lower interval 
(GG/GTvsTT) 
ABCC4 
rs9524821 G>A Intron  
Risk 
(GG/GAvsAA) 
rs1751051 T>A Intron Risk (TTvsAA) 
Risk 
(TT/TAvsAA) 
rs1678405 T>C Intron  
Protection 
(TTvsTC/CC) 
Lower time 
rs1751031 A>G Intron 
Protection 
AAvsAG 
- 
rs1678396 T>C Intron  
Protection (HR) 
TTvsTC/CC 
rs2274403 A>G Intron  
Protection (HR) 
AAvsAG/GG 
rs3742106 A<C 3’UTR  
Risk (HR) 
AAvsAC/CC 
rs6492763 T<C Intron  
Protection (HR) 
TTvsTC/CC 
rs869951 G<C 5’UTR  
Lower time 
GG/GCvsCC 
* Tags the rs2370512T>C in  3’UTR and rs34550074G>A at codon 396 that codes for 
diffferent aminoacids; 
#
 Time interval until the recurrence of colorectal adenomas. 
HR, hazard ratio for recurrence of Colorectal adenomas 
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An increasingly large body of evidence highlight the predominant role of COX-
2/PGE2 pathway in promoting cancer progression through multiple signaling 
pathways, as reviewe by several authors [1,2]. Briefly, once synthesized by COX-2 
the PGs are transported into the extracelular microenvironment by the specific 
MRP4 transporter, where PGE2 binds to G-protein coupled receptors stimulating 
downstream signals such as cAMP or PI3K [3]. After PGE2 is returned back to the 
cytoplasm by the influx PGT transporter it is enzymatically catabolized by 15-
PGDH [4,5]. Deregulation of this pathway through an overexpression of COX-
2/MRP4 and inversevely a downregulation of PGT/15-PGDH expression leads to 
the accumulation of PGE2 in microenvironment [7-12].  
In this thesis, we hypothesized that the genetic background might contribute to the 
deregulation of PGE2 pathway, with potential repercursion on the susceptibility for 
colorectal tumors development. Furthermore, a deeper understanding on 
colorectal carcinogenesis through the identification and characterization of genetic 
biomarkers will allow the characterization of individuals at higher risk for CRC that 
in the foreseeable future could offer a clinical reasoning. 
Early screening and follow-up of individuals previously diagnosed with colorectal 
adenomas is the cornerstone of CRC prevention [13,14]. Nevertheless, the 
adherence rates in countries with implemented population-based CRC screening 
guidelines, are far from the desirable for a successful decrease in CRC burden 
[15]. Complementary, the regular use of NSAIDs has been consistently effective in 
the prevention of colorectal tumors development and recurrence [16-19]. 
Nevertheless, concerns over its safety has haulted their applicability as 
chemopreventive agents in cancer at least in average-risk population [20].  
So, the challenge falls in the identification of biomarkers that could target higher-
risk populations for colorectal screening and/or chemopreventive strategies. 
To test our hypothesis, two observational studies were designed to address the 
involvement of genetic variability on COX-2, HPGD, SLCO2A1 and ABCC4 genes, 
coding for the COX-2, 15-PGDH, PGT and MRP4 proteins, respectively, on the 
susceptibility not only for CRC (Chapter IV) but also on the development of early 
stage colorectal tumors (Chapter V).  
Cohort studies provide the strongest scientific evidence among observational 
studies by creating a time framework that establishes the causality between the 
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variable of exposure and outcome, by following individuals over time, thus 
minimizing the influence of selection and recall bias [21]. Neverthless, the long 
latency period of CRC (10-15 years) and the relatively high number of subjects 
needed to be recruited (nearly 3400 individuals to detect a RR of 1.70 with 95% 
confidence interval and 80% power; MAF=15% and CRC lifetime risk =4%) that 
would translate in an overly expensive and time consuming approach hindered our 
capacity to follow this study design during the time frame of this project. 
Hence, we implemented a case-control study gathering patients diagnosed with 
CRC at a reference oncological centre for the entire North of Portugal (Chapter 
IV). Considering the time interval between cancer diagnosis and the beginning of 
this project we cannot exclude survival bias, though we did not observed any 
difference in genotypes distribution among clinicopathological variables that 
correlate with survival rate, namely stage of disease. Our control group was made 
up of unscreened blood donors from the same institute. Eighty-five percent of 
these participants were asymptomatic and still blood donors five to seven years 
after recruitment. Most of the remainder subjects quit being donors due to age 
criteria and there were no record of CRC. Taken together it is highly unlikely that 
crossover had occur. The same control group was used in the case-control study 
involving patients with personal history of colorectal adenomas (Chapter V). This 
might not be the most suitable control subjects, considering the high prevalence of 
adenomatous polyps and absence of symptomatology normaly associated with 
these lesions [22,23]. Neverthless, and as discussed in Chapter V, if selection bias 
was evident the directionality of our results is expected to remain but the 
magnitude of associations would tend to be more noticeable. Furthermore and 
although we did not matched controls to cases in the design phase we minimized 
the effect of potential confounding variables in the statistical analysis either 
through data stratification or multivariate analysis.  
In the inability to include independent replication test sets to address the 
generalisability of the results reported here, we assessed the predictive accuracy 
by resampling the original data following the bootstrap method [24]. Most of our 
association were proven to be rather stabe an robust, as mentioned in the 
individual studies.  
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The release of the first human genome draft highlighted the relevance of common 
genetic variations along side the development of high throughput genotyping 
platforms have shifted the way diseases are studied from evaluating a few 
promising SNPs in candidate genes to hundreds or even thousands. 
The false positive report probability (FPRP) was used to correct for multiple testing 
and address possible false positive findings [25].  This method calculates the 
probability of no association given a statistical significant finding. Unlike more 
stringent approaches, like Bonferroni correction that focus solely on the number of 
test performed, the determinants of FPRP magnitude include: (1) prior probability 
of a true association; (2) observed P value and (3) statistical power to detect the 
odds ratio of the alternative hypothesis at the given P value. We set the FPRP 
noteworthiness value at 0.5 recommended for small initial studies [25]. The prior 
probability cutoff depends on the availability of previous epidemiological and/or 
functional data, also as biological plausibility, thus explaining the different values 
assumed in Chapter V (Table 2). The associations observed on the recurrence of 
adenomas were more susceptible to represent false positive findings, that could 
reflect the lower statistical power. 
In this project, we took advantage of the extensive linkage desiquilibrium (LD) 
regions reported across the human genome, based on the assumption that a 
complete set of sequence variants within these blocks bear redundant information 
that can be significantly reduced to a subset of tagging markers (tagSNPs) [26]. 
This set of tagSNPs can be use to capture the vast majority of SNP variation in a 
region, thereby reducing significantly the genotyping costs and sample amounts 
[26]. We retrieved our panel of tagSNPs from the CEU population of the 
International HapMap Project, that is represented by Utah residents with northern 
and western European ancestry [27]. The tagSNPs transferability as been 
addressed in several studies [28-30]. Gu S and colleagues [30], observed a high 
tagSNPs portability among European populations that captured an average of 
95% of common variants. Nevertheless, considerable heterogeneity in LD pattern 
was noticed that could explain the discrepancies reported between the original and 
subsequent replication studies [30]. Nearly 40% of the tagSNPs recovered from 
the CEU population were included in this study.   
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One obstacle that we were faced when trying to increase our sample set from the 
preliminary study descrived in Chaper IB and gathered the subjects with previous 
history of colorectal adenomas in Chapter V, was the inability to obtain blood 
samples. This was overcomed by isolating DNA from archived formalin-fixed, 
paraffin-embedded (FFPE) tissues. Although representing a valuable an extensive 
source in biomedical research its use has been rather neglected considering the 
(1) expected chemical modifications and nucleic acids degradation; and (2) 
occurrence of somatic changes during tumor development [31,32]. Horn H and 
colleagues [33] reported a perfect concordance rate between genotypes from 
germline DNA and FFPE speciments when using the matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) with 
sequenom iPLEX technology and high genotyping detection rates (over 90%). This 
was further corroborated by others [34] and also observed when using TaqMan 
genotyping assays [35,36]. We internally validated the use of FFPE tissues by 
genotyping 20 somatic and paired germline DNAs from patients diagnosed with 
CRC. A concordance rate of 100% was noticed. The genotype call rates and 
concordance rates between replicates were high in both observational studies (97 
and 99% in the studies reported in Chapter IV and V, respectively), although the 
call rate was lower in patients with adenomas (94%) probably due to the low 
amounts of DNA extracted from small polyps (<2mm).  
After these methodological considerations we will focus on providing an overview 
of main findings integrating this PhD thesis. In the individual studies each 
worthmentioning SNP is explored. 
Common diseases such as cancer and cardiovascular diseases are believed to 
develop through a combination of genetic and environmental factors [37-39]. 
Because genes often act in group to perform a specific biological function or 
cellular process, we decided to investigate the contribution of common genetic 
variants in the four key genes regulating PGE2 levels in the extracellular milleu 
(COX-2/HPGD/SLCO2A1/ABCC4) on colorectal carcinogenesis. Furthermore, 
understanding how these genetic markers interact with each other and with the 
environment might allow the definition of more accurate risk models that could 
contribute to decrease CRC burden through individualized prevention. 
179   
To the best of our knowledge the studies described in Chapters IV and V are the 
first using this integrative approach. Previous reports focused their attention mainly 
on the PGE2 synthesis axis and more recently in 15-PGDH or other pathways in 
arachidonic acid metabolism [40-50]. 
Most of the polymorphisms identified here as biomarkers appear to have a tumor 
stage-dependent behavior. In other words, different SNPs significantly contribute 
to CRC development in diferent phases of colorectal carcinogenesis. Although 
immutables, most SNPs are located in noncoding region of genes, namely in 
portions regulating genes’ transcription and mRNA stability [51-54]. The differential 
expression of nuclear proteins or microRNA from adenomas to carcinomas might 
modulate these SNPs behavior during colorectal oncogenesis [55]. As an 
example, the rs1131598A>G polymorphism is found in the 3’UTR of SLCO2A1 
gene and bioinformatically (SNPinfo software) the presence of G allele eliminates 
the binding site for microRNA-136. Normally, microRNAs down-regulate the 
expression of target genes either through mRNA degradation or blocking of protein 
translation, although no information is available regarding the expression of this  
microRNA in colorectal tumors [56]. If and hypothesizing that miR-136 is 
preferential expressed in colorectal adenomas this would mean that the 
rs1131598G allele would disrupt the binding of this microRNA to 3’UTR leading to 
a higher expression of PGT thus explain the lower risk observed for colorectal 
adenomas. The same would not be observed in CRC if in fact no expression of 
miR-136 was observed. The rs689466A>G in COX-2 gene was one of four SNPs 
that impacted colorectal carcinogenesis in both early and later stages of tumor 
development. An increase on the risk for colorectal adenoma and cancer was 
reported, that was even more noticeable in men and ever-smokers. This finding 
supports the observations from the preliminary study described in Chapter IB [57]. 
Furthermore, the presence of G allele was associated with a higher COX-2 
transcriptional activity in two CRC cell lines, as reported in Chapter III and to a 7-
fold COX-2 mRNA overexpression, in contrast with the AA genotype, as described 
in Chapter VI. With this study we provided for the first time a biological reasoning 
underlying the epidemiological data in CRC, although further in vitro studies are 
warranted to unravel the interaction between the rs689466A>G SNP and smoke 
consumption that could uncover new molecular targets for CRC prevention. 
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Stage-specific genetic profiles were observed in the gene-gene interaction 
analysis that significantly improved the magnitude of the impact of the genetic 
background, lending further support to the common variant common disease 
hypothesis [39]. In adenomas the four-factor interaction model including 
polymorphisms in HPGD and ABCC4 genes increased by 13-fold the genetic 
predisposition. Furthermore, a nearly 80% accuracy for predicting the 
development of adenomatous polyps was observed. The multilocus analysis 
implemented in this project may help define genetic signatures for the 
development of colorectal tumors with potential repercussion on CRC prevention. 
If corroborated by further studies, this approach might provide insightful clues on 
how these genes regulate each other. 
The current guidelines for surveillance post-polypectomy are solely based on the 
endoscopic findings at baseline colonoscopy [58]. In Chapter V we also observed 
that certain genetic variations could influence not only the interval time to 
recurrence of colorectal adenomatous polyps but also the crude risk for recurrence 
at 36, 60 and 120 months. As an example, nearly half of individuals carrying the 
rs9524821AA genotype in the low-risk group developed metachronous lesions by 
60 months in contrast with the 16% reported for G allele carriers. This appears to 
suggest that subjects with rs9524821AA genotype might benefit from a shorter 
interval between surveillance colonoscopy. 
The involvement of genetic variants in COX-2, HPGD, SLCO2A1 and ABCC4 
genes in colorectal carcinogenesis was further supported, at least for some, by the 
findings from the functional study evaluating the repercussion of SNPs in genes’ 
mRNA expression,  reported in Chapter VI.  
In conclusion, this study provided new insights into colorectal carcinogenesis 
through the identification of new genetic biomarkers in COX-2/PGE2 pathway for 
different stages of colorectal cancer development. We further corroborated the 
influence of rs689466A>G (-1195A>G) COX-2 polymorphism in colorectal 
carcinogenesis and provided a biological explanation underlying the 
epidemiological data. For the first time, we defined stage-specific multilocus 
models reflecting the cumulative effect of SNPs in COX-2, HPGD, SLCO2A1 and 
ABCC4 genes. Furthermore, an influence on the time to recurrence and 
recurrence rates of adenomas at 36, 60 and 120 months was also noticed for 
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polymorphisms in SLCO2A1 and ABCC4 genes. Taken toghether, the genetic 
variability in key genes of COX-2/PGE2 pathway might help select individuals at 
higher risk for colorectal tumors that could benefit from targeted 
screening/surveillance post-polypectomy or even be included in chemopreventive 
strategies, specially those overexpressing COX-2 or 15-PGDH enzymes. The 
preventive effects of regular use of aspirin were specifically reported in patients 
overexpressing COX-2 or 15-PGDH [59,60]. 
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CHAPTER VI: FUTURE PERSPECTIVES  
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The works integrating this thesis provided insightful clues into the role of genetic 
polymorphisms in PGE2 pathway genes on colorectal carcinogenesis that need to 
be further explored. 
 To assure the generasibility of our findings and to better estimate the 
interaction between locus and the environment larger and replicative studies 
should be implemented. The control subjects should be screened for colorectal 
tumors to exclude selection bias.  Furthermore, other genes in the metabolism of 
arachidonic acid,  namely the 5 and 12-lipoxigenases (LOX), should be 
incorporated in the gene-gene interaction analysis considering their potential 
carcinogenic roles.   
 An interaction between the rs689466A>G polymorphism and smoking 
habits was observed in CRC. In the in vitro study we observed a higher 
transcriptional activity of COX-2 gene in the presence of G allele. Nevertheless, it 
is important to identify which molecular pathway is involved in this regulation, 
namely through studies involving EMSA and ChIP methodology. Additionaly, 
exposing the two CRC cell lines transfected with either allele to carcinogenic 
components of tabacco smoke might highlight new molecular pathways regulating 
COX-2 overexpression, and potentially providing new targets for chemoprevention 
of colorectal cancer. 
 It would be interesting to increase the number of colorectal tissues in the 
functional study to assess the influence of gene-gene and gene-environment 
interactions in the mRNA expression of target genes. Additionally, tissue samples 
from adenomatous polyps should be included as they might represent a better  
model when studying polymorphisms involved in the development of early stages 
colorectal tumors. Moreover, the influence of the genetic variants explored in this 
thesis, including  the gene-gene interactions, on PGE2 levels should be addressed. 
 Furthermore, the conclusion of this thesis and further results may be 
interpreted with costs of procedures and patients’ preferences to estimate the 
cost-benefit of these approaches ie, to alter the screening and follow-up 
programes according to the genetic background. 
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Background:  Colon  carcinogenesis  is  associated  with  increased  expression  levels  of  Toll-like  receptor  2
and Toll-like  receptor  4.
Aim:  To  determine  in  a  Caucasian  population  the  role  of  Toll-like  receptor  2  and Toll-like  receptor  4
polymorphisms  in  colorectal  cancer  development.
Methods:  Hospital  based  multicentre  case  control  study  involving  193  colorectal  cancer  patients  and
278  healthy  individuals.  DNA  samples  were  extracted  from  blood  cells  and  genotyping  of  TLR2+597T>C,
TLR2−4760T>C,  TLR4−3745A>G,  TLR2Arg753Gln, TLR4Asp299Gly  was  performed.  Functionality  of  risk  poly-
morphisms  was  evaluated  through  production  of  TNF-!  in  cell  culture  and  Toll-like  receptors  levels
quantified  by  real-time  RT-PCR.
Results:  TLR2+597CC  homozygous  had  5-fold  decreased  risk  (odds  ratio  (OR)  =  0.21,  95%  CI:  0.09–0.50,
p  < 0.001)  and  TLR4  299Gly  homozygous  3-fold  increased  risk  of colorectal  cancer  (OR = 3.30,  95% CI:
1.18–9.28,  p  =  0.015).  In  stratified  analysis,  TLR2+597CC  genotype  protective  effect  was  even  higher  in
overweight  individuals  (OR  =  0.17,  95%  CI:  0.06–0.53,  p  <  0.001)  and in  never  smokers  (OR  =  0.11,  95% CI:
0.02–0.51,  p =  0.001).  Also,  the  increased  risk  effect  for  TLR4  299Gly  homozygous  genotype  was  higher  in
overweight  individuals  (OR  =  8.67,  95%  CI:  1.11–87.85,  p =  0.011).  TLR2+597T>C  polymorphism  conferred
41%  less  (p =  0.03)  and  TLR4Asp299Gly  65%  more  TNF-!  production  (p  =  0.02)  with  no  differences  in  Toll-
like receptors  levels.
Conclusion: Functional  Toll-like  receptor  2 and  Toll-like  receptor  4  polymorphisms  significantly  alter
the risk  to have  colorectal  cancer.  Obesity  and  smoking  may  influence  the  risk  for  colorectal  cancer  in
individuals  presenting  these  genetic  profiles.
© 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide, being the third most common in males and the second
one in females. Its incidence rates are rapidly increasing in several
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Tel.: +351 96 7340096; fax: +351 22 5513646.
E-mail address: pedronunesml@gmail.com (P. Pimentel-Nunes).
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areas in the world, probably related to a combination of factors
like diet, obesity and smoking [1–3]. It is clear that there are at
least three distinct molecular pathways for CRC development [4,5].
Nevertheless, modifier genes and inflammatory molecules, by pro-
moting genomic instability and controlling cell growing, may  also
be important for the progression of these CRC carcinogenic path-
ways [6–8]. Indeed, COX-2 polymorphisms have been associated to
CRC risk, suggesting that other factors, namely pro-inflammatory
ones, significantly influence the adenoma–carcinoma sequence
[9–11].
Toll-like receptors (TLR) are key players in immune system,
with ten different TLRs being expressed in humans [12,13]. TLR2
1590-8658/$36.00 ©  2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
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recognizes a number of pathogen-associated molecular patterns
(PAMP) from Gram positive bacteria and TLR4 is the receptor
of the Gram negative bacteria lipopolysaccharide (LPS) [14–16].
Activation of these receptors initiates intracellular signalling path-
ways that promote cell survival and production of different
pro-inflammatory mediators such as COX-2 [12,17–20].  Because
they are not only intrinsically related to inflammation but also
to cell survival signalling, epithelial regeneration and cell pro-
liferation, recent reports associate these receptors function to
tumourigenesis [21,22]. Concerning gastrointestinal system, cur-
rent evidence suggests that TLR innate immune responses to PAMPs
from luminal microbiota may  be essential for the development of
tumours [21–24].  In fact, our own group and other authors have
shown that human colon carcinogenesis is associated with increas-
ing expression levels of TLR2 and TLR4 [25–28].
Playing an important role in the interface between host and the
environment, dysregulation of the TLR2 and TLR4 signalling path-
ways due to functional single nucleotide polymorphisms (SNPs)
can disrupt the normal cellular immune response and consequently
conditioning cytokines cellular levels, contributing for inflamma-
tion and cancer. Genetic variants in TLRs encoding genes may
contribute to different response phenotypes, including suscepti-
bility to cancer development.
A potential functional genetic polymorphism in TLR4 gene has
been described responsible for an A-to-G transition in exon 3, caus-
ing an aspartic acid/glycine substitution Asp299Gly (rs4986790).
This transition affects the extracellular domain of TLR4 receptor,
in a ligand-recognition area [29]. TLR4 Asp299Gly polymorphism
has been subject of investigation in several studies involving dif-
ferent types of cancer [30–35].  Despite some studies observed lack
association of TLR4 Asp299Gly polymorphism and the risk of CRC
development [36,37],  one study associated this SNP to CRC [38] and
others address its role in tumour prognosis [39,40]. Several TLR2
SNPs have also been associated to cancer [38,40,41],  namely, it has
been reported, that TLR2+597T>C (rs3804099) polymorphism can
alter the risk of colon cancer development [40].
We  hypothesized genetic SNPs, with potential influence on TLR2
and TLR4 receptor expression and/or function, may  have impact in
CRC development. Our purpose was to address the role of potential
functional TLR SNPs on CRC risk in a European Caucasian popula-
tion.
2. Materials and methods
2.1. Study population and data collection
The study population has been described previously [11]. This
hospital-based case–control study included 471 participants: 193
histologically confirmed CRC patients and 278 cancer-free controls
from the northern and central region of Portugal recruited at the
Portuguese Institute of Oncology, Porto (IPOP) and Coimbra (IPOC).
Eligible cases included patients aged 50–75 years with a newly
diagnosed of CRC between January 2002 and September 2007 and
CRC patients submitted to chemotherapy between January 2004
and March 2008 that were under follow-up between February
and March 2008 at IPOP and IPOC. Controls were healthy indi-
viduals aged 50 years or more without clinical evidence of cancer
(blood donors) recruited at IPOP between July 2005 and October
2007. The characteristics of the study population are summarized
in Table 1. Cases were significantly older than controls’ with a
median age of 62 years (50–75) [vs 56 years in controls (50–65),
p < 0.001]. There were no significant differences in the distribution
of gender, BMI  and smoking habits between both groups. Written
informed consent was obtained from all participants before their
inclusion in the study, according to the Declaration of Helsinki.
Table 1
Description of participants (cases and controls): age, gender, body mass index, smok-
ing habits, and summarized clinical characteristics of cases (patients with cancer).
Cases Controls p
n = 193 n = 278
Demographics
Age (years)
Mean (SD) 62 (7) 56 (4)
Median [min–máx] 62 [50–75] 55 [50–65] <0.001
Gender, n (%)
Male 123 (64) 176 (63) 0.926
Female 70 (36) 102 (37)
Lifestyle behavioursb
BMI  categorya, n (%)
<25 kg/m2 49 (26) 41 (23) 0.598
≥25  kg/m2 143 (74) 136 (77)
Smoking status, n (%)
Never smokers 142 (74) 110 (66) 0.095
Ever  smokers 51 (26) 58 (34)
Tumour characteristics
Tumour location, n (%)
Rectum 82 (42) –
Colon 111 (58) –
Stage, n (%)
I or II 76 (40) –
III or IV 116 (60) –
BMI, body mass index.
a Categorization based on the cut-off defined by WHO  for overweight people.
b The numbers may  not add-up since we were unable to gathered this information
for  all subjects, namely in controls’ group.
Furthermore, the Ethics Committee of the IPOP and IPOC approved
this research.
2.2. Sample DNA extraction and TLR2/TLR4 polymorphisms
genotyping
Genomic DNA was extracted from peripheral blood leukocytes,
using the QIAamp® DNA Blood Mini Kit (Qiagen, Madrid, Spain)
following manufacturer’s instructions.
The selection of studied TLR2 and TLR4 polymorphisms was
based on expected functional repercussion (FastSNP) and/or pre-
vious associations with cancer development of SNPs retrieved
from literature and public database search (dbSNP). The follow-
ing polymorphisms were selected: TLR2 Arg753Gln (rs5743708),
TLR2−4789T>C (rs4696483), TLR2+597T>C (rs3804099); TLR4
Asp299Gly (rs4986790) and TLR4−3869A>G (rs2737191). TLR2
Arg753Gln and TLR4 Asp299Gly variants were analysed through
PCR-RFLP method. Briefly, DNA was  amplified in a 50-!L reac-
tion mixture containing TLR4 Asp299Gly primers (forward, 5′-AGC
ATA CTT AGA CTA CTA CCT CCA TG-3′; reverse, 5′-GAG AGA TTT
GAG TTT CAA TGT GGG-3′), and TLR2 Arg753Gln primers (for-
ward, 5′-CAT TCC CCA GCG CTT CTG CAA GCT CC-3′; reverse,
5′-GGA ACC TAG GAC TTT ATC GCA GCT C-3′) (Metabion Martin-
sried, Germany), respectively, 1× PCR buffer, 1 unit Taq polymerase,
1.5 mmol/L MgCl2, 0.2 mmol/L deoxynucleotide triphosphates, and
20 ng DNA. TLR2 PCR products (129 bp) were incubated with
MspI restriction endonuclease at 37 ◦C, in the presence of allele
G the fragment is cleaved by the enzyme giving arise two frag-
ments (104 and 25 bp), whereas the A allele is not cleaved by the
enzyme. TLR4 PCR products (188 bp) were incubated overnight
with NcoI restriction endonuclease at 37 ◦C, the polymorphism was
defined by the presence (G) or absence (A) of a restriction site.
TLR2+597T>C, TLR2−4789T>C and TLR4−3869A>G polymorphisms
were analysed by allelic discrimination using 7300 real-time PCR
System (Applied Biosystems, Foster City, CA, USA). Real-time
PCR were carried out using a 6-mL reaction mixture, containing
1× Master Mix  (Applied Biosystems), with 1× probes (TaqMan
assay, C 22274563 10, C 27313261 10, C 1844485 10, respectively
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Table  2
TLR-2+597T>C and TLR-4 Asp299Gly polymorphisms-related odds ratios for colorectal cancer and genotype frequencies in patients and controls.
Controls Cases OR 95% CI p
n  (%) n (%)
TLR-2+597T>C
TT/TC 235 (86) 184 (97)
CC 37 (14) 6 (3) 0.21 0.086–0.501 <0.001
TLR-4  Asp299Gly
AA/AG 186 (97) 169 (92)
GG 5 (3) 15 (8) 3.30 1.175–9.279 0.015
OR, odds ratio; 95% CI, 95% confidence interval. Bold values represent statistical significant results and the significance of that values (p) is in the right column.
Applied Biosystems) and 20 ng of the DNA sample. Quality control
procedures implemented for genotyping included double sampling
in about 10% of the samples to assess reliability and the use of nega-
tive controls to step-away false-positives. In PCR-RFLP method, two
authors obtained the results independently, and the ambiguous
were reanalysed.
2.3. Functional evaluation of TLR’s genotypes – culture and
activation of peripheral blood monocytes (PBM)
Blood samples were obtained from 14 healthy blood donors
according to the different genotype of TLR2+597T>C and TLR4
Asp299Gly polymorphisms. Our culture cell protocol was  described
elsewhere [42]. Briefly, PBM were isolated from whole blood
by density-gradient centrifugation with Ficoll-Paque (GE Health-
care Lifesciences, UK) followed by positive selection isolation
with anti-CD11b Microbeads (MACS, Miltenyi Biotec, Germany).
Afterwards, PBM primary culture was performed. The monocytes
samples were adjusted to 1 × 105 cells per well and cultured in
quadruplicate in RPMI-1640 medium (GE Healthcare Lifesciences,
UK), supplemented with 100 U/mL penicillin, 100 !g/mL strep-
tomycin, 2 mmol/L glutamine and 12% foetal bovine serum (GE
Healthcare Lifesciences, UK) at 37 ◦C and 5% of CO2. After 3 h
incubation, nonadherent cells and supernatants were removed
and fresh medium was  added (time 0 h). PBMs from the differ-
ent genotypes were separately incubated in four different wells
with zymosan (Zym) [2 !g/mL] for TLR2/TLR6 stimulation, with
Lipopeptide (Lp) Pam3Cys-SK4 [1 !g/mL] for TLR2/TLR1 activa-
tion, with LPS [1 !g/mL] for TLR4 stimulation, and 0.9% NaCl
as internal control. The supernatants were collected after 24 h
stimulation. After collection, supernatants were frozen at −80 ◦C
until analysis of TNF-" levels (R&D Systems, USA; sensitivity
1.6 pg/mL).
2.4. Isolation of mRNA from PBM and quantification of TLR2 of
TLR4 expression
These methods were described elsewhere [42]. Briefly, after sep-
aration and isolation of PBM, 1 × 105 cells were collected and the
final cell pellet was used for mRNA isolation with TriPure Isola-
tion Reagent (Roche, Germany). Two-step real-time RT-PCR was
used to perform relative quantification of mRNA. For each stud-
ied mRNA molecule, standard curves were generated from the
correlation between the amount of starting total mRNA and PCR
threshold cycle of graded dilutions from a randomly selected sam-
ple. For relative quantification of specific mRNA levels, 100 ng of
total mRNA from each sample underwent two-step real-time RT-
PCR. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
levels were similar in all genotypes, which enabled the use of
this gene as internal control. Specific PCR primers pairs for the
studied genes were: GAPDH – fw (P1) 5′-TTG GCC AGG GGT
GCT AAG-3′ and rev (P2) 5′-AGC CAA AAG GGT CAT CAT CTC-3′;
TLR2 – fw 5′-GAT CCC AAC TAG ACA AAG ACT-3′ and rev 5′-
CTG CGG AAG ATA ATG AAC ACC-3′; TLR4 – fw 5′-CTA AAC CAG
CCA GAC CTT GAA-3′ and rev 5′-ACC TGT CCC TGA ACC CTA TGA-
3′. Results of mRNA quantification were expressed as the ratio
gene/GAPDH.
2.5. Statistical analysis
Data analysis was  performed using the computer software Sta-
tistical Package for Social Sciences – SPSS for Windows (version
17.0). The Hardy–Weinberg equilibrium was tested by a Pear-
son goodness-of-fit test to compare the observed vs the expected
genotype frequencies. Chi-square analysis was used to compare
categorical variables, using a 5% level of significance. Statistical
differences between mean values were evaluated applying the
Mann–Whitney test. Multivariate logistic regression analysis was
used to estimate odds ratio (OR) and its 95% confidence interval
(CI) as a measure of the association between variant allele carriers
and the risk for the development of CRC. The potential confound-
ing variables: age, gender, BMI  and smoking habits were addressed
through data stratification. For each OR estimation dominant and
recessive models of analysis were followed and results presented
according to the tendency observed. The Kaplan–Meier method and
log-rank test were used to compare genotype influence in the age at
CRC diagnose. One-way ANOVA and Student’s t test for paired and
unpaired data (or correspondent non-parametric test) were used
for group comparison of TNF-" production in cell culture and for
mRNA levels. Statistical significance was  set at p < 0.05.
3. Results
3.1. SNP analysis and risk evaluation
We did not find any differences between cases and controls
concerning TLR2−4760T>C, TLR2Arg753Gln and TLR4−3745A>G
polymorphisms. TLR2+597T>C and TLR4 Asp299Gly polymorphisms
genotypes’ distribution in cases and controls and genetic profile-
associated risk of CRC are presented in Table 2. According
to TLR2+597T>C polymorphism, the CC genotype was under-
represented in CRC group (3% vs 14% in controls’, p < 0.001). The
present results show lower risk for developing CRC in CC geno-
types carriers than in those individuals’ carriers of TT/TC genotypes
(OR = 0.21, 95% CI: 0.09–0.50, p < 0.001). In TLR4 Asp299Gly genotype
distribution, we observed that GG genotype was more frequent
in CRC group than in control group (8% vs 3%, p = 0.015). Fur-
thermore, we observed that GG genotype carriers had higher risk
for developing CRC than AA/AG genotype carriers (OR = 3.30, 95%
CI: 1.18–9.28, p = 0.015). We  observed an interaction between
TLR2+597T>C polymorphism and BMI  and smoking status but not
with gender (Table 3). Both, female and male CC genotype carriers
had lower risk to CRC development (OR = 0.10, 95% CI: 0.01–0.76,
p = 0.005 and OR = 0.27, 95% CI: 0.10–0.73, p = 0.004, respectively).
We observed that CC genotype is associated with lower risk to
CRC development in individuals with BMI  ≥ 25 (OR = 0.17, 95% CI:
0.06–0.53, p < 0.001) and in individuals never smokers (OR = 0.11,
95% CI: 0.24–0.51, p = 0.001). Concerning the TLR4 Asp299Gly
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Table 3
Potential interaction between gender, body mass index, smoking status and TLR-2+597T>C and TLR-4 Asp299Gly polymorphisms in the development of colorectal cancer.
Controls Cases OR 95% CI p
n  (%) n (%)
TLR-2+597T>C
Stratification
Gender
Female
TT/TC 84 (87) 67 (98)
CC  13 (13) 1 (2) 0.10 0.012–0756 0.005
Male
TT/TC 151 (86) 117 (96)
CC 24 (14) 5 (4) 0.27 0.100–0.726 0.004
BMI
<25
TT/TC 37 (97) 46 (96)
CC 1  (3) 2 (4) 1.61 0.140–18.441 0.588
≥25
TT/TC 114 (86) 138 (97)
CC 19 (14) 4 (3) 0.17 0.058–0.526 0.001
Smoking status
Never smokers
TT/TC 92 (88) 138 (99)
CC 12 (12) 2 (1) 0.11 0.024–0.508 0.001
Ever  smokers
TT/TC 50 (86) 46 (8)
CC  8 (14) 4 (8) 0.54 0.153–1.026 0.260
TLR-4  Asp299Gly
Stratification
Gender
Female
AA/AG 57 (98) 61 (91)
GG  1 (2) 6 (9) 5.61 0.655–48.015 0.083
Male
AA/AG 129 (97) 87 (92)
GG 4  (3) 9 (8) 2.77 0.805–8.969 0.084
BMI
<25
AA/AG 27 (96) 42 (93)
GG  1 (4) 3 (7) 1.93 0.191–19.512 0.502
≥25
AA/AG 91 (99) 126 (91)
GG 1 (1) 12 (9) 8.67 1.107–87.845 0.011
Smoking status
Never smokers
AA/AG 74 (100) 123 (91)
GG 1 (1) 12 (9) 7.22 1.08–56.660 0.004
Ever  smokers
AA/AG 36 (95) 46 (94)
GG  2 (5) 3 (6) 1.174 0.186–7.403 0.620
OR, odds ratio; 95% CI, 95% confidence interval. Bold values represent statistical significant results and the significance of that values (p) is in the right column.
polymorphism, we observed that individual’ carriers of GG geno-
type and BMI  ≥ 25 had a higher risk to CRC development (OR = 8.67,
95% CI: 1.11–87.85, p = 0.011). Furthermore, the GG genotype was
also associated with risk to CRC development in never smokers’
individuals (OR = 7.22, 95% CI: 1.08–56.67, p = 0.004). No difference
was found considering different cancer locations, namely compar-
ing rectal or colon cancer.
3.2. Influence of TLR2+597T>C and TLR4 Asp299Gly
polymorphisms on the time-to-diagnosis of CRC
When we evaluated the influence of TLR2+597T>C polymor-
phism in the age at CRC diagnose (Fig. 1), we observed that
the TT/TC genotype carriers tend to be younger than CC geno-
type carriers at diagnose (66 vs 69 years, p = 0.073, respectively).
Concerning TLR4 Asp299Gly polymorphism we observed a lack of
association of the polymorphism and the age at CRC, despite GG
carriers being younger at the age of diagnosis (GG vs AA/AG, 63
vs 65 years, p = 0.4 respectively). No other statistical important
association or tendency between the studied polymorphisms and
any other clinical parameter (e.g. survival, answer to therapy) was
found.
3.3. Functional characterization of TLR2+597T>C and TLR4
Asp299Gly polymorphisms
The genotypes of the 14 participants involved in the functional
study were: TLR2+597T>C, 5 CC, 6 TC and 3 TT; TLR4Asp299Gly,  5 GG,
2 AG and 7 AA. Statistical differences were found when comparing
TLR2+597T>C CC homozygous with T carriers after Lp stimulation
(TNF-! production of 127.0 ± 18.7 vs 214.3 ± 23.2 pg/mL, p = 0.03)
and after LPS stimulation when comparing TLR4 299Gly carriers vs
AA homozygous (TNF-! production of 259.5 ± 27.7 vs 157.9 ± 22.2
pg/mL, p = 0.02) (Fig. 2). The TLR2 mRNA levels for the differ-
ent TLR2 genotypes were 0.58 ± 0.11 (CC), 0.41 ± 0.08 (CT) and
0.47 ± 0.17 (TT) and the TLR4 mRNA levels for the different TLR4
genotypes were 1.5 ± 0.59 (AA), 0.52 ± 0.35 (AG) and 0.87 ± 0.26
(GG), without any statistical difference between the groups. T car-
riers for TLR2+597T>C had TLR2 levels of 0.42 ± 0.07 (p = 0.2 vs CC
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Fig. 1. TLR2 (TLR-2+597T>C) and TLR4 (TLR-4 Asp299Gly) genotype influence in the age of CRC diagnosis (Kaplan–Meier curves and log-rank test). The effect of the TLR-2+597T>C
CC  genotype in the age of diagnosis was stronger than the TLR4 299Gly homozygous genotype.
homozygous) and G carriers of TLR4Asp299Gly had TLR4 levels of
0.82 ± 0.25 (p = 0.2 vs AA homozygous).
4. Discussion
In the present study we describe that functional TLR2 and TLR4
SNPs significantly influence the risk of CRC. Our results suggest
that small changes in the normal function of these receptors due
to functional SNPs may  contribute to an unbalanced cytokine and
pro-oncogenic cellular microenvironment and thus to a higher risk
for cancer development.
Why  should TLRs SNPs influence the risk of CRC development?
It is current knowledge that a strict regulation of TLRs activation is
fundamental for maintaining colon homeostasis [24]. Normal colon
mucosa constitutively express TLRs, however, it also presents a high
Fig. 2. TNF-! 24 h production (pg/mL) after stimulation with LPS (lipopolysaccha-
ride), Zym (zymosan), and Lp (lipopeptide) in culture cell of monocytes with the
different TLR2 (TLR-2+597T>C) and TLR4 (TLR-4 Asp299Gly) genotypes. *p < 0.05 vs
CC  (TLR2) or vs AA (TLR4).
expression of TLRs inhibitors, like TOLLIP and PPAR", which cir-
cumscribe TLRs protein expression to basolateral membrane where
they are not continuously exposed to PAMPs preventing in this way
inadequate inflammation to commensal bacteria [43–48].  Basal
TLRs expression in that particular cellular location appears impor-
tant for maintaining gastrointestinal homeostasis, preventing at
the same time auto-immunity processes, controlling bacterial
infections and allowing epithelial regeneration [21,49–52].  Since
TLRs also activate cell survival signalling pathways, abnormal TLR
activation could promote colon carcinogenesis [21,22]. Indeed, sev-
eral groups including our own  have shown in human studies that
colon carcinogenesis is associated with decrease expression of TLRs
inhibitors and conversely with higher protein expression of TLR2
and TLR4 [26,28].  It was previously shown that TLR4 expression
in tumours may  have prognostic value [25,27] and several animal
studies suggest that TLR2 and TLR4 activation may  be essential for
CRC development [23,53–55].  So, it appears that dysregulation of
these receptors activation may  influence the risk of cancer.
In this line of thoughts, we found that TLR2+597T>C and TLR4
Asp299Gly SNPs significantly influence the risk of CRC development,
suggesting that these TLRs SNPs may  be genetic susceptibil-
ity markers for CRC. The CC genotype of the TLR2+597T>C SNP
was associated with 5-fold decreased risk of CRC development
(OR = 0.21), which is a remarkable result for a SNP. In our study,
the CC genotype frequency in controls was similar to that observed
in healthy European Caucasian [56] and Korean individuals [57]
and higher than that observed in Thailand [58]. The TLR2+597T>C
polymorphism in exon 3 does not appear to induce any amino
acid change, remaining its functional impact and molecular mech-
anism poor understood. According to in silico analysis, this SNP can
introduce alterations in splicing regulation, possibly leading to an
alteration in TLR2 molecule. On the other hand, it may  be in linkage
disequilibrium with another functional SNP in TLR2 and thereby
influencing promoter activity or the stability of the transcript [59].
Previous reports have shown associations of this polymorphism
in TLR2 gene with melanoma susceptibility [41], sepsis [60] and
reverse reaction in leprosy [59]. To the best of our knowledge
we showed for the first time that TLR2+597T>C SNP may  confer
hypofunctionality to the receptor. Indeed, monocytes with the CC
genotype produced 41% less TNF-! in cell culture. Moreover, we
did not find any differences in TLR2 levels between the different
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genotypes suggesting that the potential hypofunctionality con-
ferred by this polymorphism is not dependent of TLR2 levels. So, for
any given stimulus, individuals with this SNP may  have less pro-
duction of inflammatory cytokines and less cell survival signalling
and this might help to explain the increase risk of melanoma and
sepsis and the decrease risk of CRC with an early age of diagnosis.
The TLR4 Asp299Gly polymorphism leads to missense replace-
ment of a conserved aspartic acid residue with a glycine amino acid
that alters the structure of the extracellular domain of this recep-
tor. TLR4 Asp299Gly has been subject of investigation in several
studies involving different type of cancer with controversial results
[31,33,34,39,61–64]. Due to evolutionary pressure and human
migration, this TLR4 polymorphism has a distinct distribution in
different populations, and may  or not be cosegregated with the
TLR4 Thr399Ile polymorphism, which may  change the functionality
of the receptor and may  help to explain the discrepancies between
the studies [65]. We  observed that in our control population the fre-
quency of TLR4 Asp299Gly polymorphism tend to be similar to those
observed in healthy European Caucasian [31,33,34] and American
[61,62] populations. The significance of this SNP led to contradic-
tory conclusions about its functional role [66]. Studies performed
by Arbour et al. reported that this SNP was associated with a
blunted response o inhaled LPS [29]. However, Lundberg et al. sug-
gested that not only genetic variant in TLR4 should be considered in
functional studies but also the origin of LPS [67]. Furthermore, Fer-
werda et al. showed that cells from individuals’ carriers of 299Gly
variant significantly produce higher amounts of pro-inflammatory
cytokines than homozygous wild-type [65]. Recently, a study per-
formed by Eyking et al. demonstrated that Caco-2 cells which
expressed TLR4 Asp29Gly polymorphism had a significant increase
in expression levels of genes associated with inflammation and/or
tumourigenesis compared with cells that expressed other forms of
TLR4 [68]. Our results, although they are not definitive concern-
ing the functionality of this SNP, are in agreement with the results
of Eyking et al. showing that monocytes from carriers of G allele
produce 64% more TNF-! when stimulated with LPS. Clinical stud-
ies also confirm the oncogenic potential of this SNPs since this
variant allele has been associated with a more quickly relapse in
patients submitted to radiotherapy and chemotherapy [30]. Other
study showed that this TLR4 SNP might alter prognosis on patients
that receive oxaliplatin [37]. So, this gain-of-function genetic vari-
ant implies the TLR4 Asp299Gly in malignant progression of human
colon cancer [68]. Future studies should study the role of these SNPs
also for prognosis and answer to therapy.
The other aspect that is interesting in our study is that both
the protective effect of the TLR2+597T>C SNP and the risk effect of
the TLR4 Asp299Gly SNP appear to be stronger in overweight and
never smokers’ individuals. Obesity is a well known risk factor for
CRC and in last decade, increase evidence has suggested the rele-
vance of a chronic inflammatory state in obesity [69]. Long-term
smoking also causes systemic inflammation with an increase of
inflammatory mediators concentration (C-reactive protein, IL-6, IL-
8, TNF!) [70]. Indeed, and in agreement with our results, recently
it was shown that TLR2+597T>C polymorphism can interact with
nonsteroidal anti-inflammatory drug use and cigarette smoking
to alter risk of colon cancer [40]. Individuals never-smokers and
CC genotype carriers have even lower risk for CRC development
probably due to their genetic background, with attenuated TLR2
function, and due to lower exposure to environmental factors. In
that line of thoughts it is easily understood why overweight indi-
viduals TLR4 Asp299Gly homozygous have greater risk of cancer,
however, why never smokers have greater risk than smokers is not
so comprehensive. We  may  speculate that the genetic influence of
the TLR4 Asp299Gly SNP may  be blunted in the face of the delete-
rious effect of smoking and, so, this SNP may  strongly interact with
the inflammatory process of obesity but not with the distinctive
inflammation process of smoking. Indeed, it is well known that
TLR4 may  have an important influence on adiposity and metabolic
syndrome [71].
Two main drawbacks could be noticeable in our study. First,
even if a match for ages were attempted by including only controls
aged 50 or more, a difference of ages between cases and controls
existed and secondly, the level of certainty of absence of CRC among
controls. The first was  addressed in the statistical analysis and for
the second point, we  should consider that controls were recruited
in 2005–2007, and, up to now, 85% of them (235/278) were asymp-
tomatic and still blood donors, so no clinical evidence of CRC is
present 5 years after the recruitment. Moreover, of the 43 controls
that were not blood donors in 2012, 31 quit because of age crite-
ria and there were no record of CRC in any of the 278 participants
5–7 years after recruitment. Thus, taking altogether, we may  well
consider that our control population represents individuals with-
out CRC and that the difference of ages at the time of recruitment
was not an issue to our results and conclusions.
In conclusion, functional TLRs SNPs modulate in a significant
way the individual susceptibility for CRC development with the
TLR2+597CC genotype decreasing 5-fold, whereas TLR4 299Gly
homozygous genotype increasing 3-fold the CRC risk. Factors like
obesity and smoking habits may  influence the risk of CRC in individ-
uals presenting these genetic profiles. In future, the identification of
these genetic profiles may  help to define more efficacious strategies
for screening of CRC through an individual fitted schedule.
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